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Abstract 
Evidence reversal occurs when new evidence contradicts established practices. The first 
component of this thesis is an umbrella overview of investigations – reviews and collections 
of studies – into evidence reversal to gather concepts and methods that we identified as 
useful to lay a foundation for a standardized ‘theory of reversal.’ The foundation of this 
review enables the construction of a framework that will provide structure to this field, as no 
formal organization currently exists. The next component builds upon this foundation and 
proposes a framework for evidence reversal and its related concepts. The second review 
takes this framework and applies it to Original Articles from New England Journal of 
Medicine to generate the groundwork for potential causes of reversal. Reversals were found 
in 7% of randomized trials that were original articles concerning a medical practice, 
including 50% of established clinical practices. The final component suggests a framework 
of potential reasons for reversal. Improved research in this field may help improve efficiency 
of knowledge translation as it applies to getting right evidence into practice.  
(PROSPERO Protocol Registration Number: CRD42014013768). 
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1 
  Chapter 1
1 Introduction 
Before 1992, the traditional mode of clinical practice relied on a mix of theory-based 
medicine, logic-driven medicine, opinion-based medicine, and authority-based medicine. 
These traditional modes of medicine are error-ridden because they rely only on 
information sources such as: opinion and intuition; underlying yet imperfect 
understanding of physiology; and recall of clinical experience.
 1,2
 
In 1992, the concept of Evidence Based Medicine (EBM) was introduced by the 
anonymous Evidence-Based Medicine Working Group.
 1-3
 The key difference between 
EBM and the other traditional modes of practice is that EBM attempts to make decisions 
in healthcare based on rigorous scientific evidence, rather than on the other more biased 
sources. EBM combines clinical experience and patient opinions with the best available 
clinical evidence which is collected through systematic research such as systematic 
reviews and meta-analyses.
 1,2 
The systematic collection of best available clinical 
evidence into an evidence base, in theory, should provide a framework for: improved 
clinical decision-making; better medical practice; and better patient outcomes.  
However, the paradigm of EBM is challenged by inadequacies in the evidence base.  
A limitation of the best available evidence, even when appropriately and systematically 
collected, is that the best available evidence does not guarantee the best quality evidence.  
A limitation of the evidence base itself is that there may not be enough evidence to 
support any claims or recommendations for or against an intervention. For example, an 
analysis of 1016 systematic reviews published by the leading authority in systematic 
reviews, the Cochrane Collaboration, found that 49% of existing evidence was not 
enough to support or refute their respective interventions. 
4 
  
2 
 
2 
Evidence derived from scientific research will always entail some risk of error and bias. 
Unfortunately, these flaws cannot be completely eliminated, only reduced. A tool 
introduced to EBM in an effort to identify the best quality of evidence for clinical 
decision-making guidance was a hierarchical approach to evidence, also known as the 
evidence pyramid. At the bottom, with the most risk of bias, is expert opinion and general 
background information. This is followed by: case-controlled studies, case series, and 
case reports; cohort studies; and then randomized controlled trials. Research designs 
ranked closer to the top have less risk of bias than designs on the bottom. 
5
 Recently this 
unfiltered information has been supplemented with systematic reviews and meta-
analyses, which generally have even less risk of bias than single randomized controlled 
trials. This tool works within EBM to help identify if the best available evidence is the 
best quality evidence, however, it cannot determine if there is enough evidence to support 
or refute a claim. 
More recently the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) was proposed for rating quality of studies and confidence in 
evidence. 
1,2,4 
This tool assesses risk of bias, strength of evidence, and overall confidence 
in recommendations derived from the evidence, but aspects of it are subjective and it 
lacks the necessary quantitative aspects to predict risk of reversibility in the evidence.
 6-8
  
  
3 
 
3 
1.1 Defining and Characterizing Evidence Reversal 
and Related Concepts 
Evidence reversals occur when new evidence – better designed, executed, and/or 
analyzed than its predecessors – contradicts previous claims, questioning established 
practices and theories. 
9,10,15-17
 This means that some established practices currently in use 
have been shown, through accumulation of evidence, to be ineffective or even harmful to 
patients. This new evidence should involve endpoints and controls as rigorous as 
previous evidence to contradict previous claims and upset practice. 
18
 
Following the EBM paradigm, these interventions were originally implemented into 
practice based on the accumulation of the best available evidence at the time suggesting a 
beneficial result. In the meantime, more evidence was generated and accrued – often with 
better design, execution, and/or analysis, but this new evidence suggested an ineffective 
or harmful result. Although counter-intuitive results often occur in science and there is a 
perception that reversals are becoming more frequent in recent years. 
9,10,15,17
 This thesis 
attempts to standardize the concept within EBM. 
An example of evidence reversal in medicine is a drug called rofecoxib (brand-name 
Vioxx), an analgesic with purported reduced risk for upper gastrointestinal bleeding and 
peptic ulcer disease when compared with traditional non-steroid anti-inflammatory drugs 
(NSAIDs). Early randomized trials in the 1990’s demonstrated similar analgesic effects 
and lesser risk of upper gastrointestinal bleeding or peptic ulceration for patients taking 
rofecoxib instead of traditional NSAIDs. Based on these beneficial results, rofecoxib was 
marketed as safer than its competitors (NSAIDs) and taken up into practice. Subsequent 
trials suggested that the drug increased risk of myocardial infarction. Systematic accrual 
of the evidence base could have detected the harm of increased risk of myocardial 
infarctions caused by rofecoxib on patients in the year 2000. The drug was eventually 
withdrawn from the market due to safety concerns in 2004.
 19
 This is an example of a 
reversal, where initial evidence that the drug was safer and equally efficacious as its 
competitor was overturned by accumulation of the evidence to show that clinically 
relevant risks were, in fact, greater with rofecoxib than the conventional NSAIDs. 
4 
 
4 
The counterpart to evidence reversal is evidence confirmation, which occurs when new 
evidence – better designed, executed or analyzed than its predecessors – verify previous 
claims, confirming superiority of established practices and theories over lesser or prior 
standards. 
9,10
 This means that some established practices currently in use have been 
shown, through accumulation of evidence, to be effective or beneficial to patients. 
18
 
Following the EBM paradigm, these interventions were originally implemented into 
practice based on the accumulation of the best available evidence at the time suggesting a 
beneficial result. In the meantime, more evidence was generated – often with better 
design, execution, and/or analysis, and this new evidence continued to suggest similar 
results. 
9,10,15,17
 
A well-known example of confirmed evidence is the effect of intravenous streptokinase 
thrombolytic therapy following acute myocardial infarction in patients, when used in 
prevention or postponement of death after discharge. Early trials in the 1950’s and1960’s 
suggested that intravenous streptokinase thrombolytic therapy decreased the odds of 
mortality when compared to placebo control or no therapy. Subsequent trials found more 
evidence supporting this benefit. Systematic accrual of the evidence base would have 
detected the statistically significant benefit as early as 1973, but most assuredly by 1977. 
Despite this beneficial finding, intravenous streptokinase was not submitted to or 
approved by the Food and Drug Administration and ensuing uptake into practice until 
much later. 
14
 This is an example of a confirmation, where initial evidence that the drug 
was more effective than its competitor was verified by accumulation of the evidence to 
show that mortality was, in fact, less with intravenous streptokinase thrombolytic therapy 
than its comparison. 
  
5 
 
5 
This example also demonstrates another concept, evidence maturity, which is a new term 
and concept defined in this thesis as occurring when enough information has accumulated 
to imply any further research is unnecessary. This means that there is a certain point in 
the accumulation of evidence through trials and studies, where one intervention has been 
proven to be superior, inferior, or no different than its comparison and additional trials or 
studies will be unlikely to impact on this proof. Therefore, any trials or studies conducted 
after this point would be a waste of resources. The point where this occurs is when the 
evidence becomes mature, and prior to that point evidence is considered immature. 
Evidence maturity can be demonstrated using the previous example of the effect of 
intravenous streptokinase thrombolytic therapy following acute myocardial infarction in 
patients, when used in prevention or postponement of death after discharge. In 1988, 
thirty-three total trials had been conducted on a total population of 36,974 patients. 
Confirmation of evidence occurred in 1977 (p<0.001). At this time 4,314 total patients 
had participated in fifteen trials. The subsequent eighteen trials with 32,660 more 
participants are considered unnecessary research. The consequences of this superfluous 
research squandered resources and resulted in preventable mortality since patients 
continued to be recruited to placebo-controlled trials. 
14
 This is an example of evidence 
maturity where initial evidence that the drug was more effective than its competitor was 
verified by accumulation of the evidence to show that mortality was, in fact, less with 
intravenous streptokinase thrombolytic therapy than its comparison and further research 
into this question had no impact on this lifesaving effect. Taken together, this example 
demonstrates mature confirmation of evidence. 
Evidence reversals can reach maturity as well, which is evident in the previous example 
of rofecoxib versus control. In 2001, sixteen total trials had been conducted on 21,432 
patients. Reversal of evidence occurred in 2000 (p=0.10). At this time 20,742 total 
patients had participated in thirteen trials. The subsequent three trials with 690 more 
participants were wasteful and also resulted in preventable mortality, particularly when 
the fact that rofecoxib was not recalled from practice until 2004 is considered, four years 
after the evidence had matured around this reversal. 
19
 
  
6 
 
6 
An established practice, when compared to a prior or lesser practice will demonstrate 
either evidence confirmation or reversal through verification or contradiction of the 
claims supporting its implementation and with adequate evidence can also demonstrate 
maturity.
 9,10
 Ideally, evidence maturity would be calculated using the balance of all 
known risks and all known benefits, this thesis applies this concept only to the primary 
outcome – which is assumed to be the most clinically important outcome indicative of the 
very reason why the intervention is given. We propose that evidence maturity is measured 
in a body of evidence through sufficiency and stability, and in a single study through 
fragility index.  
Sufficiency and stability are measured within the course of cumulative meta-analysis, 
which is a meta-analysis that is updated whenever a new trial is published and combines 
the new evidence with all previous evidence to demonstrate evolution of total evidence 
over time.
 
Evidence sufficiency occurs when a cumulative meta-analysis adequately 
demonstrates that a clinical practice is statistically superior to another practice or placebo.
 
11,12
 This thesis supplements this definition by adding that sufficiency is not limited to 
situations of statistical significance, but rather is also related to enough evidence to infer 
that the 95% confidence intervals are narrow enough to rule out any clinical important 
differences worth further investigation. There is no difference when the confidence 
intervals hone in tightly around the line of no effect and the possibility of more precision 
is not worth pursuing because even the extreme ends of the 95% confidence intervals are 
not clinically relevant. Sufficiency can be calculated through the Failsafe Ratio (FR) – the 
number of studies with null results needed to overturn a statistically significant meta-
analytic result versus the weight of current evidence.
 11,12
 Muellerleile suggested a FR>1 
as the threshold implying sufficient evidence to conclude a medical practice is more 
effective than another – unlikely to be overturned through further evidence.  
𝐹𝑎𝑖𝑙𝑠𝑎𝑓𝑒 𝑅𝑎𝑡𝑖𝑜 (𝐹𝑅) =  
(
(Σ𝑍)
(1.645)2
) − 𝑘𝑖
5𝑘𝑖 + 10
 
Where ∑Z = the sum of the z values from individual study results and ki = the number of 
studies included in the meta-analysis at wave i. 
11,12 
 
7 
 
7 
In an example of a cumulative meta-analysis of home cardiac rehabilitation versus 
hospital cardiac rehabilitation for exercise capacity following: a myocardial infarction; 
diagnosis of a heart condition such as coronary artery disease, angina, or heart failure; or 
a heart surgery or procedure such as coronary artery bypass graft surgery, percutaneous 
coronary intervention procedures (stenting or angioplasty), valve replacement, pacemaker 
or implantable cardioverter defibrillator. Early studies in the 1980’s and 1990’s suggest 
no difference between home cardiac rehabilitation and hospital rehabilitation – 95% 
confidence intervals include the line of no effect and point estimates themselves are close 
to the line of no effect. Subsequent studies in the 2000’s continue to demonstrate no 
difference – 95% confidence intervals tighten around the line of no effect. While a 
Failsafe ratio of >1 is not reached in this cumulative meta-analysis, the extreme ends of 
the 95% confidence intervals no longer represent clinically relevant differences – any 
further narrowing of 95% confidence intervals around the line of no effect is no longer 
worth pursuing as clinically useful. 
11 
This is an example of evidence sufficiency because 
the accumulation of evidence reaches the point where any further trials or studies would 
have no impact on this null result.  
The additional component of evidence maturity is evidence stability, which occurs when 
the direction and magnitude of the measured effect is consistent over time as new studies 
are added to a cumulative meta-analysis. Stability is calculated through the regression 
line’s cumulative slope of cumulative results repeated over time. Muellerleile suggested a 
cumulative slope estimate of less than 0.005 from this linear regression implying stable 
evidence to conclude it is unlikely that further evidence will shift the direction and 
magnitude of the measured cumulative effect.
 11,12 
 
Evidence stability is demonstrated in the previous cumulative meta-analysis of home 
cardiac rehabilitation versus hospital cardiac rehabilitation for exercise capacity. Early 
studies have varying direction and magnitudes of the effect of these interventions on 
exercise capacity – point estimates are on either side of the line of no effect and while 
95% confidence intervals are overlapping, they are different magnitudes. In 2006, the 
cumulative slope of the regression line of the cumulative meta-analytics results reaches 
the criteria of a slope of <0.005 and is considered stable. 
11
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In 2006, when the evidence for home cardiac rehabilitation versus hospital cardiac 
rehabilitation for exercise capacity demonstrates both evidence sufficiency and stability, 
this evidence is considered mature around the effect of no difference. Any additional 
trials or studies on this topic in this evidence base are redundant. 
Fragile evidence can also be used as an indicator of evidence maturity within the confines 
of a single study and indicates the fortitude of a study’s conclusion. Fragility is measured 
through the Fragility Index (FI), which determines fragility of a dichotomous primary 
outcome conclusion. The FI is tabulated by the number of events required to change a 
conclusion from statistically significant to non-significant; Although no threshold has yet 
been suggested, in general the higher the FI, the stronger the evidence in support of a 
primary outcome conclusion from a clinical trial where significance has been claimed.
 13
 
Evidence fragility is described in The statistical significance of randomized controlled 
trial results is frequently fragile: a case for fragility index by Walsh et al.
 13 
This was a 
review of 399 randomized controlled trials in high-impact medical journals which 
reported significant results for at least one dichotomous outcome. They discovered that 
the median FI was 8 – meaning that it would take only 8 people out of a median of 682 
patients in a trial to for the results of the study to no longer be significant. In 25% of these 
trials, the FI was ≤3, such that in a quarter of trials, if three people had a different 
outcome, the conclusion of the trial would be different. Additionally, 53% of trials had a 
FI number that was less than the loss to follow-up. This means that the number of people 
who did not finish the trial, and thus did not have recorded outcomes, was greater than 
the number of people with recorded outcomes needed to change the trial’s conclusion 
from significant to non-significant. 
13
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These previous terms and concepts have focused on the comparison between established 
practices and inferior or previous practices. Additional terms include the comparison 
between new practices and established practices. 
Evidence replacement occurs when new evidence – better designed, executed or analyzed 
than its predecessors – verifies superiority of a new practice over established practices 
and theories. This means that some new practices are better than the established practices 
currently in use and if the evidence is mature, this new practice should replace the 
established practice. 
An example of evidence confirmation is Technology-Enhanced Simulation-Based 
Medical Education (TES-ME) when compared with no intervention for skills outcomes in 
educating health professionals. Early randomized trials in the 1970’s and 1980’s showed 
beneficial effects of TES-ME over no intervention, subsequent trials showed the same 
effect. Despite the improved outcomes with TES-ME, it was not adopted into practice. 
20
 
This is an example of a replacement, where clear benefit is shown for a new practice over 
an established practice prior to its adoption into practice.  
Additionally, this is an example of the need for measures and awareness of evidence 
maturity. Evidence maturity was reached by 1990 after ten trials had been conducted on 
1069 health professionals, but trials were still being conducted in 2012 after 432 trials 
had been conducted on 20,934 health professionals. This means that funds, time, and 
other resources were used on unproductive research for 422 trials conducted on 19,865 
healthcare providers. Use of measures for maturity and awareness of maturity could have 
detected this mature replacement and provided firm justification for adoption into 
practice. 
20
 
The counterpart to evidence equivalent or less occurs when new evidence – better 
designed, executed or analyzed than its predecessors – fails to demonstrate superiority of 
a new practice over established practices and theories, or when an effect fails to rule out 
clinically important effect sizes. This means that some new practices are no better or 
worse than the established practices currently in use. 
10 
 
10 
The knowledge contained in the mature evidence base is not always translated into 
medical practice. There are practices that are established, which should not be in practice, 
and practices which are not established, but should be in practice. Table 1 serves to place 
the terms of evidence reversal, confirmation, replacement and equivalent or less in the 
context of what is / is not in practice and whether it should / should not be in practice. 
While this is a preliminary conceptual model, it may help to map the relationship 
between these concepts. 
Table 1: Knowledge Translation of Mature Evidence into Practice 
 What we are / are not doing 
Are Are Not 
What we should / 
should not be 
doing 
Should Evidence confirmation  Evidence replacement 
Should not Evidence reversal  Evidence equivalent or less 
Figure 1 is a logic model for Evidence Reversal and related concepts. This model was 
used to classify evidence and guides the decision-making in Chapter 3 and Chapter 4. 
This thesis seeks to explore the topic of Evidence Reversals, and to propose a framework 
to clarify the term evidence reversals and related terms. In doing so, we will also attempt 
to propose concepts which help to classify evidence as well as potential predictors or 
descriptors for associated reversibility.  
We propose the following terms as additional components of the concepts surrounding 
evidence reversal: evidence maturity, sufficiency, stability, and fragility index. They are 
intended to be indicative of the robustness of evidence supporting or refuting an 
established medical practice or theory and compose key framework classifications 
proposed in this thesis. 
11 
 
11 
 
Figure 1: Logic Model for Evidence Reversal and Related Topics 
12 
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1.2 Hypothetical Cumulative Meta-Analyses 
1.2.1 Hypothetical Forest Plot for Evidence Confirmation 
A cumulative meta-analysis is an analysis where each line represents the aggregate 
results of each subsequent new trial combined with all previous evidence. 
11,12
  
Figure 2 represents a forest plot from a hypothetical meta-analysis for the comparison 
between an existing practice and a prior practice. The left side of a forest plot represents 
aggregate relative effects that favour the intervention studied whereas the right side 
represents aggregate relative effects that favour the comparator. The line of no effect 
represents the point where there is no difference between the intervention and 
comparator. Each of these blue lines and boxes show the results of a new trial published 
merged with all prior results, such that line 1 contains the results of the first trial 
published on this topic, line 2 contains the results of the second trial published combined 
with line 1, line 3 combines a new trial with the results of line 2, and so on.  
Figure 2 demonstrates evidence confirmation because it is a comparison between an 
existing practice and another practice, and also because this existing practice has been 
shown, through accumulation of evidence, to be more effective or beneficial than the 
other alternative (green dotted line).  
 
Figure 2: Hypothetical Forest Plot for Evidence Confirmation 
13 
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1.2.2 Hypothetical Forest Plots for Evidence Reversal 
Figure 3 represents a forest plot for a hypothetical meta-analysis for the comparison 
between an existing practice and another practice. This forest plot demonstrates evidence 
reversal because it is a comparison between an existing practice and another practice and 
also because this established practice is initially suggested as beneficial (green dotted 
line), but eventually, through accumulation of evidence, confirmed as more harmful (red 
dotted line).  
 
Figure 3: Hypothetical Forest Plot for Evidence Reversal (Harmful) 
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Figure 4 represents a forest plot from a hypothetical meta-analysis for the comparison 
between an existing practice and another practice. This forest plot also demonstrates 
evidence reversal because it is a comparison between an existing practice and another 
practice, and also this established practice is initially suggested as incrementally 
beneficial over the other practice (green dotted line), but eventually, through 
accumulation of evidence, confirmed as having no proven benefit over the other 
alternative (yellow dotted line).  
 
Figure 4: Hypothetical Forest Plot for Evidence Reversal (No proven increment in 
benefit versus other practice) 
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1.2.3 Hypothetical Forest Plots for Evidence Equivalent or Less 
Figure 5 represents a forest plot from a hypothetical meta-analysis similar to Figure 3, but 
this comparison is between a new practice and an existing practice, not between an 
existing practice and another practice. 
Figure 5 demonstrates evidence equivalence or less because it is a comparison between a 
new practice and an existing practice, and also because this new practice is confirmed, 
through accumulation of evidence, as worse than the existing practice. 
 
 
Figure 5: Hypothetical Forest Plot for Evidence Equivalent or Less (Worse) 
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Figure 6 represents a forest plot from a hypothetical meta-analysis similar to Figure 4, but 
this comparison is between a new practice and an existing practice, not between an 
existing practice and another practice. 
Figure 6 forest plot also demonstrates evidence equivalence or less because it is a 
comparison between a new practice and an existing practice, and also this new practice is, 
through accumulation of evidence, confirmed as no better. The red dotted lines represent 
the Minimal Clinically Important Difference (MCID), which is the smallest difference 
detectable by a patient. When the confidence intervals for a line no longer cross the 
MCID (red dotted lines), any measured effect is no longer clinically relevant.  
 
Figure 6: Hypothetical Forest Plot for Evidence Equivalent or Less (No Better) 
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1.2.4 Hypothetical Forest Plot for Evidence Replacement 
Figure 7 represents a forest plot from a hypothetical meta-analysis similar to Figure 2, but 
this comparison is between a new practice and an existing practice, not between an 
existing practice and another practice. 
Figure 7 demonstrates evidence replacement because it is a comparison between a new 
practice and an existing practice, and also because this new practice has been shown, 
through accumulation of evidence, to be better. 
 
Figure 7: Hypothetical Forest Plot for Evidence Replacement 
 
1.2.5 Hypothetical Forest Plots for Evidence Maturity 
– Mature Confirmation or Mature Replacement 
To measure evidence maturity in a cumulative meta-analysis, additional measures of 
sufficiency and stability must be added to the cumulative meta-analysis.  
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Figure 8 represents evidence confirmation or replacement because the intervention is 
favoured over the comparator. In evidence confirmation, the intervention is an existing 
practice and the comparator is another practice and in evidence replacement, the 
intervention is a new practice, and the comparator is an existing practice. 
Sufficiency is calculated through the FR after each new trial is added to the evidence base 
(red dotted line with triangles for each line). The threshold for sufficient evidence is >1 
(red dotted line). The evidence base is considered sufficient evidence when the FR crosses 
the sufficiency threshold, which it does at line 7. 
Stability is calculated through the cumulative slope of the regression line through the 
accumulated results (dotted blue line with circles). The threshold for stable evidence is 
<0.005. The evidence base is considered stable evidence when the dotted blue line with 
circles reaches a slope of <0.005, which it does at line 9. 
To demonstrate evidence maturity, evidence must be both sufficient and stable, therefore 
Figure 8 demonstrates evidence maturity at line 9. 
 
Figure 8: Hypothetical Forest Plot for Mature Evidence (Confirmation or 
Replacement) 
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– Mature Reversal or Mature Equivalent or Less 
Figure 9 represents evidence reversal or equivalent or less because the intervention is not 
favoured over the comparator. In evidence reversal, the intervention is an existing 
practice and the comparator is another practice and in evidence equivalent or less, the 
intervention is a new practice, and the comparator is an existing practice. 
Sufficiency is reached at line 7 when the FR (red dotted line with triangles for each line) 
crosses the threshold for sufficient evidence (red dotted line).  
Stability is reached at line 10 when the cumulative slope of the regression line through 
the accumulated results (dotted blue line with circles) reaches the threshold slope for 
stable evidence.  
To demonstrate evidence maturity, evidence must be both sufficient and stable, therefore 
Figure 9 demonstrates evidence maturity at line 10. 
 
Figure 9: Hypothetical Forest Plot for Mature Evidence (Reversal or Equivalent or 
Less - Harmful/Worse) 
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Figure 10 also represents evidence reversal or equivalent or less because the intervention 
is not favoured over the comparator.  
Sufficiency is also calculated when the extremes of 95% confidence intervals no longer 
represent a MCID (red dotted MCID line). The evidence base is considered sufficient 
because the 95% confidence intervals no longer represent a MCID at line 8.  
Stability is reached at line 9 when the cumulative slope of the regression line through the 
accumulated results (dotted blue line with circles) reaches the threshold slope for stable 
evidence.  
To demonstrate evidence maturity, evidence must be both sufficient and stable, therefore 
Figure 10 demonstrates evidence maturity at line 9. 
 
Figure 10: Hypothetical Forest Plot for Mature Evidence (Reversal or Equivalent or 
Less – No Better)  
21 
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1.3 Evidence Reversal as a Product of Scientific 
Method in All Fields 
Science is a process of enquiry, which is assumed to be self-correcting through fair 
process of iterative enquiry and transparent reporting of all results, with openness to 
subsequent confirmation or refutation of findings. The science of astronomy was 
drastically altered through the shift from a geocentric to a heliocentric view of the 
universe. In the geocentric view proposed by Ptolemy in the 2
nd
 century, the sun and 
planets revolved around an immobile earth.
 21 
However, in 1543, Copernicus proposed 
the heliocentric view, where the world and other celestial bodies are spherical with 
everlasting circular movements, and the world revolved on its axis in its circular 
movement around the sun. 
22
 This example demonstrates an evidence reversal as a 
paradigm shift in an entire field of research, as well as in the entire worldview. 
Originally, reversal was only defined as a medical reversal with effects only within the 
medical field. This thesis seeks to expand that definition to include all evidence and 
science, not just the medical field. Since the medical field is the leading edge of evidence 
reversal, the scope of this thesis will be limited to medicine.  
In many areas of scientific enquiry, scientific theories are accepted as ‘scientific laws’ 
only in the face of overwhelming evidence that creates a stable predictive model – mature 
evidence. In medicine this orderly march of evidence with repeated testing until 
uncertainty is adequately reduced prior to translation to practice is not always respected 
or even expected due to the limitations of time and other resources to adequately test all 
relevant clinical questions. Consequently, evidence reversals should, to some degree, be 
recognized as an expected part of the maturing scientific process; identified and handled 
appropriately through disinvestment when reversals occur. Without the ability to 
recognize and manage reversals, EBM may lose credibility. 
25
 Accountability for 
disinvestment of reversed practices and higher standards for implementation would help 
to better retain credibility. Patients may be protected from ultimately flawed care and 
resources may be saved from unnecessary and wasted efforts of implementation and de-
implementation if medical practices are supported by a sufficient, stable and mature 
evidence base.  
22 
 
22 
Healthcare must be accountable for the abandonment of low-value practices. This 
abandonment may be driven through disinvestment, where established clinical practices 
demonstrating little to no net benefit or cost-effectiveness and representing inefficient 
resource allocation have their vital health resource reinforcement withdrawn. 
18,23 
Furthermore, any incentives to continue these practices – such as funding – should be 
removed so that these practices are no longer supported.  
Decisions to invest/disinvest and implement/de-implement any clinical intervention – 
including medications, surgical procedures, medical devices or any intervention that may 
impact health – should be made in context of the quality and quantity of evidence to 
uphold the efficacy and safety of those interventions versus their alternatives. However, 
in reality, adequate evidence does not always precede implementation into practice, and 
may even still be at the stage of low-quality evidence with high risk of bias. Recognition 
that not all research is equal has increased – some evidence is at a higher risk of reversal. 
Practices may be at higher risk of future reversal when evidence is put into practice 
before adequate high quality evidence is generated to prove net benefits outweigh harms 
and costs. 
18,24 
Fundamentally, the gap between a weak evidence base and effective 
patient practice should be closed by undertaking new studies – higher quality than their 
predecessors – to address weak evidence, increase the probability of improved health 
outcomes and pursue replication of findings. Ideally, all replication attempts would be 
published regardless of results and the entire body of evidence could be cumulated to 
determine the overall balance of benefits and risk. Furthermore, subsequent research 
would add to prior, systematic accumulation of evidence. Subsequent research would be 
higher powered, better controlled, or better-targeted research to delineate effect size for 
benefits and risks and increase the quality of the evidence base. Additionally, research 
would be appropriately translated into practice, either: through implementation of 
interventions into practice when evidence sufficiently demonstrates benefits greater than 
associated risks and costs; or though withdrawal or abandonment from practice when 
sufficient research contradicts the promising early findings.  
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1.4 Addressing Evidence Reversal 
Awareness of evidence reversal has emerged in medicine in recent years and has been led 
primarily by Dr. John P. A. Ioannidis of Stanford University and Dr. Vinay Prasad of 
Johns Hopkins University. John P. A. Ioannidis started the momentum in 2005 with his 
article Contradicted and Initially Stronger Effects in Highly Cited Clinical Research, 
when he compared the measured effects of highly cited articles and less cited articles to 
the measured effects of subsequent studies of equal or greater sample size and equal or 
better designs. These highly cited research studies were often followed by studies with 
contradicting results (16%) or with lower effect sizes (16%). Only 44% were replicated, 
24% were not followed by any subsequent studies. 
16
 
Prasad et al published The Frequency of Medical Reversal in reply to Marc W. Deyell et 
al Impact of National Clinical Guideline Recommendations for Revascularization of 
Persistently Occluded Infarct-Related Arteries on Clinical Practice in the United States. 
10,26
 Prasad et al briefly outlined a study wherein they reviewed all Original Articles in 
the New England Journal of Medicine in 2009 looking for evidence reversal. As 
described by Prasad et al, “reversal … signif[ies] the phenomenon of a new trial – 
superior to predecessors because of better design, increased power, or more appropriate 
controls – contradicting current clinical practice.” Of the 124 original articles describing 
a medical practice, 13% demonstrated reversal. 
10
 
Prasad et al repeated this study, with more co-authors and greater scope in A Decade of 
Reversal: An Analysis of 146 Contradicted Medical Practices. Reversal was defined as 
“occur[ing] when new studies – better powered, controlled, or designed than their 
predecessors – contradict current practice.” This study spanned 10 years of original 
publications in the New England Journal of Medicine, from 2001-2010. Of the 1344 
original articles addressing a medical practice, 11% demonstrated reversal. 
9
 
These articles identified medical reversal in the evidence base. This thesis seeks to 
expand reversals to include all evidence as evidence reversal, add the concept of 
evidence maturity, replicate A Decade of Reversal, 
9
 and expand during the replication to 
identify areas of violation as potential predictors of reversal.   
24 
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Many recent efforts have arisen to address concepts which overlap with evidence 
reversals, such as: The UK National Institute for Health and Care Excellence (NICE) 
Database of Uncertainties about the Effects of Treatments (UK DUETs); 
27
 The UK 
National Institute for Health and Care Excellence (NICE) Savings and Productivity and 
Local Practice Collection “Do not do” list; 28 The American Board of Internal Medicine 
(ABIM) Foundation Initiative Choosing Wisely; 
29 
The Canadian Medical Association 
(CMA) Campaign Choosing Wisely Canada; 
30
 and The British Medical Journal (BMJ) 
Campaign Too Much Medicine. 
31
  
Although recent research in the area of Evidence Reversal has created a heightened 
awareness of this concept, many examples of evidence reversal are found in medicine for 
currently used practices. As a formal research area however, Evidence Reversal is an 
emerging field characterized by a variety of terms and definitions for these terms, and as 
a result, frameworks and classifications in this field are underdeveloped with no 
standardization. Given the endeavours to identify evidence reversal in medicine and the 
lack of documentation in the literature, the objective of this thesis is to identify all 
necessary terms and formulate a framework. The core chapters of this thesis consist of 
pairings of systematic reviews to identify all necessary terms and frameworks to 
standardize and organize those terms.  
Chapter 2 and Chapter 3 consist of the first such pairing. Chapter 2 describes the results 
of an umbrella systematic review of the topic of Evidence Reversals to identify terms and 
definitions for concepts related to this field, including evidence maturity for an evidence 
base. Chapter 3 consolidates these terms and definitions into a standardized framework.  
Chapter 4 and Chapter 5 comprise the second pairing. Chapter 4 describes the frequency 
and characteristics of evidence reversal in The New England Journal of Medicine by 
updating A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices by 
Prasad et al to include 2000 to 2014 and expanding it with additional variables for 
identification of potential reasons for reversal, including evidence maturity within a 
single study. 
9
 Chapter 5 combines these reasons into a standardized framework to 
suggest potential predictors for reversal.  
25 
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  Chapter 2
2 A Systematic Overview of Evidence Reversals and the 
Remaining Gaps in the Literature 
2.1 Introduction 
Evidence reversals are “the phenomenon of a new trial—superior to predecessors 
because of better design, increased power, or more appropriate controls—contradicting 
current clinical practice.” 1,2 These reversals cause problems in the medical field because 
some patients are being given ineffective or harmful treatments, causing patients and 
care-givers alike to lose confidence in medicine. 
2
 There have been many endeavours to 
identify evidence reversals in evidence-based medicine, 
1-7
 but it remains an emerging 
topic with little standardization of terms, definitions and classifications. Standardization 
helps to maximize comparability, repeatability, and quality of the evidence, which in turn 
will improve the development of the topic of Evidence Reversal. This review seeks to 
identify the currently used terms, definitions and classifications related to the topic of 
Evidence Reversal as well as introduce methodologies to this topic for determining 
evidence sufficiency, stability and maturity. 
2.2 Methods 
Full Methodology is available through PROSPERO Protocol Registration Number 
CRD42014013768.
 8 
A summary of this protocol is briefly described here. 
2.2.1 Structure of Umbrella Review 
In accordance with the Cochrane Editorial Decision Tree for Overviews we conducted an 
umbrella systematic review because the purpose is to target reviews rather than individual 
trials or studies and to provide a synthesis of results at the review level.
 9
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2.2.2 Search Strategy 
A search strategy was tailored for each database, which includes grey literature and hand 
searches. When available, controlled vocabulary (subject headings) was used in 
conjunction with text word searches (keywords). A combination of relevant subject 
headings (Evidence-Based Practice, Patient Care Management, and Guidelines) and 
keywords (Medical, Clinical, and Standard of Care Reversals or Changes; Divestment, 
Disinvestment or De-Implementation; as well as Surprising or Unexpected Results) were 
used, including a list of researchers in fields that are related to Evidence Reversal (Drs 
Vinay Prasad, John Ioannidis, and Adam Elshaug). Since Evidence Reversal is an 
emerging field, there are very few researchers publishing their work on this topic. These 
researchers are included as they are pioneers in the subject matter. The topics of their 
papers will directly reference evidence reversal and their references or papers citing their 
papers will contain indirect references to evidence reversal, which all are included in the 
eligibility criteria for this review. 
Publications of systematic reviews, meta-analyses, evidence syntheses, reviews and 
collections of studies were included. Observational studies and clinical trials were 
excluded. No language or date restrictions were applied. 
2.2.3 Eligibility Criteria of Included Reviews 
All reviews examining evidence reversal as defined below were included, as well as 
reviews that did not directly use this term or definition of evidence reversal but which 
could be inferred from the text related to evidence reversal. 
1
 
We used the definition of evidence reversal and related concepts pioneered by Prasad et 
al. Evidence reversal was directly defined using as “the phenomenon of a new trial—
superior to predecessors because of better design, increased power, or more appropriate 
controls—contradicting current clinical practice.” 1,2 Indirect inferences to evidence 
reversal discovered in our initial pilot phase included: Medical, Clinical, and Standard of 
Care Reversals or Changes; Divestment, Disinvestment or De-Implementation; as well as 
Surprising or Unexpected Results. 
29 
 
29 
Due to time constraints, study selection was not evaluated in duplicate. 
2.2.4 Data Extraction and Critical Appraisal 
We used customized data extraction forms in Microsoft Excel® to collect information on: 
review design, methodology, and summary of results; as well as evidence reversal terms, 
definitions, and future considerations. Methodological quality of included reviews was 
assessed using A Measurement Tool to Assess Systematic Reviews (AMSTAR) for 
critical appraisal of reviews.
 10 The Screener’s (DS) data extraction and critical appraisal 
assessment was reviewed by another team member (JM) to assure accuracy. 
Data extracted from the review design, methodology, and summary of results included 
author(s), title, digital object identifier (DOI), population, intervention, comparison, 
outcome(s), study design, results (# reversals/population), and conflicts of interest. 
Data extracted from evidence reversal terms, definitions, and future considerations 
included terms used, definitions used, and future considerations. 
The AMSTAR ratings are yes, no, unclear, or not applicable for presence of AMSTAR 
items. These items include: a priori design, duplication of study selection and data 
extraction, comprehensive literature search, publication status in inclusion criteria (grey 
literature search), list of included and excluded studies, characteristics of included 
studies, quality of included studies, appropriate conclusion based on that quality, 
appropriate pooling of findings, likelihood of publication bias, and conflicts of interest. 
2.2.5 Data Analysis 
Descriptive statistics for number of reversals per eligible studies for included reviews are 
reported. A table organizing the collection of terms and definitions for Types of Reversal, 
including the number of reviews describing these terms are shown. Additional tables list 
reasons for reversal posed by included reviews and the number of reviews offering these 
reasons, plus a timeline of publication for included reviews was also constructed. 
30 
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2.3 Results 
2.3.1 Inclusion/Exclusion Screening 
 
Figure 11: PRISMA Flowchart of Screening Thresholds and Eligibility 
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2.3.2 Data Extraction for Included Reviews 
Complete data extraction for included reviews is available in Appendix A: A Systematic 
Overview of Evidence Reversals and the Remaining Gaps in the Literature, Table 12. 
2.3.3 Prevalence of Evidence Reversal 
Most of the included studies were not true systematic reviews, but merely collections of 
examples.
 12-39 
The true systematic reviews addressed different populations and 
interventions, making it impossible for direct comparisons of evidence reversal 
prevalence.
 1,4,40-49
 Full results are in Appendix A: A Systematic Overview of Evidence 
Reversals and the Remaining Gaps in the Literature, Table 13. 
2.3.4 Defining Evidence Reversal 
Our operational definition of evidence reversal occurs when new evidence – better 
powered, controlled or designed than its predecessors – compares established practices or 
theories with lesser or prior practices or theories and contradicts the previous claims 
based on presumably “definitive” evidence from studies originally supporting its uptake. 
Terms and definitions used in the included reviews, as well as the number of reviews 
supporting each term, are listed in Appendix A: A Systematic Overview of Evidence 
Reversals and the Remaining Gaps in the Literature, Table 14. 
Nine reviews used “Medical Reversal” instead of evidence reversal, but their definitions 
were similar to our operational definition. 
1,2,13,24,36,37,50,52,53 
As three of those reviews 
were the rationale for this review, this is unsurprising. 
1,2,50 
For instance, “Contradicted 
established medical practices” 30,32,40 is quite similar in definition, but a study of 
contradicted medical practices focuses on the comparison of initial conceptual studies 
with subsequent research, while evidence reversal compares new evidence to previous 
evidence.
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32 
The “Proteus phenomenon” 32,38,43 also compares initial conceptual studies with 
subsequent research, but is used exclusively in the research silo of systematic reviews of 
genome wide association studies and concentrates on the ineffective portion of the 
evidence reversal. definition. “Inflated results,” 42 “Unfavourable or favourable shifts 
over time,” 44 “Discrepancies of effect over time,” 46 “Spuriously effective treatments,” 32 
“Non-replication,” 48 “Between-study inconsistent results,” 48 “The average time to 
changes in evidence that are sufficiently important to warrant updating systematic 
reviews” 47 and “False positive” 41,42 are also in the realm of how systematic reviews can 
demonstrate evidence reversal, spotlighting the evidence behind the label reversed 
practice. 
“Low value practices,” 12,14,34,49,54 “Obsolete/outmoded/abandoned technologies,” 26 
“Overused or Misused Tests and Treatments,” 29 “Ineffective, non-cost-effective or 
harmful interventions,” 35 “Unnecessary tests, treatments and procedures,” 6 “Ineffective 
or harmful interventions,” 55 “Inappropriate use of testing/procedures,” 23 “Legacy 
items,” 35 “Technology development,” 35 “Unproven Practices,” 44,56 “Sacred Cows,” 
31,33,39,57
 “Snake Oil,” 58-60 “Waste,” 25,54 “Negative Evidence,” 40 “Too Much Medicine,” 
7
 and “Overdiagnosis” 7 refer to descriptions of the reversed practice – qualifications such 
as ineffectiveness and harms outweighing benefits. 
Recommendations based on the evidence and qualifications of practices that have been 
reversed are in the form of “Classes of recommendation – II, IIa, IIb, and III,” 61 “Do not 
do recommendations,” 4 “Grade D Recommendations,” 62 “Grade I Recommendations,” 
62
 “Uncertainty,” 3,45 and “Things Providers and Patients Should Question.” 5 
Terms such as “Research updates most likely to change clinical practice,” 15-22 
“Disinvestment,” 26-28 and “De-implementation” 30 focus on the consequences of evidence 
reversal – changing clinical practice through the removal of reversed items. 
2.3.5 Timeline of Publications 
Publications related to evidence reversal per year are shown in Figure 12 and a timeline 
of publication for included reviews is provided in Table 2. 
33 
 
33 
The genesis of evidence reversal, as defined for this review, began with the use and 
development of Recursive Cumulative Meta-Analysis in 2001. 
45
 Cumulative meta-
analysis and systematic reviews continued to play a role in identifying Evidence Reversal
 
41,42,44,47
 and will continue to play a role in labelling medical practices as Reversed. 
63,64
  
In 2005 and 2006, the Proteus Phenomenon and Contradicted Evidence are introduced 
and are closely related to evidence reversal – comparing initial studies to subsequent 
research and discovering contradicting evidence, often shortly after initial publication. 
32,38,40,43
 
Publications surrounding evidence reversal have been increasing steadily over time since 
2001, but its definition as a Medical Reversal – comparing high quality evidence to 
previous research – its definition has only been accepted since 2011. 2,37 This review, in 
turn, seeks to expand this definition to fit all evidence – and highlights the importance in 
creating an accepted definition of terms for the expansion into all fields of research. 
 
Figure 12: Number of Publications Related to Evidence Reversal per Publication 
Year 
34 
 
34 
Table 2: Timeline of Published Reviews or Collections of Studies Related to 
Evidence Reversal 
Year Date Publication 
2001 30-Jan-01 Evolution of treatment effects over time: empirical insight from recursive cumulative meta-analyses.
45 
2002   
2003 15-Feb-03 Genetic associations in large versus small studies: an empirical assessment.
46 
2004 28-Feb-04 Why do doctors use treatments that do not work?
55 
24-Nov-04 Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time.44 
2005 18-Apr-05 Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in 
molecular genetics research and randomized trials.43  
13-Jul-05 Contradicted and initially stronger effects in highly cited clinical research.40 
01-Sep-05 Molecular bias.38 
2006 17-Nov-06 Evolution and translation of research findings: from bench to where?
32 
2007 06-Jun-07 Non-replication and inconsistency in the genome-wide association setting.
48  
21-Aug-07 How Quickly Do Systematic Reviews Go out of Date? A Survival Analysis.47 
01-Oct-07 Building the Evidence Base for Disinvestment from Ineffective Health Care Practices: A Case Study in 
Obstructive Sleep Apnoea Syndrome.27 
31-Oct-07 Challenges in Australian policy processes for disinvestment from existing, ineffective health care 
practices.28 
2008 01-Apr-08 Seven evidence-based practice habits: putting some sacred cows out to pasture.
57 
2009 01-Feb-09 Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
41 
25-Feb-09 Scientific evidence underlying the ACC/AHA clinical practice guidelines.61 
02-Mar-09 Identifying existing health care services that do not provide value for money.35 
2010 01-Oct-10 Snake Oil Supplements?
59 
2011 01-Apr-11 Evidence-based practice habits: putting more sacred cows out to pasture.
31 
01-Jun-11 Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in 
subsequent meta-analyses.42 
10-Oct-11 The frequency of medical reversal.
2
 
01-Dec-11 Medical reversal: why we must raise the bar before adopting new technologies.37 
2012 04-Jan-12 Reversals of established medical practices: evidence to abandon ship.
50 
06-Feb-12 A medical burden of proof: Towards a new ethic.13 
25-May-12 Breaking up is hard to do: why disinvestment in medical technology is harder than investment.26 
Fall-2012 Advancing evidence-based practice - a quarterly compilation of research updates most likely to change 
clinical practice.15 
19-Nov-12 Over 150 potentially low-value health care practices: an Australian study.49 
Winter-12 Advancing evidence-based practice - a quarterly compilation of research updates most likely to change 
clinical practice.21  
2013 04-Feb-13 Medical reversal: What are you doing wrong for your patient today?
36 
12-Feb-13 Foregoing low-value care: how much evidence is needed to change beliefs?34 
27-Feb-13 The Value of Low-Value Lists.54 
Spring-13 Advancing evidence-based practice: a quarterly compilation of research updates most likely to change 
clinical practice.17 
01-Apr-13 Putting Evidence Into Nursing Practice: Four Traditional Practices Not Supported by the Evidence.39 
Summer-13 Advancing evidence-based practice - a quarterly compilation of research updates most likely to change 
clinical practice.19 
22-Jul-13 A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices.1 
Fall 2013 Advancing evidence-based practice: a quarterly compilation of research updates most likely to change 
clinical practice.16 
01-Sep-13 Snake Oil Superfoods?58 
03-Sep-13 A "Top Five" list for emergency medicine: a policy and research agenda for stewardship to improve the 
value of emergency care.12 
06-Sep-13 Choosing wisely in headache medicine: the American Headache Society's list of five things physicians 
and patients should question.29 
16-Sep-13 Unproven Therapies in Clinical Research and Practice: The Necessity to Change the Regulatory 
Paradigm.56 
02-Nov-13 Adding value to health care through discontinuation of low-value practices: ESSENCIAL Project in 
Catalonia.14 
35 
 
35 
Winter-13 Advancing evidence-based practice: a quarterly compilation of research updates most likely to change 
clinical practice.22 
01-Dec-13 The reversal of cardiology practices: interventions that were tried in vain.52 
01-Dec-13 When medicine reverses itself: avoiding practice pitfalls.53 
2014 
**As 
of 
July 
22, 
2014 
08-Jan-14 Biomedical research: increasing value, reducing waste.25 
08-Jan-14 Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices.30 
09-Jan-14 Back to the future: Medical reversals and perioperative medicine.24 
01-Feb-14 Snake Oil Version 2.60 
Spring-14 Advancing evidence-based practice - a quarterly compilation of research updates most likely to change 
clinical practice.18 
01-Apr-14 Examining the Evidence to Guide Practice: Challenging Practice Habits.33 
Summer-14 Advancing evidence-based practice - a quarterly compilation of research updates most likely to change 
clinical practice.20 
2.3.6 Modified “A Measurement Tool to Assess Systematic 
Reviews” (AMSTAR) Item Ratings for Individual Included 
Reviews and Aggregate Scores 
A modification of the AMSTAR tool was used to rate the quality of the reviews included 
in our umbrella systematic review of evidence reversals. The modification involved 
excluding AMSTAR Items 9) Appropriate Pooling of Findings and 10) Likelihood of 
Bias, which were labelled as “N/A – deviation from high methodological practice would 
not appreciably bias results” for all included reviews since pooling of results across 
different Populations, Interventions, Comparators, Outcomes, Timing and Study Designs 
(PICOTS) is illogical. As a result of this modification, the maximum number of points 
that a review could achieve on AMSTAR was nine. 
Included reviews were rated very low quality on the modified AMSTAR, which is to be 
expected because our permissive inclusion criteria allowed for reviews were not 
systematic reviews since this field of enquiry is still new and emerging (Table 3 and 
Figure 13). A total of 81% of included reviews scored a two or lower on the modified 
AMSTAR with an average score of 1.93 out of a possible nine points.  
Only the National Institute for Health and Care Excellence (NICE) “Do not do” List 
received a score of eight – missing only a reference to conflicts of interest present in 
studies used to generate guidelines. 
4
 The next highest score was a tie at five - Over 150 
potentially low-value health care practices: an Australian study by Elshaug et al
 49
 and 
Can trial sequential monitoring boundaries reduce spurious inferences from meta-
analyses? by Thorlund et al.
 41 
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None of the included reviews commented on the declared or undeclared conflicts of 
interest within their respective studies. Few of the included reviews evaluated the quality 
of their included studies (9%) or integrated study quality considerations into their overall 
conclusions and recommendations (9%). Appropriate reports of literature searches (3%) 
and lists of excluded studies (2%) were rarely provided within the included reviews. 
Number of databases searched and number of people screening or extracting data was 
unclear for 72% and 78%, respectively, of included studies. The only AMSTAR item 
with a moderate level of confidence was AMSTAR Item 6) Reported Characteristics of 
Included Studies (84%). The remaining AMSTAR items fall under low or very low level 
scores that indicate that the reader should attribute a low level of confidence in the 
conclusions provided by these reviews (Table 3 and Figure 13).  
Similarly, synthesis of the modified AMSTAR confidence rating across all included 
reviews suggests that existing conclusions from the umbrella review can provide 
conclusions only with very low confidence (18%) due to underlying limitations in the 
methodologies (Table 3 and Figure 13).  
Complete AMSTAR Item Ratings for included reviews are available in Appendix A: A 
Systematic Overview of Evidence Reversals and the Remaining Gaps in the Literature, 
Table 15. The underlying support for the rating scores is available upon request. 
Table 3: Aggregate of AMSTAR Item Ratings 
AMSTAR Items Yes (%) No (%) Unclear (%) N/A (%) 
01. a priori design 33 (57%) 8 (14%) 17 (29%) 0 (0%) 
02. Study selection and data extraction in 
duplicate 9 (16%) 4 (7%) 45 (78%) 0 (0%) 
03. Comprehensive literature search 8 (14%) 8 (14%) 42 (72%) 0 (0%) 
04. Publication status in inclusion 2 (3%) 45 (78%) 11 (19%) 0 (0%) 
05. List of included and excluded studies 1 (2%) 57 (98%) 0 (0%) 0 (0%) 
06. Characteristics of included studies 49 (84%) 9 (16%) 0 (0%) 0 (0%) 
07. Quality of included studies 5 (9%) 52 (90%) 1 (2%) 0 (0%) 
08. Appropriate conclusions 5 (9%) 52 (90%) 1 (2%) 0 (0%) 
09. Appropriate pooling of findings 0 (0%) 0 (0%) 0 (0%) 58 (100%) 
10. Likelihood of publication bias 0 (0%) 0 (0%) 0 (0%) 58 (100%) 
11. Conflict of interest 0 (0%) 58 (100%) 0 (0%) 0 (0%) 
Total 112 (18%) 293 (46%) 117 (18%) 116 (18%) 
37 
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Figure 13: Visual Aggregate of AMSTAR Item Ratings and Translational 
Confidence Levels 
  
38 
 
38 
2.3.7 Proposed Methodologies for Determining Evidence Maturity 
within Cumulative Meta-Analysis 
Evidence Reversal has recently become an area of research interest, and there is a gap in 
the literature for identification of true reversals and true confirmations where enough 
evidence has been gathered that further research is not necessary. To fill this gap, we 
propose the concepts of evidence maturity, sufficiency, and stability. When combined 
with evidence confirmation and reversal, these concepts will form a ‘theory of Evidence 
Reversal.’ In this context, these terms can be applied to the evolving evidence base to 
serve as indicators of the robustness of evidence for an established practice or theory. 
Evidence maturity determines when enough information has accumulated to imply any 
further research is unnecessary and can be estimated through cumulative meta-analysis 
using sufficiency and stability. Cumulative meta-analysis is a meta-analysis which is 
updated with each trial reported to demonstrate evolution of evidence over time, where 
each line represents the results of the new trial collected in with the results from all of the 
previous evidence. 
63
 Ideally, evidence maturity is calculated using the balance of all 
known risks and all known benefits. 
If initial evidence indicates benefit for an established practice over a prior practice, and 
continues to indicate benefit until it meets the criteria for maturity, then this is mature 
evidence confirmation. However, if initial evidence indicates benefit for an established 
practice, but subsequent evidence identifies risks, then this is mature evidence reversal. 
Evidence sufficiency occurs when a cumulative meta-analysis adequately demonstrates 
that a clinical practice is statistically superior to another practice or placebo. Sufficiency is 
calculated through the Failsafe Ratio – the number of studies with null results needed to 
overturn the statistically significant meta-analytic result versus the weight of current 
evidence. A Failsafe Ratio >1 is the threshold implying sufficient evidence to conclude a 
medical practice is more effective than another – unlikely to be overturned through 
further evidence. 
63,64
 Sufficiency is not limited to situations of statistical significance 
such as sufficiently narrow 95% confidence intervals around the line of no effect to rule 
out clinically relevant effects. 
39 
 
39 
Evidence stability occurs when the direction and magnitude of the measured effect is 
consistent over time as new studies are added to the meta-analysis. Stability is calculated 
through the regression line’s cumulative slope of cumulative results repeated over time. 
A cumulative slope estimate <0.005 from this linear regression implies stability of the 
evidence to conclude it is unlikely that further evidence will shift the direction and 
magnitude of the measured cumulative effect. 
63,64
 
 
2.4 Discussion 
2.4.1 Strengths and Weaknesses of Review and in Relation to 
Other Reviews 
This review was very labour-intensive and needs to be completed by a team of reviewers 
such that screening is performed independently and in duplicate with Kappa statistics 
calculated after each screening level for agreement. Data extraction and risk of bias 
assessment should also be performed independently and in duplicate, particularly since 
risk of bias judgements can be subjective when items are not clearly stated. 
Since included reviews are of very low quality they should be interpreted on the basis 
that not all studies were systematic reviews, therefore there is very low confidence in the 
conclusions and recommendations of this umbrella review. This is the first overview 
review conducted on the topic of Evidence Reversal. Evidence reversal occurs in the 
medical literature in highly cited articles 
40,42 
and high impact journals. 
1,2
  
The strength of this study is the inclusive nature of the search strategy, which should have 
captured the vast majority of relevant reviews related to the emergent topic of evidence 
reversal. Additional search terms were discovered during the screening process that 
would have expanded the search criteria: excess significance, comparative effectiveness 
research, health technology assessment, reanalyses of randomized clinical trial data, 
reanalyses of randomized controlled trials, reproducibility, reassessment, spurious 
inferences, obsolete/abandoned technologies, unnecessary/excessive tests/treatments, 
overdiagnosis, overtreatment, the Proteus phenomenon, updated guidelines downgrading 
prior claims and authors Ray Moynihan, Shannon Brownlee, and Adam Cifu. 
40 
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Lacking in the addition to the definition of evidence sufficiency is a method to measure 
sufficiency when there is no difference between the compared interventions. 
2.4.2 What This Review Adds to the Literature Surrounding 
Evidence Reversal 
Expands Evidence Reversal to Include General Science 
Prior evidence focused on medical literature and medical practices. 
1,2,40,50
 This review 
expands the definition of reversal to include evidence reversal in all scientific fields and 
all evidence. Despite this expansion, the scope of this thesis remains firmly in the 
evidence of evidence-based medicine. 
The expanded definition for Evidence reversal occurs when new evidence – better 
powered, controlled or designed than their predecessors – contradicts previous claims, 
upsetting established practices and theories based on presumably “definitive” evidence 
from original studies.  
Informs the Development of Framework for Evidence 
Reversal 
This review will inform the development of framework to standardize evidence reversal 
terms and definitions, which promotes the consistent use of terms and concepts for 
universal discussion of this topic and higher quality reviews on this topic in the future. 
Proposes the Incorporation of Methodologies for 
Determining Evidence Sufficiency, Stability and Maturity 
into the field of Evidence Reversal 
This review suggests measures of evidence sufficiency and stability to lay a foundation 
for when evidence has matured as a reversal or confirmation such that additional 
research for efficacy and benefit is superfluous. 
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2.5 Conclusions 
2.5.1 Unanswered Questions 
The concept of evidence reversal has been identified in medical literature, and now the 
term and its definition needs to be: standardized; more highly integrated and recognized; 
and the reasons behind its occurrence need to be investigated. Additionally, a unifying 
theory or underlying framework would be beneficial to aid conceptualization of the issue 
of evidence reversal and its relationship to other related concepts.  
The presence of evidence reversal is evident in medical practice but can the term become 
a mainstream science analog verified independently in all journals – not simply in highly 
cited, and high impact medical journals?  
2.5.2 Future Research 
A framework for evidence reversal will aid in standardizing related terms and their 
definitions to maximize comparability, repeatability, and quality of the evidence, which 
will advance work on the topic of Evidence Reversal. 
Alternate measures of evidence maturity should be investigated to find robustness of 
evidence that do not require a cumulative meta-analysis for verification. Predictive tools 
could prove useful as alternate measures of evidence maturity where the evidence base 
lacks sufficient and stable evidence. These predictive tools could be developed from an 
investigation into reasons underlying evidence reversal for the probability of reversal. 
Current research related to Evidence Reversal is of very low quality and focuses on 
collections of studies and future research needs to be of higher quality, applied to 
systematic reviews, and more transparent to allow for independent replication.   
42 
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  Chapter 3
3 Defining Evidence Reversal Framework 
3.1 Introduction 
Evidence reversal occurs when new evidence contradicts the use of established practices 
or theories. Since the topic of Evidence Reversal is still developing, its associated terms, 
definitions and classifications have not been fully formed or standardized. Despite recent 
endeavours to identify evidence reversal in medical practice, the lack of standardization 
may mean that research pertinent to Evidence Reversal and its effect on clinical practice 
is overlooked because there are so many different terms for the same concepts. 
1-7
 
Standardization of these terms and definitions into a framework can further clarify 
understanding in this important emerging topic as well as maximize comparability, 
repeatability, and quality of its evidence. 
This thesis seeks to initiate and inform the development of such a framework for the topic 
of Evidence Reversal and its related concepts. 
3.2 Methods 
Full Methodology is available through PROSPERO Protocol Registration Number 
CRD42014013768. 
8
 A summary of this protocol is briefly described here and previously 
in Chapter 2. 
3.2.1 Search Strategy 
Available controlled vocabulary and text word searches were tailored for each database 
using relevant subject headings, key words and a list of Evidence Reversal specialists 
with foremost publications in the field. 
Included publications were systematic reviews, meta-analyses, evidence syntheses, 
reviews and collections of studies. Excluded publications were observational studies and 
clinical trials. No language or date restrictions were applied. 
48 
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3.2.2 Eligibility Criteria of Included Reviews 
All reviews directly and indirectly defining evidence reversal were included under the 
direct definition of evidence reversal by Prasad et al: “the phenomenon of a new trial—
superior to predecessors because of better design, increased power, or more appropriate 
controls—contradicting current clinical practice.” 9,10 
Indirect definitions of evidence reversal include: Medical, Clinical, and Standard of Care 
Reversals or Changes; Divestment, Disinvestment or De-Implementation; as well as 
Surprising or Unexpected Results. These terms were acquired during an initial pilot phase 
of this review. 
Study selection was not evaluated in duplicate due to time constraints. 
3.2.3 Data Extraction and Critical Appraisal 
All previously obtained reviews from Chapter 2 were examined to identify the following 
using a customized data extraction form in Microsoft Excel®: Evidence Reversal terms, 
definitions, future considerations and measure methodological quality using the 
AMSTAR Measurement Tool to Assess Systematic Reviews. 
11
 
Data extraction and critical appraisal (DS) was reviewed by another team member (JM) 
for correctness.  
3.2.4 Data Analysis 
A descriptive synthesis of extracted data from the previously obtained reviews was used 
to develop a new draft framework summarizing and condensing the different terms and 
definitions for Evidence Reversal. 
  
49 
 
49 
3.3 Results 
3.3.1 Review of Reviews: 
The data set contained 36 terms and 73 definitions for evidence reversal. Of these, nine 
included reviews used the term “Medical Reversal” and definitions similar to our direct 
definition of evidence reversal used as inclusion criteria for the previously obtained set of 
reviews. 
9-18 
The direct definition of evidence reversal used as inclusion criteria occurs: 
“when new studies – better powered, controlled or designed than its predecessors – 
contradict current practice.” 9,10 
Other potential terms such as the “Proteus phenomenon” 19-21 and “Contradicted 
established medical practices
” 20-23
 use a comparison between initial conceptual studies 
and subsequent research, whereas most evidence reversal terms focus on new evidence 
added to an established evidence base. 
Nine reviews used terms and definitions to demonstrate utility of systematic reviews in 
identifying reversal of evidence. These terms included: “Inflated results”; 24 
“Unfavourable or favourable shifts over time”; 25 “Discrepancies of effect over time”; 26 
“Spuriously effective treatments”; 20 “Non-replication”; 27 “Between-study inconsistent 
results”; 27 “The average time to changes in evidence that are sufficiently important to 
warrant updating systematic reviews”; 28 and “False positive”. 24,29 
Qualities of reversed practices used sixteen terms: “Low value practices”; 30-34 
“Obsolete/outmoded/abandoned technologies”; 35 “Overused or Misused Tests and 
Treatments”; 36 “Ineffective, non-cost-effective or harmful interventions”; 37 
“Unnecessary tests, treatments and procedures”; 4 “Ineffective or harmful interventions”; 
38
 “Inappropriate use of testing/procedures”; 6 “Legacy items”; 37 “Technology 
development”; 37 “Unproven Practices”; 25,39 “Sacred Cows”; 40-43 “Snake Oil”; 44-46 
“Waste”; 34,47 “Negative Evidence”; 22 “Too Much Medicine”; 5 and “Overdiagnosis”. 5 
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Graded recommendations of medical practice evidence for evidence reversal are “Classes 
of recommendation – II, IIa, IIb, and III”, 48 “Do not do recommendations”, 2 “Grades D 
and I Recommendations”, 7 “Uncertainty”, 1,49 and “Things Providers and Patients Should 
Question”. 3 
Three terms focus on the effect of reversed evidence and their removal from clinical 
practices: “Research updates most likely to change clinical practice”, 50-57 
“Disinvestment”, 35,58,59 and “De-implementation”. 23  
In general, the overall quality of included reviews is very low.
 2.3.6
 Given that the topic of 
Evidence Reversal is still in the early stages of its development, low quality is not 
surprising. 
3.3.2 Evidence Reversal Definition Evolution 
A timeline of terms and definitions from each publication is provided in Table 4. This 
table illustrates the evolution of the terms and associated definitions for evidence reversal 
over time as greater awareness and focus develops the field of Evidence Reversal. 
Our direct definition used for inclusion criteria involved the evolution of the concept first 
launched by the use and construction of Cumulative Meta-Analysis in 2001. 
49 
Continuing use of meta-analyses and systematic reviews was crucial to identifying 
reversed practices in Medical literature 
24,25,28,29 
and is essential for detecting matured 
reversals in the literature.  
Evidence reversal as a concept continues to develop in 2005 and 2006 as early 
publications on a topic, particularly in Genome Wide Association (GWA) Studies, is 
compared with subsequent research and found contradicting evidence occurring shortly in 
the publication cycle. This discovery was named the “Proteus Phenomenon” and 
“Contradicted Evidence.” 19-22 
The currently accepted direct definition of evidence reversal for our inclusion criteria was 
based on “Medical Reversal”, a term that has only been utilized since 2011. 10,16 
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Table 4: Terms and Associated Definitions for Evidence Reversal Development over 
Time, from January 01, 2001 to July 22, 2014 
Year Terms used 
2001 Uncertainty. 
49 
- “How much the treatment effect has changed over time and how much the pooled treatment effect will change in 
the future.” 49 
2002  
2003 Discrepancy. 
26 
- “Magnitude of the genetic effect as it changes over time.” 26 
2004 Ineffective or Harmful Interventions. 
38 
- “Treatments previously commonly practiced, but now known to not work or cause harm.” 38 
Unfavourable or Favourable Shifts over Time. 25 
- “Changes in whether results become less or more favorable for the experimental intervention over time.” 25 
2005 Contradicted. 
22 
- “Subsequent research contradicts efficacy claim.” 22 
Initially Stronger Effects. 22 
- “Subsequent research shows smaller magnitude of efficacy claim.” 22 
Proteus Phenomenon. 19,21 
- “Rapid, early succession of very contradictory conclusions.” 19 
- “Extreme between-study opposing estimates of effect in the results of early studies followed by studies with 
diminishing between-study variance.” 21 
2006 Proteus Phenomenon.
 20 
- “Rapid alternation between exaggerated claims and extreme contradictions in early studies followed by studies 
with diminishing effects for the strength of research findings.” 20 
2007 Change in Evidence. 
28 
- “Quantitative changes include differences of statistical significance or ≥50% effect change in magnitude for 
important outcomes. Qualitative changes include differences in definition of effectiveness, new data on harm, 
and caveats about previous evidence.” 28 
Disinvestment. 58, 59 
- “The processes of withdrawing (partially or completely) resources from any existing healthcare practices, 
procedures, technologies or pharmaceuticals that are deemed to deliver little or no health gain relative to their 
cost, and thus are not efficient health resource allocations.” 58 
- “Removing currently used ineffective, or inappropriately applied, health care practices.” 59 
Inconsistency. 27 
- “Inconsistency occurs when there is large between-study heterogeneity (diversity) in the magnitude of the 
genetic effects.” 27 
Non-Replication. 27 
- “Occurs when the GWA study proposes that there is a gene-disease association, but the accumulation of data 
from subsequent studies find no genetic effect.” 27 
2008 Sacred Cows. 
43 
- “Practices are considered routine and beyond dispute” 43 
- “A clinical practice despite research that shows that the practice is not helpful and may even be harmful to the 
patients we serve.” 43 
52 
 
52 
2009 Class II Recommendation. 
48 
- “Class II: conditions for which there is conflicting evidence and/or a divergence of opinion about the 
usefulness/efficacy of a procedure or treatment.” 48 
- “Class IIa: weight of evidence/opinion is in favor of usefulness/efficacy.” 48 
- “Class IIb: usefulness/efficacy is less well established by evidence/opinion.” 48 
Class III Recommendation. 48 
- “Class III: conditions for which there is evidence and/or general agreement that the procedure/treatment is not 
useful/effective and in some cases may be harmful.” 48 
False Positive Result. 29 
- “Report a treatment effect when in reality there is no effect.” 29 
Ineffective, Harmful, or Non-Cost-Effective Interventions. 37 
- “Ineffective, non-cost-effective or harmful interventions.” 37 
Legacy Items. 37 
- “Long-established technologies that have never had their cost-effectiveness assessed — look for coupling with 
other identification items. Automatically considered and assessed for disinvestment.” 37 
Technology Development. 37 
- “When an intervention has evolved to the point that it differs markedly from the initial or prototype intervention 
that was originally assessed or funded, then the initial intervention should be reviewed (eg, 256-slice compared 
with four-slice computed tomography).” 37 
2010 Snake Oil. 
45 
- “Nutritional supplements that are not worth it (inconclusive, slight or no evidence of efficacy).” 45 
2011 False Positive and Inflated Results. 
24 
- “Report a treatment effect when in reality there is no effect.” 24 
- “RRs were in opposite direction, larger, more than twice as large, more than 4 times as large, or different 
beyond chance in the highly cited vs the largest study and in the highly cited study vs the meta-analysis.” 24 
Medical Reversal. 10,16 
- “The phenomenon of a new trial—superior to predecessors because of better design, increased power, or more 
appropriate controls—contradicting current clinical practice.” 10 
- “The phenomenon of a new trial — superior to predecessors because of better design, increased power, or more 
appropriate controls – contradicting current clinical practice.” 16 
- “A medical practice falls out of favor not by being surpassed, but when we discover that it did not work all 
along, either failing to achieve its intended goal or carrying harms that outweighed the benefits.” 16 
Sacred Cows. 40 
- “Practices are considered routine and beyond dispute.” 40 
- “A clinical practice despite research that shows that the practice is not helpful and may even be harmful to the 
patients we serve.” 40 
2012 Disinvestment. 
35 
- “The process of withdrawing health resources from any existing healthcare practices, procedures, technologies 
and pharmaceuticals that are deemed to deliver no or low health gain for their cost and thus [do] not [represent] 
efficient health resource allocation.” 35 
- “The cessation or restriction of potentially harmful, clinically ineffective or cost inefficient practices.” 35 
- “The process of taking resources from one service in order to use them for other purposes (i.e. reallocation of 
resources).” 35 
Low-Value Practices. 33 
- “Ineffective and/or unsafe services, treatments not proven to be clinical effective.” 33 
Medical Reversal. 12,13 
- “Established standards must be abandoned not because a better replacement has been identified but simply 
because what was thought to be beneficial was not.” 12 
- “Oftentimes, years after a practice was introduced, the medical community puts it to the test in large, well done 
randomized trials. Empirical evidence suggests that when this happens, nearly half of those practices are 
contradicted. We call this phenomenon ‘medical reversal’.” 13 
Obsolete/Outmoded/Abandoned Technologies. 35 
- “Those that have been superseded or demonstrated to be ineffective or harmful.” 35 
Research updates most likely to change clinical practice. 50,56 
- “Research updates most likely to change clinical practice.” 50,56 
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2013 Low-Value Practices. 
30-34 
- “Clinical decisions that are of little value to patients, amenable to improvement through standardization, and 
actionable by front-line providers.” 30 
- “Ineffective or lack evidence on their effectiveness, negative risk-benefit balance, more cost-effective 
alternatives exists, obsolete due to the introduction of new technologies.” 31 
- “Interventions that robust evidence reveals are of no benefit, or even harmful.” 32 
- “Health care services that provide little or no benefit – whether through overuse or misuse.” 34 
Medical Reversal. 9,15,17,18 
- “Reversal was designated when a current medical practice was found to be inferior to a lesser or prior standard.” 
9 
- “The phenomenon of a new superior trial that contradicts current clinical practice.” 15 
- “Medical reversal happens when new trials—better powered, designed or controlled than predecessors--
contradict current standard of care.” 17 
- “Modifications or even retractions, of important medical practice recommendation… [which] Challenge 
traditional medical opinion” 18 
Overused or Misused Tests and Treatments. 36 
- “Unnecessary tests and procedures that don’t benefit the patient and can even cause harm.” 36 
Research updates most likely to change clinical practice. 51,52,54,57 
- “Research updates most likely to change clinical practice.” 51,52,54,57 
Sacred Cows. 42 
- “Practices are considered routine and beyond dispute.” 42 
- “A clinical practice despite research that shows that the practice is not helpful and may even be harmful to the 
patients we serve.” 42 
Snake Oil. 46 
- “Nutritional supplements that are not worth it (inconclusive, slight or no evidence of efficacy).” 46 
Unproven Therapies. 39 
- “No proven value by current Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) guidelines, US Preventive Task Force Services criteria, or other similar criteria.” 39 
Waste. 34 
- “Inappropriate overuse of an otherwise effective intervention.” 34 
2014 
*As 
of 
July 
22, 
2014 
Contradicted established medical practices. 23 
- “When large, well-done randomized trials have contradicted current medical practice.” 23 
De-implementation. 23 
- “Abandonment of medical interventions.” 23 
- “Stopping practices that are not evidence-based.” 23 
Medical Reversal. 14 
- “A phenomenon in which ‘a medical practice is found to be inferior to some lesser or prior standard of care.’” 14 
 [Sacred Cows] Practices Not Supported by the Evidence. 41 
- “Practices are considered routine and beyond dispute.” 41 
- “A clinical practice despite research that shows that the practice is not helpful and may even be harmful to the 
patients we serve.” 41 
Snake Oil. 46 
- “Nutritional supplements that are not worth it (inconclusive, slight or no evidence of efficacy).” 46 
Research updates most likely to change clinical practice. 53,55 
- “Research updates most likely to change clinical practice.” 53,55 
Research Waste. 47 
- “Avoidable waste or inefficiency in biomedical research.” 47 
Unproven medical practice. 41 
- “Many medical practices are largely untested or have insufficient evidence unable to support or refute 
interventions.” 41 
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3.4 Proposed Framework 
Our proposed framework focuses on specific components of Evidence Reversal: 
classification of evidence, levels of evidence, reasons for reversal, consequences of 
reversal, and recommendations. For clarification purposes, our preferred operational 
definitions of terms are provided in boxes linked to each section. 
3.4.1 Classifying Evidence 
To identify evidence reversal and related terms in the evidence base, we need to first 
classify these terms and standardize how they are detected. Table 5 seeks to illustrate the 
mechanism through which reversals and related terms are detected and classified. Any 
comparison between new research of an established practice and an inferior or prior 
practice that contradicts its use is a reversal. If new research continues to support its use, 
then this is a confirmation. Any comparison between new research on a new practice to 
an established practice such that the new practice is superior is a replacement. If this 
comparison shows that the new practice is no different or inferior to current practice, this 
is an equivalent or less practice. 
Table 5: Classification of Evidence 
Practice Comparison Superior Practice Classification of Evidence 
New vs Current  New  Replacement 
New vs Current  Current Equivalent or Less 
Current vs Inferior / Prior  Current  Confirmation 
Current vs Inferior / Prior Inferior / Prior Reversal 
To be a valid reversal, confirmation, replacement, or equivalent or less, the study design, 
execution, and analysis of trials or studies must be assessed for quality. Several tools 
exist for evaluation of study design, execution, and analysis. By sequentially linking 
these tools, we can follow a study from inception, to operation, and then on to publication 
while monitoring the quality of reporting at each stage.  
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A Populations, Interventions, Comparators, Outcomes, Timing and Study Designs 
(PICOTS) assessment can evaluate quality of a study’s reported inception and question. 
62
 A PICOTS evaluation determines if aspects of a study’s question are sufficiently 
described and appropriate. These aspects are: population studied and appropriateness of 
chosen population; intervention used and appropriateness of intervention studied, 
including timing and dosage; comparator used and appropriateness of chosen comparator 
as well as timing and dosage; outcomes selected and appropriateness of selected 
outcomes, plus if they are patient-important, composite, or surrogate outcomes; timing or 
length of follow-up and whether the outcomes could have occurred in that time frame; 
and study design and whether the selected study design was appropriate. Evaluations of a 
study’s design can identify deviances from well-composed and transparent study designs. 
Evaluating a study’s inception and question has broader implications not only on overall 
study outcome measures, but also on execution and overall study quality. 
A Risk of Bias assessment helps evaluate quality of a study’s design and execution. 62 
Validated Risk of Bias assessment tools include: The Cochrane Collaboration’s Tool for 
Assessing Risk of Bias (ROB) 
63 
for trials and A Cochrane Risk Of Bias Assessment 
Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI) 
64
 for 
observational studies. A ROB evaluation determines the level of risk of bias for aspects 
of a study’s design and execution. The levels of risk are definitely high, probably high, 
probably low, or definitely low risk of bias. The aspects are: sequence generation or 
randomization; allocation concealment or disguise of group assignment; blinding or 
cover-up of intervention provided; completeness of outcome data or presence of missing 
data; completeness of reported outcomes or presence of missing outcomes; and other 
sources of bias. 
63
 Evaluations of a study’s design and execution can identify deviations 
from transparent, well-executed study designs can affect study analysis. 
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A Grading of Recommendations Assessment, Development and Evaluation (GRADE)
 
can evaluate the features of a meta-analysis’ report and analysis. 65 A modified and 
unvalidated GRADE (mGRADE) assessment applied to individual studies can evaluate 
those same features within the context of a single study. A GRADE assessment 
determines the level of quality of aspects of a meta-analysis’ report and analysis while a 
mGRADE determines the level of quality in a single study. Quality ratings are high, 
moderate, low, and very low quality. Aspects of GRADE are: study design; risk of bias; 
directness and applicability; imprecision; and publication bias for quality of evidence 
analysis and reporting. Modifications to GRADE for mGRADE include: no changes to 
how study design is evaluated; risk of bias using the ROB assessment; directness and 
applicability using the PICOTS assessment; imprecision using a modified optimal 
information size assessment; and publication bias based on differences between trial 
registration and final report. Evaluation of a study’s analysis and report can identify the 
severity of any deviances from transparent, well-analyzed study designs and their 
adoption into practice. 
62
  
If these assessments for new evidence demonstrate higher quality than previous evidence, 
then it is a valid reversal, confirmation, replacement, or equivalent or less. 
 
Evidence Replacement occurs when new evidence – better designed, executed or 
analyzed than its predecessors – verifies superiority of a new practice over established 
practices and theories.  
Evidence Equivalent or Less occurs when new evidence – better designed, executed or 
analyzed than its predecessors – fails to demonstrate superiority of a new practice over 
established practices and theories, or when an effect fails to rule out clinically important 
effect sizes. 
Evidence Confirmation occurs when new evidence – better designed, executed or 
analyzed than its predecessors – verifies previous claims, confirming superiority of 
established practices and theories over lesser or prior standards. 
Evidence Reversal occurs when new evidence – better designed, executed or analyzed 
than its predecessors – contradicts previous claims, upsetting established practices and 
theories based on presumably “definitive” evidence from original studies. Evidence 
showing no efficiency or harms outweighing benefits should involve endpoints and 
controls at least as rigorous as the previous evidence to contradict previous claims and 
upset practice. 
Box 1: Proposed Framework for Classifying Evidence   
57 
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3.4.2 Level of Evidence 
Once evidence has been classified as a valid reversal, confirmation, replacement, or 
equivalent or less the authenticity of this conclusion must be assessed. Cumulative meta-
analysis is currently the best way of determining robustness of evidence as it is updated 
with each subsequent published study and illustrates the evolution of evidence over time. 
60
 Through this process, scientific methods can reveal maturation of evidence. 
Maturation of evidence occurs when evidence for a conclusion is so robust that any more 
evidence is wasteful. Evidence maturity is best shown in a cumulative meta-analysis 
using measures of sufficiency and stability. Any cumulative meta-analysis that 
demonstrates both sufficiency and stability is matured evidence.  
Sufficient evidence clearly proves that one practice is statistically superior to another 
practice or placebo. The Failsafe Ratio is used to determine evidence sufficiency and if 
this ratio is >1, then the evidence is sufficient.  
𝐹𝑎𝑖𝑙𝑠𝑎𝑓𝑒 𝑅𝑎𝑡𝑖𝑜 =  
(
(Σ𝑍)
(1.645)2
) − 𝑘𝑖
5𝑘𝑖 + 10
 
Where ∑Z = the sum of the z values from individual study results and ki = the number of 
studies included in the meta-analysis at wave i (the number of times the meta-analysis has 
been updated because of a newly published study). 
60,61
 Sufficient evidence also shows 
when there is no difference between the two practices. No difference is shown when the 
point estimates of an effect converge on the line of no effect and the 95% confidence 
intervals narrow beyond the Minimal Clinically Important Difference (MCID). Any 
additional research would no longer find clinically relevant effects – effects too small to 
be felt by a patient. Sufficient evidence is unlikely to be overturned through additional 
research. 
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Stable evidence shows very little movement of effect over time as new studies are added 
to the cumulative meta-analysis. The direction and magnitude of effect are consistent 
over time if the point estimates start to line up at the same size of effect and are on the 
same side of the line of no effect. The threshold for stability is a regression line 
cumulative slope of < 0.005 of cumulative results repeated over time. 
60,61
 Stable 
evidence is unlikely to shift in direction or magnitude through additional research.  
Maturity of evidence should be paired with other evidence classifications to authenticate a 
valid confirmation, reversal, replacement or equivalent or less.  
 
Evidence Sufficiency occurs when a cumulative meta-analysis demonstrates that one 
practice is statistically superior to another practice – or placebo if a comparison practice 
is not available. Indicated by a Failsafe Ratio >1.  
Occurs when a cumulative meta-analysis demonstrates that there is no difference between 
the practices. Indicated by 95% confidence intervals that do not cross the lines of 
minimal clinically important difference (MCID). 
Evidence Stability occurs when the effect size from a cumulative meta-analysis is 
consistent over time in terms of both direction and magnitude of effect as new studies are 
added. Indicated by a Regression Line Cumulative Slope of <0.005.  
Evidence Maturity occurs when a cumulative meta-analysis demonstrates both 
Sufficiency and Stability, indicating that additional research is superfluous and unlikely 
to overturn this conclusion.  
This term is paired with Evidence Classifications: Matured Reversal of Evidence, 
Matured Confirmation of Evidence, Mature Replacement of Evidence, or Mature 
Equivalent or Less Evidence. 
Box 2: Proposed Framework for Level of Evidence 
3.4.3 Indications of Reversed Medical Practices 
There are several indications of reversed practices: they are ineffective; 
6,7,12,14,16,22,24,29-
38,40-48,58,59 
their harms outweigh their benefits; 
4-7,16,22,31-33,35-38,40-43,48 
they are inferior to 
prior/lesser practice; 
9,14,22
 they lack evidence proving efficacy 
1,7,31,33,37,44,45,46,48 
such that 
confidence intervals fail to incorporate even minimally clinically important differences 
(MCID); they are overused/misused; 
3,4,5,25,34,36,39,59
 they are of low value/not cost-
effective; 
4,6,30,31,35,37,39,58 
and/or the evidence challenges use of traditional 
practices.
1,2,7,9,10,12-18,22,23,38,40-43,50-57
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3.4.4 Proposed Actions of Evidence Reversal on Medical 
Practices 
The definition and traits of mature reversed medical practices mark them unsuitable for 
use in healthcare.
 
Ideally, mature reversed practices could be easily removed and a prior 
practice would just replace them, but this mindset is naïve to the many other factors 
surrounding removal of practices, such as policy, infrastructure, resource allocation, and 
effectiveness in subpopulations. De-implementation implies that these additional factors 
need to be proactively addressed through carefully sequenced actions in order to 
strategically and safely remove the reversed intervention from practice while replacing it 
with alternate practice(s). 
23
  
Disinvestment occurs when investment of health resources is withdrawn from matured 
reversed medical practices or immature reversed or confirmed practices. 
35,58 
Lack of
 
funding or decreased funding towards continued use of a reversed healthcare practice 
encourages slow de-implementation. Other approaches beyond this withdrawal of funding 
may be required, such as reduction in supporting or interdependent processes which 
typically have reinforced the intervention within the healthcare system. These processes 
could involve changing medical policies or procedures, decreasing available operating 
room time for a procedure, or decreasing available support staff. 
 
De-implementation occurs when Matured, Reversed practices are removed from 
practice. 
Disinvestment occurs when investment of healthcare resources is withdrawn from 
immature practices or Matured, Reversed practices. 
Box 3: Consequences of Reversed Medical Practices 
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3.4.5 Tiered Recommendations for Medical Practices 
Different pairings between classifications and levels of evidence require distinct proposed 
actions. Mature practices should be considered sufficient and stable enough for 
implementation into practice or de-implementation out of practice. Further research into 
mature evidence is considered inefficient and unnecessary use of limited research 
resources.  
Immature evidence, however, requires more research before a decision should be made. 
Immature established practices should be a high priority for research to generate enough 
evidence to evaluate stability and sufficiency for maturity of this evidence. Once the 
evidence is mature, further actions such as implementation, dis-investment, or de-
implementation are fully justified. While the evidence remains immature, there is only 
weak justification for the practice and any established practice should be disinvested in 
until evidence reaches maturity or it gets replaced by a new practice that demonstrates 
evidence maturity.  
 
Evidence 
Class 
Level of 
Evidence 
Proposed Actions 
Replacement Mature Implement 
Replacement Immature Additional Research is Needed to Implement 
Equivalent or 
Less 
Mature Decision to Implement is Based on Other Factors, 
such as Cost and Convenience 
Equivalent or 
Less 
Immature Additional Research is Needed to Implement or Not 
Confirmation Mature Continue Practice  
Confirmation Immature Disinvest, Additional Research is Needed to 
Continue or De-Implement 
Reversal Mature De-Implement 
Reversal Immature Disinvest, Additional Research is Needed to 
Continue or De-Implement 
Box 4: Tiered Recommendations for Medical Practices 
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3.5 Conclusion 
Current research surrounding evidence reversal terms and definitions has concentrated on 
the field of Medicine; however, comparing new high quality evidence to previous 
evidence is an inherent part of advancing all research – and not limited to Medicine – we 
expand the term to include any and all evidence. The framework proposed in this thesis 
provides a summarization of all current research surrounding evidence reversal by 
aggregating and pairing terms and with definitions. This summation in turn informs 
classification, level, traits, proposed actions and recommendations for evidence. 
Validation and use of this framework could assist in universality and generalizability of 
future research into Evidence Reversal while increasing the quality of this research. 
Previously obtained research related to evidence reversal from Chapter 2 is primarily low 
to very low quality as scored by AMSTAR tool. 
2.3.6
 This rating is due to inclusion of 
collections of studies, not only systematic research. To build confidence in the 
recommendations of the field of Evidence Reversal, future research must be of higher 
quality with better transparency of methods and data extraction. 
Evidence reversals have been identified in the evidence base, but their underlying causes 
have yet to be investigated. Identification of their underlying causes could help develop 
and validate a predictive tool for risk of reversal or improve research in general as the 
evidence base and quality measures mature.  
Current measures for evidence maturity require a wealth of research on a topic to 
determine sufficiency and stability, while most topics encounter a dearth of research. 
Alternate measures for maturity for use with a scarcity of evidence must be developed. 
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  Chapter 4
4 A Systematic Examination of Contradicted Practices – 
Initial Pilot Phase 
4.1 Introduction 
Evidence reversal and its related concepts are important in providing solid, justifiable 
basis for Evidence-Based Medicine (EBM). A framework for evidence reversal and 
related concepts should standardize terminology and definitions for widespread use in 
medicine and science. Standardization increases the generalizability, replicability and 
quality of the evidence, which will improve future research into the field of Evidence 
Reversal. Chapter 3 proposes such a framework. The primary objective of this review is 
to identify the classifications of this framework in the New England Journal of Medicine.  
The most robust previous venture into systematic examination of evidence reversal and 
its related concepts is A Decade of Reversal: An Analysis of 146 Contradicted Medical 
Practices by Prasad et al. They investigated the presence of evidence reversal in the New 
England Journal of Medicine from 2000 to 2010. 
1 
This review replicates and exands on 
their work for the years 2000 to 2010, and furthermore updates it to include the years 
2011-2014, and expands it to identify potential reasons why reversals occur. An initial 
pilot phase was performed prior to the full review to: determine the feasibility of this 
replication, update and expansion; improve clarity of inclusion and exclusion language 
and data extraction methods and tools; and improve accuracy and consistency of 
screening and data extraction.  
4.2 Objectives 
1. To quantify the presence of evidence reversals in the New England Journal of 
Medicine. 
2. To characterize the reversals while exploring potential indicators or predictors of 
reversibility. 
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4.3 Methods 
Full methodology is available Appendix B: Evidence Reversal: A Formal Examination of 
Contradicted Medical Practices – Protocol. A summary of this protocol modified for the 
initial pilot phase is briefly described here.  
4.3.1 Search Strategy 
The New England Journal of Medicine was hand-searched for all articles published under 
the heading “Original Article” from 2000-2014 – including replication of the years 2000-
2010 covered by A Decade of Reversal: An Analysis of 146 Contradicted Medical 
Practices by Prasad et al.
 1
  
Articles included in this initial pilot phase represent a random 5% sample of all original 
articles in the New England Journal of Medicine online database from 2000-2014. Data 
sampling was stratified by year, and 5% of the total articles for each year were randomly 
selected using a random number generator in Microsoft Excel®. 
4.3.2 Eligibility Criteria of Included Trials 
In this pilot phase, articles were excluded during the title and abstract screening if they 
did not address a clinical practice. A clinical practice is described by a screening, 
stratifying, or diagnostic test; a medication; a procedure or surgery; or any kind of change 
in health care provision systems. 
1
 All other articles were included. 
Articles were excluded during the full-text screening if they were not randomized trials or 
prospective follow-ups of randomized trials. From this sample, randomized trials or 
prospective follow-ups of randomized trials indicating a medical practice were included. 
Any original article not a randomized trial or indicating a medical practice was excluded.  
Study selection was performed by one review team member (DS). 
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4.3.3 Data Extraction and Critical Appraisal 
Customized data extraction forms were created in Microsoft Excel® to collect information 
on: General information; Methodology; Results; Conclusions; Additional items for 
potential reasons for reversal; and Conflicts of interest. Methodological quality of 
included trials was assessed using a Populations, Interventions, Comparators, Outcomes, 
Timing and Study Designs (PICOTS) Assessment Tool, The Cochrane Collaboration’s 
Tool for Assessing Risk of Bias for randomized studies (ROB) and a Modified Grading 
of Recommendations Assessment, Development and Evaluation (mGRADE) tool. 
2,3
 The 
review team’s (DS, JT, AZ, AP) data extraction and quality assessment was reviewed by 
another team member (JM, DS) to ensure accuracy.  
General information collected included: author(s), title, Digital Object Identifier (DOI), 
date and year of publication, registration number, year of registration, year started, and 
year completed. These last 4 items were extracted from the trial’s registered protocol. 
Methodology information contains: population, intervention, comparison group, primary 
outcome, major secondary outcome, study design, study type, clinical practice type, 
presence of randomization, duration of follow-up, and sample size.  
Results section involves: loss to follow-up, and primary outcome results (point estimate, 
confidence interval, and p-value). 
Conclusions include: author’s endpoint conclusion, if it contradicts current medical 
practice, and whether it was based on subgroup or secondary analyses. 
Additional items for potential reasons for reversal encompass: whether the intervention 
was a new or established practice, classification of evidence using the framework from 
Chapter 3, Fragility Index (FI) calculation, modified Optimal Information Size 
assessment (mOIS), PICOTS assessment, ROB assessment, and mGRADE assessment. 
A mOIS was calculated by if the actual sample size met the sample size calculation 
provided, or if the 95% confidence intervals clearly included both harm and benefit. 
Conflicts of interest cover: industry or non-industry conflicts.  
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A PICOTS assessment can evaluate quality of a study’s reported inception and question 
to determine if the aspects of a study’s question are sufficiently described and 
appropriate. These aspects are: population studied and appropriateness of chosen 
population; intervention used and appropriateness of intervention studied, including 
timing and dosage; comparator used and appropriateness of chosen comparator as well as 
time and dosage; outcomes selected and appropriateness of selected outcomes plus if they 
are patient-important, composite, or surrogate outcomes; timing or length of follow-up 
and whether the outcomes could have occurred in that time frame; and study design and 
whether the selected study design was appropriate.
 4
 
A ROB assessment can evaluate quality of a study’s design and execution to determine 
the level of risk of bias within aspects of a study’s design. 4 The aspects are: sequence 
generation or randomization; allocation concealment or disguise of group assignment; 
blinding or cover-up of intervention provided; completeness of outcome data or presence 
of missing data; completeness of reported outcomes or presence of missing outcomes; 
and other sources of bias. 
2
 
A GRADE assessment can evaluate quality of a meta-analysis’ report and analysis to 
determine the level of quality of aspects of the meta-analysis. A mGRADE assessment 
can evaluate quality of a study’s report and analysis to determine the level of quality of 
those same aspects within a single study. 
4
 Aspects of GRADE are: study design; risk of 
bias; directness and applicability; imprecision; and publication bias for quality of 
evidence analysis and reporting. 
3
 Modifications to GRADE for mGRADE include: no 
changes to how study design is evaluated; risk of bias using the ROB assessment; 
directness and applicability using the PICOTS assessment; imprecision using a modified 
optimal information size assessment; and publication bias based on differences between 
trial registration and final report. 
4
 
4.3.4 Data Analysis 
Descriptive statistics for the number of reversals and related concepts are reported below. 
A table for characteristics of reversal and bar graphs detailing PICOTS Assessment Tool 
results, ROB Tool results, and mGRADE Tool results are also included. 
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4.4 Results 
4.4.1 Inclusion/Exclusion Screening 
 
Figure 14: PRISMA Flowchart of Screening Thresholds and Eligibility 
5,6
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Included studies were randomized trials indicating a clinical practice. 
10-79 
Excluded 
studies were not randomized trials and / or did not indicate a clinical practice.
 80-166
  
4.4.2 Data Extraction for Included Reviews 
Complete data extraction for included reviews is available in Appendix C: A Systematic 
Examination of Contradicted Practices – Initial Pilot Phase, Table 16-Table 21. 
4.4.3 Classifying Evidence Reversal 
Our operational definitions for this review are from the classification portion of the 
framework in Chapter 3. “Evidence reversal occurs when new trials – better designed, 
executed or analyzed than its predecessors – contradicts previous claims, upsetting 
established practices and theories based on presumably “definitive” evidence from 
original studies. Evidence showing no efficacy or harms outweighing benefits should 
involve endpoints and controls at least as rigorous as the previous trials in order to 
contradict previous claims and upset practice.” 3.4.1 Seven percent of included trials were 
classified as reversed (Table 6). This represents 50% of included established practices. 
 “Evidence confirmation occurs when new evidence – better designed, executed or 
analyzed than its predecessors – verifies previous claims, confirming superiority of 
established practices and theories over lesser or prior standards.” 3.4.1 Seven percent of 
included trials were classified as replaced (Table 6). 
“Evidence replacement occurs when new evidence – better designed, executed or 
analyzed than its predecessors – verifies superiority of a new practice over established 
practices and theories.” 3.4.1 Seventy-one percent of included trials were classified as 
replacements (Table 6).  
“Evidence equivalent or less occurs when new evidence – better designed, executed or 
analyzed than its predecessors – fails to demonstrate superiority of a new practice over 
established practices and theories, or when an effect fails to rule out clinically important 
effect sizes.” 3.4.1 Fourteen percent of included trials were classified as equivalent or less 
(Table 6). 
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Table 6: Prevalence of Evidence Reversal and Related Concepts 
Evidence 
Classification 
Number 
of Trials 
Percent of Included 
Reviews 
Percent of Established 
Practices 
Percent of New 
Practices 
Reversal 5 7% 50% - 
Confirmation 5 7% 50% - 
Replacement 50 71% - 83% 
Equivalent or Less 10 14% - 17% 
Table 7 lists the identified reversals from this sample and why each established practice 
represents a reversal. These reversals represent 50% of established practices in the 
sample (Table 6). 
Table 7: Reversals from 2000-2014 
Reference, Year Description 
Endovascular therapy after 
intravenous t-PA versus t-PA 
alone for stroke (Broderick et 
al, 2013) 68 
This randomized trial found that intravenous t-PA alone had the same effect on safety 
outcomes as a combination of t-PA and endovascular therapy in patients with 
symptom onset for stroke. 
Endovascular therapy represents the reversed practice due to ineffectiveness (no effect 
on safety outcomes). 
Fetal pulse oximetry and 
caesarean delivery (Bloom et 
al, 2006)  35 
This randomized trial found that no fetal pulse oximetry (oxygen saturation) had the 
same effect on rate of caesarean delivery or condition of newborn as fetal pulse 
oximetry for nulliparous women who were at term and in early labour. 
Fetal pulse oximetry represents the reversed practice due to ineffectiveness (no effect 
on rate of caesarean delivery or condition of newborn). 
Coronary revascularization 
before elective major 
vascular surgery (McFalls et 
al, 2004) 28 
This randomized trial found that no revascularization had the same effect on mortality 
and myocardial infarctions as coronary revascularization before elective major 
vascular surgery.  
Coronary revascularization before elective major surgery represents the reversed 
practice due to ineffectiveness (no effect on mortality and myocardial infarction).  
Prophylactic implantation of 
a defibrillator in patients with 
myocardial infarction and 
reduced ejection fraction 
(Moss et al, 2002) 18 
This randomized trial found that prophylactic implantation of a defibrillator increased 
survival over conventional medical therapy in patients with myocardial infarction 
and reduced ejection fraction.  
Conventional medical therapy represents the reversed practice due to harm (decreased 
survival). 
Comparison of coronary-
artery bypass surgery and 
stenting for the treatment of 
multivessel disease (Serruys 
et al, 2001) 17 
This randomized trial found that stenting was less expensive than coronary-artery 
bypass surgery while offering the same protection against death, stroke, and 
myocardial infarction, but was associated with increased revascularization in 
patients with multivessel disease.  
Coronary-artery bypass surgery represents the reversed practice due to harm (higher 
expense). 
These conclusions were not defined statistically, but were based upon the conclusions 
written by the trial author(s). Independent verification of whether the article truly 
represented a new or existing practice or truly contradicted or verified prior evidence 
would have required investigating hundreds of topics and would have been too time-
consuming.  
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4.4.4 Populations, Interventions, Comparators, Outcomes, Timing 
and Study Designs (PICOTS) Item Ratings for Individual 
Included Trials Classified as Evidence Reversal, 
Confirmation, Replacement, or Equivalent or Less Plus 
Aggregate Overall Scores 
Within the included trials, the overall assessments of individual trial PICOTS were: 69% 
sufficient; 30% somewhat sufficient – lacking in adequacy of a single PICOTS item; and 
1% clearly insufficient – lacking in adequacy of multiple PICOTS items (Figure 15). 
Each of the separate components were mostly sufficient.  
 
Figure 15: PICOTS Assessment of Included Trials 
Confirmed and replacement trials follow the same trend as the overall PICOTS 
assessment with the exception that 40% of comparators in confirmed trials were 
insufficient (Figure 16 and Figure 17). A full 80% of reversed trials were rated somewhat 
insufficient with 40% inadequacy in describing patient populations and follow-up 
duration (Figure 18). This inadequacy generates uncertainty on whether these reversals 
are “true” reversals or merely artefacts of ineffective study conception. Trials classified 
as equivalent or less were 50% insufficient overall with 40% describing insufficient 
outcomes (Figure 19). The PICOTS assessment is based on PICOTS items reported in the 
published articles, actual PICOTS may differ from what is reported here.
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Figure 16: PICOTS Assessment of Confirmed Trials  
 
 
 
 
 
 
Figure 17: PICOTS Assessment of Replacement Trials 
 
 
 
 
 
 
 
Figure 18: PICOTS Assessment of Reversed Trials  
  
 
 
 
 
 
      
Figure 19: PICOTS Assessment of Equivalent or Less Trials 
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4.4.5 Risk of Bias (ROB) Item Ratings for Individual Included 
Trials Classified as Evidence Reversal, Confirmation, 
Replacement, or Equivalent or Less Plus Aggregate Overall 
Scores 
Within the included trials, allocation concealment and other types of bias mostly 
demonstrated high risk of bias, while the other items mostly demonstrated low risk of 
bias. The truly concerning statistic is that 53% of overall ROB ratings for all included 
studies displayed high risk of bias. Figure 20 is a visual aggregate of ROB items in 
included trials. 
 
Figure 20: ROB Assessment of Included Trials 
  
77 
 
77 
The overall bias assessment within trials categorized as equivalent or less is 60% 
probably low risk of bias and 10% definitely low risk of bias. The main drivers behind 
this rating are the low risk of bias of reported sequence generation, blinding, 
completeness of outcome data and outcome reporting (Figure 21).  
Replacement trials were only 12% and 32% definitely and probably low risk of bias, but 
risk of bias of individual items follows the same trend as those labeled equivalent or less 
(Figure 22). 
Lack of blinding, incomplete outcome data and selective outcome reporting manoeuvre 
ROB ratings for reversal to 60% high risk of bias in addition to the lack of reported 
allocation concealment and other sources of bias seen in all included studies (Figure 23). 
The high risk of bias throws suspicion upon whether these reversals are “true” reversals 
or merely artefacts of ineffective study execution. 
Confirmed trials have similar ROB ratings as reversed trials, but the risk of bias is rated 
more towards definite risk of bias whereas reversed trials were rated more towards 
probable risk of bias (Figure 23 and Figure 24). 
The ROB assessment is based on reported ROB items, actual ROB may differ from what 
was reported in included articles and therefore from what is reported here. If an included 
trial did not report some aspect that they had actually performed, it would not show up in 
this assessment. 
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Figure 21: ROB Assessment of Equivalent or Less Trials  
 
 
 
 
 
   
Figure 22: ROB Assessment of Replacement Trials 
 
 
 
 
 
 
Figure 23: ROB Assessment of Reversed Trials    
 
 
 
 
 
   
Figure 24: ROB Assessment of Confirmed Trials 
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4.4.6 Modified Grading of Recommendations Assessment, 
Development and Evaluation (mGRADE) Item Ratings for 
Individual Included Trials Classified as Evidence Reversal, 
Confirmation, Replacement, or Equivalent or Less Plus 
Aggregate Overall Scores 
Within the included trials, 39% were moderate quality and 23% were high quality. Figure 
25 is a visual aggregate of mGRADE items. 
Trials evaluating new interventions – classified as replacement or equivalent or less – 
followed a similar trend towards moderate and high quality studies. However, trials 
evaluating existing interventions – classified as confirmation or reversal – were less than 
50% good quality with both high quality and moderate quality combined. Confirmed 
trials demonstrated a massive 40% of trials were of very low quality – were downgraded 
at least three times for items that decrease confidence in the reported results. Reversed 
trials were 80% low or very low quality, casting even more doubt upon whether these 
reversals are “true” reversals or merely artefacts of ineffective study assessment.  
 
Figure 25: GRADE Assessment of Included Trials 
The mGRADE assessment is based on reported GRADE items reported in the published 
articles, actual mGRADE items may differ from what is reported here.  
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4.4.7 Duration between Trial Start, Registration, and Publication 
The progress and results of a trial can affect the timing of trial registration and 
publication after launch of a new trial. Most trials are registered within five years of trial 
start, with replacement and confirmed trials being registered earlier than reversal or 
equivalent or less trials (Figure 26). Similarly, most trials are published within five years 
of trial registration (Figure 27). All included trials were published within four years of 
study completion, with the exception of one trial publishing interim results three years 
prior to trial completion (Figure 28). More complete trends in this area may be more 
relevant in the follow-up to this pilot study. 
 
Figure 26: Number of Years between Trial Start and Registration 
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Figure 27: Number of Years between Trial Registration and Publication 
 
Figure 28: Number of Years between Trial Completion and Publication 
4.4.8 Effect of Trial Conclusions and Conflicts of Interest  
The author’s reported results of a trial are best shown in the conclusion section of a 
publication’s abstract. As expected from the operation definitions used in this review, 
confirmed and replacement trials report mostly positive conclusions while reversed and 
equivalent or less trials report mostly negative conclusions. For the most part, 
conclusions are not altered by focus on subgroup analyses or secondary endpoints over 
primary analyses and endpoints. These results are shown in Table 8. 
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Table 8: Trial Author(s)' Conclusions by Evidence Classification 
Evidence 
Classification 
Author(s)' Conclusions Based on subgroup? Based on secondary endpoint? 
Positive 
Negative or 
No Difference Yes No Yes No 
Reversal 40% 60% 0% 100% 20% 80% 
Confirmation 60% 40% 0% 100% 20% 80% 
Equivalent or 
Less 20% 80% 10% 90% 20% 80% 
Replacement 96% 4% 8% 92% 20% 80% 
Overall 79% 21% 7% 93% 20% 80% 
 
Industry funding, design, execution, and analysis of a study can affect spin in conclusions 
as investigators attempt to market their sponsor’s intervention. The majority of trials, 
across all evidence classifications, are funded by or declare conflicts of interest with 
industry as opposed to non-industry government grants (Table 9). 
Table 9: Reported Funding and Conflicts of Interest by Evidence Classification 
 Reported Funding and Conflicts of Interest 
Evidence Classification Industry Non-Industry None Disclosed 
Reversal 60% 40% 0% 
Confirmation 60% 40% 0% 
Equivalent or Less 80% 20% 0% 
Replacement 74% 20% 6% 
Overall 73% 23% 4% 
mOIS determines whether individual trials have sufficient patients for adequate power to 
actually detect the study’s results. Recruitment and randomization of a sufficient number 
of subjects is necessary for adequate power in a trial – meet the mOIS. Most trials were 
able to meet the mOIS, with the exception of 60% of reversed trials (Table 10). This only 
further validates the previous misgivings of whether these reversals are “true” reversals. 
Table 10: Modified Optimal Information Size by Evidence Classification 
 Modified Optimal Information Size 
Evidence Classification Sufficient Insufficient 
Reversal 40% 60% 
Confirmation 100% 0% 
Equivalent or Less 60% 40% 
Replacement 76% 24% 
Overall 73% 27% 
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4.4.9 Proposed Methodology for Determining Evidence Maturity 
within a Single Study 
Evidence Reversal has recently become an area of research interest, and there is a gap in 
the literature for identification of true reversals and true confirmations through maturity 
within a single study. To fill this gap, we propose applying the concept of evidence 
fragility. When combined with evidence confirmation and reversal, these concepts will 
contribute to forming a ‘theory of Evidence Reversal.’ In this context, these terms can be 
applied to a single study to serve as indicators of the robustness of evidence for an 
established practice or theory. 
Evidence maturity indicated when enough information has accumulated to imply further 
research is unnecessary and can be estimated for a single study through evidence fragility. 
Evidence fragility is measured using the Fragility Index (FI), which currently has been 
developed only for determining fragility of dichotomous primary outcome conclusions. 
9
 
The FI is evaluated by recalculating the two-sided p-value for Fischer’s exact test by 
converting a non-event to an event in the group with fewer reported events. This process 
continues iteratively until the originally significant p-value becomes greater or equal to 
0.05 or the originally non-significant p-value becomes less than 0.05 – statistical 
significance is converted to non-significance or non-significance to significance. The 
number reported as the FI is the number of converted events required to change the p-
value from significant to non-significant. A low FI score indicates a weak conclusion and 
high fragility score indicates the opposite. 
9
 
The FI is most worrying when the loss to follow-up is greater than the calculated FI 
score, which was the case in 38% of the included trials in this pilot study; 20% of 
confirmed, 34% of replacement, 30% of equivalent or less, and 0% of reversed trials. 
Half of the replacement trials had FI’s ≤10 as well as all of the equivalent or less trials, 
all other FI’s were >10. While these proportions do not represent the majority of included 
trials, the proportion is concerning and requires closer examination in the future. This 
may even be the only indication that the trials classified as reversals in this review are 
‘true’ reversals as their FI’s were all more robust than their respective loss to follow-up.  
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4.5 Discussion 
4.5.1 PICOTS Assessment 
A PICOTS assessment was completed to indicate comprehensiveness of conception 
categories: population, intervention, comparator, outcome, timing, and study design. 
Insufficient populations occurred most often when entry into a study is reliant upon 
completion of a pre-trial run-in phase that measures tolerance of the chosen intervention 
in patient populations before a trial is conducted.  
Chosen interventions were all considered sufficient in this review, this was not validated 
since it was beyond the scope of the review to critique the index interventions.  
Comparators were judged inadequate when: placebos were used when an active 
comparator or standard-of-care was available; only when investigators vary doses of the 
intervention drug; or a historical cohort was used in lieu of a comparator group when a 
sufficient comparator was already part of the trial.  
Outcomes were insufficient when outcomes were not hard (patient-important) outcomes – 
clinical outcomes of distinct relevance to patients. 
7,8 
Non-patient-important outcomes 
included un-validated surrogate endpoints – where the surrogate outcome is a point on 
the causal-pathway to a hard outcome, and is used as a substitute for this hard outcome. 
7
 
The failing of an un-validated surrogate is that it may not capture the entire effect of an 
intervention on the hard outcome. 
7
 Another non-patient-important outcome is use of an 
un-validated composite outcome – where multiple endpoints are grouped into 
components of a single measure. 
8
 The weaknesses of un-validated composite outcomes 
are two-fold: one, component endpoints may be of differing levels of patient-importance; 
or two, component endpoints may occur with differing frequencies. 
8  
Insufficient follow-up occurs when trials are ended early or when duration of follow-up is 
at the discretion of the attending physician.  
Only one study design evaluated was inadequate; blinding was possible, but was not 
performed.  
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4.5.2 ROB Assessment 
A ROB assessment was completed to indicate comprehensiveness of design and 
execution categories: sequence generation, allocation concealment, blinding, incomplete 
data reporting, selectively reported outcomes, and other sources of bias. 
Sequence generation demonstrated high risk of bias when method of randomization was 
not reported. Most trials reported their method of randomization or at least reported that 
patients were randomized into their groups. 
Allocation concealment was often not declared. Mostly this occurred because method of 
allocation concealment was not mentioned and not because allocation assignment to the 
various study groups could be predicted.  
Mostly blinding was adequate, however, high risk of bias occurred when blinding was 
possible but was not utilized; or no blinding occurred and outcomes were subjectively 
measured.  
Incomplete data reporting often transpired when per-protocol analyses were used; when 
trials were stopped early based on a data-driven process; or loss to follow-up and missing 
data were not appropriately handled.  
Outcomes were selectively reported when a priori stated outcomes were not reported in 
publication, or were altered during the course of the study.  
Other sources of bias included: industry funding, design, execution, and/or assessment of 
a trial; extreme baseline imbalance of intervention and comparison groups; and use of un-
validated outcomes. 
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4.5.3 mGRADE Assessment 
A mGRADE assessment was completed to indicate comprehensiveness of report and 
analysis categories: study design; risk of bias; directness and applicability; imprecision; 
and publication bias. 
Due to the inclusion criteria for this review, all included studies were of a randomized 
trial study design. Thus, the mGRADE assessment began with the default of “high 
quality” and could only be downgraded from there. 
Overall risk of bias was completed using the ROB assessment and found that 53% of 
included trials had reasons to downgrade the initially high quality rating. Reasons for 
lower ROB assessments are found in Section 4.5.2. 
Directness and applicability was measured using the PICOTS assessment and found that 
31% of included trials had reasons to downgrade the initially high quality rating. Reasons 
for lower PICOTS assessments are found in Section 4.5.1.  
Imprecision was evaluated using a mOIS assessment and found that 27% of included 
trials could be downgraded. The reason to downgrade imprecision was if loss to follow-
up was greater than the FI.  
Publication bias was estimated based on differences between trial registration and final 
report and found that 9% of included trials had detected or suspected publication bias. 
Collating all the downgrades, the mGRADE assessment found that only 62% of all 
included trials were of high or moderate quality. 
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4.5.4 Strengths and Weaknesses of Review and What This 
Review Adds to the Literature Surrounding Evidence 
Reversal 
Evidence-base medicine has few check-and-balance systems to disinvest from potentially 
harmful treatments, or to prevent premature uptake of immature evidence, and a new 
model for gauging evidence is required. We propose that renewed attention to PICOTS, 
ROB, GRADE, and FI may change the way in which researchers conduct studies. Adding 
FI into the framework may heighten awareness of the fragility of evidence. When newer 
tools are developed and new language is used, clinical research is made that much 
stronger with higher standards for trial design. 
Awareness of Evidence Reversal may lead to better designed trials by identifying factors 
that lead to increased risk of reversal. Evidence-based medicine needs to undergo an 
upheaval, where robust studies and their conclusions are favoured over their ineffectual 
counterparts. Ultimately the carry-over may lead to improved study and trial quality 
which may in turn lead to improved patient outcomes. 
The findings of this review will inform the development of framework to standardize 
potential reasons for evidence reversal, which could guide future research into this topic. 
Additionally, we propose the incorporation of methodologies for determining evidence 
maturity through fragility and its measure FI in single studies. 
The practices classified as reversals in this thesis are not authenticated as mature 
reversals. Newer, larger, better designed and better powered studies contradicting the use 
of established practices does not mean that these established practices are wrong and the 
comparator interventions are right. Currently they represent immature reversals and 
require further investigation into the evidence base and/or research to form an 
authenticated conclusion. However, these reversals did not meet the criteria for fragile 
evidence as their FI’s were all more robust than their respective loss to follow-up and 
their FIs ranged from 36 to 747, making them mature evidence in terms of a single study. 
In general, newer, larger, better designed and better powered studies reach more valid 
conclusions than their older, smaller, poorer designed and lesser powered studies. 
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Practice classifications were based on a trial report’s abstract, introduction, and 
discussion. We did not perform an independent search to verify if a practice was new or 
existing, or against its evidence base to determine stability and sufficiency of the 
evidence. Screening was also not performed in duplicate. As such, there may be some 
errors of inclusion and exclusion. This independent verification would have been too time 
consuming and require a greater number of reviewers. 
The choice of journal was originally made in A Decade of Reversal using impact factor 
rankings. 
1
 These results may not apply to all journals and may only apply to the New 
England Journal of Medicine. Since this is a high impact journal, there may be bias 
towards publication of trials that overturn established practices (either replacements or 
reversals). However, research on already established practices is rare and this may be 
notable enough on its own that confirmations are not likely selected against.  
4.5.5 Comparison to Previous Research 
This thesis found that 7% of randomized trials concerning a clinical practice were 
reversals, which is also 50% of those that concerned an existing practice. 
Dr. John P. A. Ioannidis of Stanford University found in in 2005 with his article 
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research that highly 
cited research studies were often followed by studies with contradicting results (16%) or 
with lower effect sizes (16%). 
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Dr. Vinay Prasad of Johns Hopkins University et al found in 2011 that 13% of 124 
articles describing a medical practice were reversals, 46% of these articles which 
described an established practice. 
169 
Also in 2014 that 11% of 1322 original articles 
describing a medical practice were reversals and 40% of the 363 trials testing an 
established practice. 
1
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4.6 Conclusions 
4.6.1 Unanswered Questions 
Since there are only a handful of investigators and professionals working toward evidence 
reversal, many questions remain unanswered.  
What threshold denotes an authentic reversal? Are the proposed measures of maturity 
adequate for this threshold? What is an appropriate FI threshold for evidence maturity? 
How else can maturity be measured in an evidence base? In a dearth of evidence? In a 
single study? 
Can maturation of reversal be predicted without these proposed measures of maturity? 
What other factors and tools (i.e. PICOTS, ROB, GRADE, FI, sufficiency and stability) 
could be potential predictors of risk of reversal? 
How can maturity of evidence be better translated into practice? 
4.6.2 Future Research 
A prudent next step in this emerging field is to address trials not only at the level of 
systematic research, but at the level of an individual study. This review seeks to propose 
a solution in the form of a fragility index (FI) as a measure of evidence maturity within 
the parameters of a single study. 
A framework of indications for risk of evidence reversal will aid in guiding future 
research into underlying causes of reversal. Preventing or decreasing reasons for reversal 
should also decrease risk of reversal. Predictive tools could be useful in this way to 
identify key aspects of a trial or evidence base that are potential predictors for risk of 
reversal. These tools could then aid decision makers when questioning how and why 
medical practice is implemented into patient populations. 
Alternate measures of evidence maturity should be investigated to find robustness of 
evidence that may require less accumulation of evidence than needed for a cumulative 
meta-analysis, yet more evidence than the robustness of results within a single study.  
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  Chapter 5
5 Risk of Reversal Framework 
5.1 Introduction 
Evidence reversal occurs when new evidence contradicts established practice. It is 
troublesome in Evidence Based Medicine (EBM) because this indicates that some 
medical practices have been implemented in error, or at least prematurely. These 
circumstances may arise because a practice was adopted into Medicine since the evidence 
was immature, insufficient and unstable with high risk of bias and conflicted evidence. 
The costs to EBM are profound. Currently, research into this area has only investigated 
the presence of reversal in medical literature without delving into the underlying causes 
or indications for risk of reversal. 
1-9
 Our review from Chapter 4 identifies some potential 
indicators for evidence reversal; the objective of this chapter is to compile these reasons 
into a comprehensive framework. This framework can be used to guide future research 
into the underlying causes of reversal and increase awareness of evidence reversal. 
5.2 Methods 
Full Methodology is available through Appendix B: Evidence Reversal: A Formal 
Examination of Contradicted Medical Practices – Protocol. A summary of this protocol 
and the modification to this protocol for the initial pilot phase is briefly described here 
and previously in Chapter 4. 
5.2.1 Search Strategy 
The New England Journal of Medicine online database was hand-searched for all 
“Original Articles” from 2000-2014 – including replication of the years 2000-2010 
covered by A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices.
 1
  
Articles included in this initial pilot phase represent a random 5% sample of this 
population. Data sampling was stratified by year, and random selection of 5% of the total 
articles for each year was done using a random number generator in Microsoft Excel®. 
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5.2.2 Eligibility Criteria of Included Reviews 
All randomized trials directly examining medical practices were included under the direct 
definition of medical practices: a screening, stratifying, or diagnostic test; a medication; a 
procedure or surgery; or any kind of change in health care provision systems.
 
All other 
articles were excluded. 
Study selection was not evaluated in duplicate due to time constraints. 
5.2.3 Data Extraction and Critical Appraisal 
All previously obtained trials from Chapter 4 were examined to identify the following 
using a customized data extraction form in Microsoft Excel®: General information; 
Methodology; Results; Conclusions; Additional items for potential reasons for reversal; 
and Conflicts of interest. Methodological quality of included trials was assessed using a 
Populations, Interventions, Comparators, Outcomes, Timing and Study Designs 
(PICOTS) Assessment Tool, The Cochrane Collaboration’s Tool for Assessing Risk of 
Bias (ROB) for randomized studies and a Modified Grading of Recommendations 
Assessment, Development and Evaluation (mGRADE) Tool.
 10,11  
Data extraction (DS) was reviewed by another team member (JM) to assure accuracy.  
A PICOTS assessment can evaluate appropriateness of a study’s population, intervention, 
comparator, outcome, timing and study design for the quality of its inception. 
12
 
A ROB assessment can evaluate risk of bias for a study’s sequence generation, allocation 
concealment, blinding, completeness of outcome data, completeness of reported 
outcomes, and other sources of bias for quality of a study’s design and execution. 10,12 
A GRADE assessment can evaluate quality of a meta-analysis included studies’ study 
design, risk of bias, directness and applicability, imprecision, and publication bias for the 
quality its analysis and report. 
11 
A mGRADE assessment can evaluate quality of a 
study’s study design, risk of bias, directness and applicability, imprecision, and 
publication bias for the quality its analysis and report. 
12
 
105 
 
105 
5.2.4 Data Analysis 
A descriptive synthesis of extracted data was aggregated, and based on different reasons 
identified in these trials; we propose a new draft framework using indicators for risk of 
reversal collected into subcategories, which will be grouped to form categories, and then 
finally synthesized into key domains of indicators for risk of reversal. 
 
5.3 Results 
5.3.1 Review of Trials 
The data set demonstrated that 7% of randomized trials concerning a clinical practice 
were reversals, and 50% of randomized trials concerning an existing clinical practice. 
Classification of trials included 5 reversals, 5 confirmations, 10 equivalent or less trials, 
and 50 replacements.
 4.4.3 
 
The overall quality of reviews is alarmingly – each assessment had over 30% of all 
included studies as low quality (Table 11 and Figure 29). High risk of bias from the ROB 
assessment is fairly consistent across the different classifications of evidence (Figure 29).  
However, insufficient ratings from the PICOTS assessment as well as low quality ratings 
from the mGRADE assessment are much higher for reversals than the other 
classifications (Figure 29). 
Table 11: Quality Assessments by Evidence Classification 
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Figure 29: Percent of Low Quality Articles by Evidence Classification 
 
5.4 Proposed Framework 
Our proposed framework focuses on specific components of design, execution, and 
analysis of evidence including indicators of risk of reversal in a trial’s question, design, 
and report.  
For clarification purposes, our preferred operational definitions of terms will be provided 
in boxes linked to each section. 
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5.4.1 Trial Question 
Poor study questions may be potential predictors of reversal. The PICOTS assessment 
tool is used to rate a trial’s reported target question. An evaluation of a study’s question 
identifies deviances which can lead indirectly to reversal through effects on overall study 
design, execution and analysis or directly to reversal itself through study question. 
 
Category Subcategory Risk of Reversal Criteria 
PICOTS 
Assessment 
Adequate 
Population 
Chosen population is inappropriate for targeted 
population. 
Adequate 
Intervention 
Chosen intervention is inappropriate for targeted 
population. 
Adequate 
Comparator 
Chosen comparator is inappropriate for targeted 
population and intervention. 
Adequate 
Outcomes 
Chosen outcomes are not patient-important and/or not 
validated within the targeted population. 
Type of 
Outcomes 
Chosen outcomes are subjectively measured, not 
patient-important, inappropriate surrogates or 
imbalanced composite outcomes. 
Adequate 
Follow-Up 
Chosen follow-up is incomplete and/or inappropriate 
for targeted intervention and outcomes. 
Adequate Study 
Design 
Chosen study design is inappropriate for targeted 
population, intervention, comparator, and outcomes. 
Additional 
Assessment 
Optimal 
Information Size 
Chosen sample size has inadequate power to detect an 
effect if one exists. 
Box 5: Proposed Domain of Trial Question for Risk of Reversal Criteria 
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5.4.2 Trial Design 
Poor trial design is another potential predictor for reversal. The ROB assessment helps 
evaluate how well a trial was carried out. 
2
 Evaluations of the execution of a study can 
identify deviances which can lead indirectly to reversal through effects on overall study 
analysis or directly to reversal itself through study design and execution.  
 
Category Subcategory Risk of Reversal Criteria 
ROB 
Assessment 
Randomization / 
Sequence Generation 
Chosen method of randomization would not 
produce comparable groups. 
Non-randomization method used. 
Allocation 
Concealment 
Chosen method of allocation concealment would 
not obstruct prediction of assignment prior to and 
during enrolment. 
Blinding Chosen method of blinding would not conceal 
assignment following enrolment. 
Incompleteness of 
Outcome Data / 
Early Termination 
Chosen reporting of outcome data does not 
include any changes to population size, 
availability of data, or analyses. 
Selectiveness of 
Outcome Reporting 
Chosen reporting of outcomes suggested by 
generated results and not based on outcomes 
determined a priori. 
No Other Sources of 
Bias 
Chosen execution of study demonstrates other 
forms of bias. 
Additional 
Assessment 
Fragility Index Resulting number of events which could change a 
conclusion from statistically significant to non-
significant is lower than the loss to follow-up. 
Box 6: Proposed Domain of Trial Design for Risk of Reversal Criteria 
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5.4.3 Trial Report 
Poor trial analysis and reporting can also potentially predict reversal. A mGRADE 
assessment evaluates more than just the quality of a study’s reported question, design, 
execution and analysis, here it is also used to appraise how well a study conducts its 
analysis. Evaluation of a study’s analysis can identify deviances which can lead directly 
to reversal though study question, design, execution, report and analysis. 
 
Category Subcategory Risk of Reversal Criteria 
GRADE 
Assessment 
Risk of Bias Chosen study execution would meet ROB 
assessment high risk of bias criteria. 
Indirectness Chosen study design would meet PICOTS 
assessment insufficient criteria. 
Imprecision Chosen sample size would not meet the 
modified Optimal Information Size (mOIS). 
Publication Bias Pre-determined study design features, 
execution, and analyses were changed and 
not conducted as planned. 
Overall Confidence Level of quality of trial would be low or 
very low. 
Publication 
Assessment 
Duration from Trial 
Start to Registration 
Time from trial commencement to 
registration would occur after 
randomization. 
Duration from Trial 
Completion to 
Publication 
Time from trial completion to publication 
would be large, or no publication would 
ensue. 
Results 
Assessment 
Conclusion based on 
Subgroup Analysis 
The reported conclusion focuses on 
subgroup analyses and not primary 
analyses. 
Conclusion based on 
Secondary Analysis 
The reported conclusion focuses on 
secondary analyses and not primary 
analyses. 
Box 7: Proposed Domain of Trial Report for Risk of Reversal Criteria 
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5.4.4 Full Proposed Framework for Indicators of Reversal 
The consolidated framework for all discovered potential predictors serve as a guideline 
for risk of reversal. Identifying these markers within studies should inform likelihood of 
reversal for healthcare decision-makers to suggest delaying adoption of new practices or 
disinvesting established practices until research has matured. 
 
Domain Category Subcategory 
Trial 
Question 
PICOTS 
Assessment 
Adequate Population 
Adequate Intervention 
Adequate Comparator 
Adequate Outcomes 
Type of Outcomes 
Adequate Follow-Up 
Adequate Study Design 
Additional 
Assessment 
Optimal Information Size 
Trial Design ROB Assessment Randomization / Sequence Generation 
Allocation Concealment 
Blinding 
Incompleteness of Outcome Data / Early 
Termination 
Selectiveness of Outcome Reporting 
No Other Sources of Bias 
Additional 
Assessments 
Fragility Index 
Trial Report mGRADE 
Assessment 
Risk of Bias 
Indirectness 
Imprecision 
Publication Bias 
Overall Confidence 
Publication 
Assessment 
Duration from Trial Start to Registration 
Duration from Trial Completion to Publication 
Results Assessment Conclusion based on Subgroup Analysis 
Conclusion based on Secondary Analysis 
Box 8: Full Proposed Framework for Risk of Reversal Criteria 
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5.5 Conclusion 
Evidence Reversal is an emerging topic in EBM; as such, its underlying causes are 
currently undiscovered. Research into this area has established the presence of reversal in 
medical literature without hunting for indications for risk of reversal.
 1-9 
The framework 
proposed in this paper provides a guide for future research into risk of reversal. 
Future research must be of higher quality and higher transparency to fully develop robust 
proofs of results. Higher quality research with higher transparency reduces the risk of 
bias and random error.  
Researchers need to ensure their research is necessary – that it adds to an immature 
evidence base to fill the gaps between a weak evidence base and effective patient 
practice. Adequate evidence should be generated to guarantee mature evidence for uptake 
into practice and safeguard against future reversals.  
Within the Medical Field, established practices need to be reassessed for efficacy and to 
ensure that their benefits outweigh their harms and costs. If the evidence surrounding 
these established practices fail to prove effectiveness or benefits outweighing harms and 
costs, then they should be de-implemented or at least disinvested. New practices need 
mature evidence bases, mature trials, or at least few indicators for risk of reversal prior to 
adoption. 
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  Chapter 6
6 General Discussion and Conclusions 
This thesis is a compilation of successive phases of enquiry into an emerging area of 
Evidence Based Medicine (EBM) with several methodological limitations, which were 
noted in their respective chapters. This final chapter serves to present a broad discussion 
of the topic of Evidence Reversal. 
In general, our goal was to update previous workings from Prasad et al, by replicating 
their work on the years 2000 to 2010, updating it to include the years 2011-2014, and 
expanding it to identify potential reasons why reversals occur. 
1
 An initial pilot phase 
was performed prior to the full review to: determine the feasibility of this endeavour; 
improve clarity of inclusion and exclusion language and data extraction methods and 
tools; and improve accuracy and consistency of screening and data extraction. 
In order to accomplish our objective, we needed to introduce several concepts and 
propose new definitions based on our experience in the field of EBM. We first set out to 
identify and standardize the key terms and definitions for the field of Evidence Reversal. 
The identification of these terms is detailed in Chapter 2, while the framework for 
standardization of these terms is proposed in Chapter 3. 
Additionally, we set out to identify and standardize the key terms and definitions for the 
reasons for reversal. The identification of these terms is described in Chapter 4 and the 
framework for standardization is itemized in Chapter 5. 
We also proposed evidence maturity to signify that eventually there will be enough 
evidence for a firm conclusion. We also propose that evidence maturity is measured in a 
body of evidence using stability and sufficiency methods, and using fragility methods in a 
single study. Evidence sufficiency, and stability were proposed for evidence maturity in 
Chapter 2, and evidence fragility was proposed in Chapter 4. 
This thesis identified 7% of randomized trials concerning a clinical practice as reversals, 
including 50% of those concerning an established practice.  
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6.1 What is Evidence Reversal? 
Evidence reversal occurs when new evidence – better designed, executed, or analyzed 
than prior evidence – compares established practices or theories with lesser or prior 
practices or theories and contradicts routine usage of the established practice either 
through harms in excess of benefits or through lack of efficacy. 
Chapter 2: A Systematic Overview of Evidence Reversals and the Remaining Gaps in the 
Literature used a comprehensive search strategy to acquire all relevant reviews related to 
the emergent topic of Evidence Reversal. This literature review examined previous 
research on the topic of Evidence Reversal for all terms and definitions currently used. 
Chapter 3: Defining Evidence Reversal Framework expands Evidence Reversal as a 
concept to include general science. This framework consolidated all terms and definitions 
used in the topic of Evidence Reversal into a standardized set of associated terms and 
definitions. These terms are: evidence reversal, confirmation, replacement, and 
equivalent or less. The operational definitions are in Section 3.4.1. 
Chapter 4: A Systematic Examination of Contradicted Practices – Initial Pilot Phase used 
the classifications from this framework to investigate all original articles in the New 
England Journal of Medicine from 2000-2014 for the presence of evidence reversal and 
associated terms as well as potential reasons for reversal. The presence of evidence 
reversal was detected in 7% of randomized trials concerning a clinical practice were 
reversals. Previous research in 2005 identified reversal in 16% of highly cited research, 
13% of articles concerning a clinical practice in 2011, and 11% in 2014. 
2, 3, and 1, respectively
 
These reversals have not been authenticated as mature evidence, despite being newer, 
larger, and better controlled studies than their predecessors. In general, these aspects 
indicate more valid conclusions, but that does not always hold true. 
4
 
Chapter 5: Risk of Reversal Framework lays the foundation for further research into 
causes and risk of evidence reversal by uniting all the potential reasons for reversal into 
one framework. 
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6.2 What is Evidence Maturity? 
Evidence maturity occurs when enough information has accumulated to imply any further 
research is unnecessary. This definition we propose predicts a stable threshold level of 
evidence to ensure, whenever possible, all evidence relating to a study can withstand 
repetition, sampling and is broadly generalizable. Importantly, authentic reversals can be 
identified for disinvestment. Similarly, accumulated evidence can firmly confirm a dosage 
or efficacy of a screening, stratifying, or diagnostic test; a medication; a procedure or 
surgery; or any kind of change in health care provision systems. 
Chapter 2 and Chapter 3 outline evidence maturity as it is measured in a body of evidence 
through sufficiency and stability whereas Chapter 4 and Chapter 5 outline evidence 
maturity as it is measured in a single trial through fragility.  
Evidence sufficiency and stability in a body of evidence are the most robust form of 
maturity, which also comes with the highest cost of resources and time. At the rate new 
trials are published, many meta-analyses are out-of-date as soon as they are published, if 
not sooner. 
5
 Evidence sufficiency also requires a measure for determining when sufficient 
evidence of no difference is met. Currently we propose the Minimal Clinically Important 
Difference (MCID) as the threshold, but the MCID is difficult to identify and could also 
be subjectively selected. A more objective method is needed. 
Evidence fragility in a single study is the least robust, but also the least labour-intensive. 
While it uses the Fragility Index (FI), an intuitive measure – the number of people with a 
different outcome that would change the results – it also lacks a threshold. Currently we 
propose the number lost to follow-up to determine when evidence is fragile, but the 
difference between these two numbers are also interesting, as is the FI number itself. 
Investigation into alternate thresholds is recommended. 
The proposed frameworks in this thesis should help achieve consensus in the field of 
Evidence Reversal such that we can begin to move past generation of theories and 
frameworks to act with a united front to elevate EBM and uphold its ideals by enforcing 
adequate evidence maturity prior to implementation and de-implementation of practices.  
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The majority of research ends with a call for more evidence, but this need for evidence is 
not infinite, it is limited when the evidence reaches maturity. Excessive research can 
occur when investigators conduct studies completely unaware of the extent of previous 
research in the field, publish research on conveniently available data, when studies are 
designed to address a particular aspect of a topic but also end up informing the topic as a 
whole, replication in different populations, and replication in different setting. 
Replication in different populations and settings is needed for generalizability, but 
eventually enough populations and settings are tested to be declared generalizable.  
Researchers need to be aware of the extent and maturity of the previous evidence base 
prior to designing their study. Syntheses such as systematic reviews and meta-analyses 
can aid this by condensing studies published over a view range of journals and fields into 
one comprehensive package. These syntheses should be designed to cover wide topics 
and include several between-study contrasts of interest to particular aspects of the topic.  
Once the evidence is mature, continuing to conduct research represents a waste of 
researcher time, editor time, journal publication space, synthesis author time, 
unnecessarily delays the knowledge translation of evidence into practice and, in fact, is 
unethical because the topic is no longer in equipoise. 
While the evidence is immature, failing to conduct research represents a paucity of 
evidence to definitely form a conclusion for a topic, results are not generalizable across 
different populations and settings, results are not replicated in the same population and 
settings, and lack statistical significance for a reasonably precise estimate on the 
magnitude of effect for informed decision-making. 
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6.3 Future of Evidence Reversal 
EBM has few check-and-balance systems to disinvest from potentially harmful 
treatments; a new model for gauging evidence is required. We propose that the suggested 
frameworks in this thesis may provide the framework for this model. These additional 
tools will help ensure proper methodologies and protocols are created and adhered to, 
perhaps even improving patient outcomes.  
Alternate means to measure evidence maturity should be investigated such that mature 
evidence can be identified without the labour-intensive cumulative meta-analysis for an 
evidence base or the delicacy in a single study. A gap in this proposal lies in the inability 
to determine maturity with more studies than a single study, but fewer studies than 
required for a proper meta-analysis. Development of a predictive tool for risk of reversal 
could fill this gap. The framework of reasons for reversal proposed in Chapter 5 is a good 
starting point to develop a predictive tool. 
6.4 Implications 
Within the Medical Field, established practices need to be reassessed for efficacy and net 
benefits outweighing harms and costs. Reversed practices will need to be de-implemented 
or at least disinvested. Accumulated evidence also needs to be assessed for the emergence 
of mature confirmed practices, which may be safely implemented with low risk of 
reversal. This level of assessment and reassessment is required at the policy level as well 
since policies can develop guidelines for practice. 
Researchers themselves will need to ensure their research is not superfluous – adding to 
an already matured confirmation of effect. They also should perform useful high quality 
research, such that risk of bias and random error is reduced as well as filling in the gaps 
between a weak evidence base and effective patient practice. Adequate evidence should 
be generated to evaluate the degree to which evidence is mature enough to introduce into 
patient populations and combat the number of untested established medical practices with 
inadequate evidence for implementation. 
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6.5 Next Steps 
The field of Evidence Reversal needs to acquire consensus on the terms and definitions 
used. We recommend our proposed framework of Evidence Reversal and its related 
concepts. 
Alternate measures of evidence maturity should be developed to find robustness of 
evidence that require less accumulation of evidence than needed for a cumulative meta-
analysis, yet more evidence than the robustness of results within a single study. 
Development of predictive tools for risk of reversal could provide this alternate measure, 
navigate the evidence base to identify reversals, and “predict” when reversals are likely 
to happen. We recommend our proposed framework of reasons for evidence reversal as 
potential predictors for risk of reversal. 
Investigations into the reasons for evidence reversal need to be verified across all 
scientific journals such that practices in every scientific field demonstrating reversal can 
be de-implemented and confirmed practices can be implemented. The review from 
Chapter 4 should be replicated in other journals to ensure that its findings are universal 
and not just unique to the New England Journal of Medicine.  
More in-depth analyses of the review from Chapter 4 should be conducted to include 
independent searches to verify if a practice is new or established, and into the evidence 
base for any article identified as a reversal to measure the maturity of that reversal. 
EBM needs to evaluate its practices for those instituted in error prior to the development 
of mature evidence. Policies favouring evidence of mature replacements prior to adoption 
of a new practice should be developed. Costs of reversal and de-implementation on 
society and the medical system are immense – and include confidence in EBM, trust in 
healthcare providers, and harm to patients in addition to monetary cost. 
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Appendix A: A Systematic Overview of Evidence Reversals and the Remaining Gaps 
in the Literature 
Table 12: Data Extraction of Included Reviews 
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 c
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w
-v
al
u
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E
S
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 c
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u
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b
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h
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[E
x
is
ti
n
g
 r
es
ea
rc
h
 e
v
id
en
ce
] 
[A
g
en
ci
a 
d
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 d
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D
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u
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n
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A
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 d
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 d
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u
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d
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C
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u
n
y
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I 
d
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B
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L
o
w
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u
e 
P
ra
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ic
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Ineffective 
or lack 
evidence on 
their 
effectiveness
, negative 
risk-benefit 
balance, 
more cost-
effective 
alternatives 
exists, 
obsolete due 
to the 
introduction 
of new 
technologies
. 
[17 selected 
examples] 
Such type of 
initiatives need 
to provide timely 
information, but 
are very time- 
and resource-
consuming. 
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Research 
updates most 
likely to 
change 
clinical 
practice 
[7 selected 
examples] 
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Research 
updates most 
likely to 
change 
clinical 
practice 
[12 selected 
examples] 
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updates most 
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clinical 
practice 
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examples] 
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Research 
updates most 
likely to 
change 
clinical 
practice 
[6 selected 
examples] 
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Research 
updates most 
likely to 
change 
clinical 
practice 
[9 selected 
examples] 
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Research 
updates most 
likely to 
change 
clinical 
practice 
[8 selected 
examples] 
None 
B
as
u
 R
ay
 I
 
A
d
v
an
ci
n
g
 
ev
id
en
ce
-
b
as
ed
 
p
ra
ct
ic
e 
- 
a 
q
u
ar
te
rl
y
 
co
m
p
il
at
io
n
 
o
f 
re
se
ar
ch
 
u
p
d
at
es
 m
o
st
 
li
k
el
y
 t
o
 
ch
an
g
e 
cl
in
ic
al
 
p
ra
ct
ic
e.
 
W
in
te
r 
2
0
1
2
.2
0
 
[C
o
ll
ec
ti
o
n
 o
f 
S
tu
d
ie
s]
 
[S
el
ec
te
d
 
ex
am
p
le
s 
] 
[N
ew
 o
r 
ex
is
ti
n
g
 
p
ra
ct
ic
e]
 
[P
ri
o
r 
ev
id
en
ce
] 
N
o
n
e 
D
is
cl
o
se
d
 
R
es
ea
rc
h
 
u
p
d
at
es
 m
o
st
 
li
k
el
y
 t
o
 
ch
an
g
e 
cl
in
ic
al
 
p
ra
ct
ic
e 
Research 
updates most 
likely to 
change 
clinical 
practice 
[10 selected 
examples] 
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Research 
updates most 
likely to 
change 
clinical 
practice 
[7 selected 
examples] 
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A
u
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v
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n
m
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D
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o
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H
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n
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A
g
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n
g
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M
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A
u
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ra
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o
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n
m
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D
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en
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o
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H
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lt
h
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n
d
 
A
g
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n
g
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M
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o
m
p
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h
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v
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M
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ag
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t 
F
ra
m
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o
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v
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o
n
m
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l 
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A
u
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ra
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C
o
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ec
ti
o
n
 o
f 
S
tu
d
ie
s 
[S
el
ec
te
d
 e
x
am
p
le
s]
  
E
n
v
ir
o
n
m
en
ta
l 
S
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n
n
in
g
: 
D
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a 
an
al
y
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it
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u
re
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v
ie
w
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v
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o
ry
 c
o
m
m
it
te
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m
p
li
an
ce
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ct
iv
it
y
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st
ak
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o
ld
er
 f
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d
b
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k
 
E
x
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ti
n
g
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B
S
 S
er
v
ic
es
 
M
ed
ic
ar
e 
B
en
ef
it
s 
S
ch
ed
u
le
 (
M
B
S
) 
In
ap
p
ro
p
ri
at
e 
u
se
 o
f 
te
st
in
g
/ 
p
ro
ce
d
u
re
s 
To 
determine 
whether 
testing/ 
procedures 
are 
appropriate 
for MBS 
reimburseme
nt, 
considering 
the safety, 
efficacy, 
effectiveness 
of the tests 
and the 
effect that 
the results of 
the test have 
on treatment 
[5 selected 
examples] 
MBS reviews 
seek to ensure 
that existing 
MBS services 
reflect 
contemporary 
evidence, offer 
improved health 
outcomes for 
patients and 
represent value 
for money.  
B
ry
so
n
 G
.L
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B
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k
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o
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h
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re
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M
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n
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p
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p
er
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m
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C
o
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o
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S
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d
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d
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x
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p
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N
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n
g
 p
ra
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e 
P
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o
r 
ev
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N
o
n
e 
D
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o
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d
 
M
ed
ic
al
 R
ev
er
sa
l 
A 
phenomenon 
in 
which ‘‘a 
medical 
practice is 
found to be 
inferior to 
some 
lesser or 
prior 
standard of 
care’’ 
[7 selected 
examples] 
Medical 
reversals are 
indeed 
concerning; 
however, the 
fact that 
accepted 
practices were 
challenged and 
subsequently 
reversed in the 
face of better 
evidence 
highlights the 
self-correcting 
nature of an 
evidence-based 
practice. 
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A-VI 
M
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le
o
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M
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h
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R
o
b
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D
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n
ag
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C
h
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m
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n
id
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A
l-
S
h
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S
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m
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 R
 
C
h
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W
 
G
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u
 P
 
B
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m
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h
: 
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u
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g
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A
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m
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o
n
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A
p
p
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p
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e 
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io
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ra
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N
o
t 
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an
sl
at
ed
 t
o
 p
ra
ct
ic
e 
N
o
n
e 
D
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cl
o
se
d
 
R
es
ea
rc
h
 W
as
te
 
Avoidable 
waste or 
inefficiency 
in 
biomedical 
research. 
Research 
decisions not 
based on 
questions 
relevant to 
users of 
research. 
Inappropriat
e research 
designs, 
methods, or 
analysis. 
Inefficient 
research 
regulation or 
management
. 
Inaccessible 
research 
information. 
Biased or 
unusable 
research 
reports) 
More than 
50% studies 
designed 
without 
reference to 
systematic 
reviews of 
existing 
evidence  
Adequate 
steps to 
reduce bias 
not taken in 
more than 
50% of 
studies  
More than 
50% of 
studies 
never fully 
reported  
More than 
30% of trial 
interventions 
not 
sufficiently 
described 
More than 
50% of 
planned 
study 
outcomes 
not reported 
Systems of 
oversight and 
regulation 
should be 
developed to 
promote rigour, 
protect the 
integrity of the 
scientific 
process, and 
protect scientists 
from some of the 
perverse 
influences. 
H
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H
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V
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G
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B
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g
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p
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h
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 d
o
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w
h
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d
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v
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m
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h
n
o
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g
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ar
d
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 t
h
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v
es
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C
o
u
n
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o
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al
 
H
T
A
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g
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S
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d
 e
x
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D
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o
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p
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o
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N
o
n
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D
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o
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D
is
in
v
es
tm
en
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The 
cessation or 
restriction 
of 
potentially 
harmful, 
clinically 
ineffective 
NICE has 
identified 
102 
interventions 
for which 
there is little 
or no 
evidence of 
The key to 
disinvestment is 
not just what to 
stop doing but 
how to make it 
happen - that is, 
decision makers 
need to be aware 
A-VII 
 
A-VII 
or cost 
inefficient 
practices. 
The process 
of taking 
resources 
from one 
service in 
order to use 
them for 
other 
purposes 
(i.e. 
reallocation 
of 
resources). 
benefit; 27 
are 
covered by 
guidance, 
guidance is 
being 
developed 
for a further 
30, and 
further 
assessment 
is being 
considered 
for 45 +. 
of funding 
disincentives.  
Because 
removing 
resources is 
more difficult 
than providing 
additional 
resources, the 
threshold for 
disinvestment 
may need to be 
different from 
the threshold for 
investment.  
 
O
b
so
le
te
/ 
o
u
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o
d
ed
/ 
ab
an
d
o
n
ed
 
te
ch
n
o
lo
g
ie
s 
Those that 
have been 
superseded 
or 
demonstrate
d to be 
ineffective 
or harmful. 
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ls
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B
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d
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h
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E
v
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tm
en
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o
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n
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H
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P
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A
 C
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S
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d
y
 i
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b
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S
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p
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o
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y
n
d
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m
e.
2
6
 
[C
o
ll
ec
ti
o
n
 o
f 
S
tu
d
ie
s]
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p
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N
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P
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o
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N
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D
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v
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The 
processes of 
withdrawing 
(partially or 
completely) 
resources 
from any 
existing 
healthcare 
practices, 
procedures, 
technologies 
or 
pharmaceuti
cals that are 
deemed to 
deliver little 
or no health 
gain relative 
to their cost, 
and thus are 
not efficient 
health 
resource 
allocations. 
20-30% of 
patients do 
not receive 
treatments of 
proven 
effectiveness 
and that 20-
25% of 
patients have 
treatments 
that are 
unnecessary 
or 
potentially 
harmful.  
Investigative 
issues 
associated 
with 2 
chosen 
health care 
practices 
Defining and 
proving 
inferiority of 
health care 
practices is not 
only 
conceptually 
difficult, but is 
also limited by 
data availability 
and 
interpretation.  
The potential 
over-utilisation 
of less than 
effective clinical 
practices and the 
potential under-
utilisation of 
effective clinical 
practices not 
only result in 
less than optimal 
care but also 
fragmented, 
inefficient and 
unsustainable 
resource 
allocation. 
Systematic 
policy 
approaches to 
disinvestment 
will improve 
equity, 
efficiency, 
quality and 
safety of care, as 
well as 
sustainability of 
resource 
allocation. 
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p
u
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o
u
s 
in
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n
ce
s 
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o
m
 m
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a
-
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2
 m
et
a-
an
al
y
se
s,
 p
re
v
io
u
sl
y
 a
ss
em
b
le
d
 
fo
r 
tw
o
 e
m
p
ir
ic
al
 r
es
ea
rc
h
 s
tu
d
ie
s 
o
n
 b
in
ar
y
 
o
u
tc
o
m
es
 
co
n
d
u
ct
ed
 a
t 
th
e 
C
o
p
en
h
ag
en
 T
ri
al
 U
n
it
. 
 
R
an
d
o
m
 e
ff
ec
ts
 m
o
d
el
, 
p
 ≤
 5
%
, 
cr
o
ss
es
 T
S
M
B
 
af
te
r 
su
rp
as
si
n
g
 H
IS
 b
as
ed
 o
n
 R
R
R
 =
 1
5
%
 
as
su
m
p
ti
o
n
. 
S
en
si
ti
v
it
y
 a
n
al
y
se
s 
(f
ig
u
re
 1
) 
N
o
n
e 
D
is
cl
o
se
d
 
F
al
se
 p
o
si
ti
v
e 
re
su
lt
s 
Report a 
treatment 
effect when 
in reality 
there is no 
effect 
3 false 
positive/12 
meta-
analyses 
p>0.05 
Meta-analysis 
[Information 
Size] 
considerations 
and trial 
sequential 
monitoring 
boundaries may 
provide a 
valuable tool for 
guarding against 
false positive 
results and 
premature 
dissemination of 
marginal or 
useless 
interventions. 
E
ls
h
au
g
 A
G
 
H
il
le
r 
JE
 
T
u
n
is
 S
R
 
M
o
ss
 J
R
 
C
h
al
le
n
g
es
 i
n
 A
u
st
ra
li
an
 p
o
li
cy
 p
ro
ce
ss
es
 f
o
r 
d
is
in
v
es
tm
en
t 
fr
o
m
 e
x
is
ti
n
g
, 
in
ef
fe
ct
iv
e 
h
ea
lt
h
 c
ar
e 
p
ra
ct
ic
es
.2
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[C
o
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ti
o
n
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f 
S
tu
d
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[S
el
ec
te
d
 e
x
am
p
le
s]
  
N
ew
 o
r 
ex
is
ti
n
g
 p
ra
ct
ic
e 
P
ri
o
r 
ev
id
en
ce
 
N
o
 c
o
m
p
et
in
g
 i
n
te
re
st
s.
 
D
is
in
v
es
tm
en
t 
Removing 
currently 
used 
ineffective, 
or 
inappropriat
ely 
applied, 
health care 
practices 
[2 selected 
examples] 
Developing 
health services 
and policy 
research 
methodologies 
that tackle these 
complexities to 
assist policy- 
makers will 
advance the 
disinvestment 
agenda. This is 
a growing area 
of priority 
setting in health 
care that 
requires national 
and international 
perspectives, 
debate and 
collaboration. 
A-X 
 
A-X 
L
o
d
er
 E
 
W
ei
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n
b
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m
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F
ri
sh
b
er
g
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S
il
b
er
st
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n
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A
m
er
ic
an
 H
ea
d
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h
e 
S
o
ci
et
y
 
C
h
o
o
si
n
g
 W
is
el
y
 T
as
k
 F
o
rc
e 
C
h
o
o
si
n
g
 w
is
el
y
 i
n
 h
ea
d
ac
h
e 
m
ed
ic
in
e:
 t
h
e 
A
m
er
ic
an
 
H
ea
d
ac
h
e 
S
o
ci
et
y
's
 l
is
t 
o
f 
fi
v
e 
th
in
g
s 
p
h
y
si
ci
an
s 
an
d
 p
at
ie
n
ts
 
sh
o
u
ld
 q
u
es
ti
o
n
.2
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[C
o
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ti
o
n
 o
f 
S
tu
d
ie
s]
 
[S
el
ec
te
d
 e
x
am
p
le
s]
  
R
el
ev
an
t 
so
ci
et
y
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u
id
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in
es
 
[E
x
is
ti
n
g
 r
es
ea
rc
h
 e
v
id
en
ce
] 
A
m
er
ic
an
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ea
d
ac
h
e 
S
o
ci
et
y
 
O
v
er
u
se
d
 o
r 
M
is
u
se
d
 T
es
ts
 
an
d
 T
re
at
m
en
ts
 
Unnecessary 
tests and 
procedures 
that don’t 
benefit the 
patient and 
can even 
cause harm 
[11 
candidate 
items 5 
recommenda
tions] 
It is important to 
think critically 
about the 
evidence for 
commonly used 
tests and 
procedures, and 
whether possible 
harms are likely 
to exceed 
potential 
benefits 
A-XI 
 
A-XI 
Io
an
n
id
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P
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m
p
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o
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it
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m
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k
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s 
re
p
o
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n
 h
ig
h
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 c
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n
d
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u
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d
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n
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u
b
se
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u
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t 
m
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W
e 
co
n
si
d
er
ed
 b
io
m
ar
k
er
s 
th
at
 h
ad
 a
 r
el
at
iv
e 
ri
sk
 (
R
R
) 
es
ti
m
at
e 
p
re
se
n
te
d
 n
u
m
er
ic
al
ly
 
in
 t
h
e 
ab
st
ra
ct
 o
f 
an
 a
rt
ic
le
 t
h
at
 
h
ad
 r
ec
ei
v
ed
 m
o
re
 t
h
an
 4
0
0
 c
it
at
io
n
s 
in
 I
S
IW
eb
o
f 
S
ci
en
ce
 u
n
ti
l 
D
ec
em
b
er
 2
0
1
0
. 
T
h
e 
m
ag
n
it
u
d
e 
o
f 
th
e 
ef
fe
ct
 
si
ze
 (
R
R
) 
in
 t
h
e 
h
ig
h
ly
 c
it
ed
 s
tu
d
y
 
T
h
e 
m
ag
n
it
u
d
e 
o
f 
th
e 
ef
fe
ct
 
si
ze
 (
R
R
) 
in
 t
h
e 
m
et
a-
an
al
y
si
s 
an
d
 a
g
ai
n
st
 t
h
e 
la
rg
es
t 
st
u
d
y
 u
si
n
g
 t
h
e 
sa
m
e 
ex
p
o
su
re
 
co
n
tr
as
t 
N
o
n
e 
D
is
cl
o
se
d
 
F
al
se
 p
o
si
ti
v
e 
In
fl
at
ed
 r
es
u
lt
s 
RRs were in 
opposite 
direction, 
larger, more 
than 
twice as 
large, more 
than 4 times 
as large, 
or different 
beyond 
chance in the 
highly 
cited vs the 
largest study 
and in the 
highly cited 
study vs the 
meta-
analysis 
For 30 of the 
35 (86%), 
the highly 
cited studies 
had a 
stronger 
effect 
estimate 
than the 
largest 
study; for 3 
the largest 
study was 
also the 
highly cited 
study; and 
only twice 
was the 
effect size 
estimate 
stronger 
in the largest 
than in the 
highly cited 
study. For 
29 of the 35 
(83%) 
highly cited 
studies, the 
correspondin
g meta-
analysis 
found a 
smaller 
effect 
estimate. 
Our study 
documents that 
results in highly 
cited biomarker 
studies often 
significantly 
overestimate the 
findings seen 
from meta-
analyses. 
Evidence from 
multiple studies, 
in particular 
large 
investigations, is 
necessary to 
appreciate the 
discriminating 
ability of these 
emerging 
risk factors. 
Rapid clinical 
adoption in the 
absence of such 
evidence may 
lead to wasted 
resources. 
Io
an
n
id
is
 
JP
 
C
o
n
tr
ad
ic
t
ed
 a
n
d
 
in
it
ia
ll
y
 
st
ro
n
g
er
 
ef
fe
ct
s 
in
 
h
ig
h
ly
 
ci
te
d
 
cl
in
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al
 
re
se
ar
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E
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u
d
ed
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p
u
b
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o
n
s 
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at
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re
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iv
ed
 
m
o
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h
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1
0
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S
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–
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d
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ta
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o
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H
ig
h
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d
 s
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d
y
 
S
u
b
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q
u
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t 
re
se
ar
ch
 
N
o
n
e 
D
is
cl
o
se
d
 
N
eg
at
iv
e 
  
When they 
claimed the 
tested 
experimental 
intervention 
7 (16%) 
were 
contradicted 
by 
subsequent 
Evidence from 
recent 
trials, no matter 
how impressive, 
should 
A-XII 
 
A-XII 
was 
ineffective, 
harmful, or 
no better 
from the 
control 
intervention 
studies, 7 
others 
(16%) had 
found effects 
that were 
stronger than 
those of 
subsequent 
studies 
be interpreted 
with caution, 
when only 
one trial is 
available  
C
o
n
tr
ad
ic
t
ed
 
Subsequent 
studies that 
either reach 
opposite 
conclusions 
Io
an
n
id
is
 J
P
 
T
ri
k
al
in
o
s 
T
A
 
E
ar
ly
 e
x
tr
em
e 
co
n
tr
ad
ic
to
ry
 e
st
im
at
es
 m
ay
 a
p
p
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r 
in
 p
u
b
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sh
ed
 
re
se
ar
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P
ro
te
u
s 
p
h
en
o
m
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o
n
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n
 m
o
le
cu
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r 
g
en
et
ic
s 
re
se
ar
ch
 a
n
d
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n
d
o
m
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ed
 t
ri
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re
v
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u
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y
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 c
u
m
u
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ti
v
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m
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a
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n
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o
f 
g
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o
ci
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n
 s
tu
d
ie
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w
it
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 b
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ar
y
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u
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o
m
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n
d
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n
 
M
E
D
L
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E
  
M
o
st
 p
o
si
ti
v
e 
re
su
lt
s 
M
o
st
 n
eg
at
iv
e 
re
su
lt
s 
N
o
n
e 
D
is
cl
o
se
d
 
P
ro
te
u
s 
p
h
en
o
m
en
o
n
 
Rapid, early 
succession 
of extreme 
findings. 
Studies 
reporting 
very 
contradictor
y 
conclusions 
in short 
sequence. 
At the time 
of the first 
heterogeneit
y 
assessment, 
the most 
favorable-
ever result in 
support of a 
specific 
association 
was more 
likely to 
appear than 
the least 
favorable-
ever result 
(22 vs. 10, 
P=0.017); 
the opposite 
was seen at 
the second 
heterogeneit
y assessment 
(15 vs. 5, 
P=0.031). 
This bias 
highlights the 
importance of 
performing 
further 
validation 
research and of 
systematically 
appraising the 
evolving 
accumulated 
evidence on each 
research 
question. 
A-XIII 
 
A-XIII 
T
ri
k
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C
h
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h
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u
n
ai
n
en
 A
 
W
ah
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n
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E
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E
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u
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v
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o
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v
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m
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M
et
a-
an
al
y
se
s 
o
f 
m
en
ta
l-
h
ea
lt
h
-
re
la
te
d
 i
n
te
rv
en
ti
o
n
s 
b
y
 s
cr
ee
n
in
g
 t
h
e 
1
6
1
 p
er
ti
n
en
t 
C
o
ch
ra
n
e 
sy
st
em
at
ic
 
re
v
ie
w
s 
in
cl
u
d
ed
 i
n
 t
h
e 
M
en
ta
l 
H
ea
lt
h
 L
ib
ra
ry
. 
 [
N
ew
 o
r 
ex
is
ti
n
g
 m
en
ta
l 
h
ea
lt
h
 
p
ra
ct
ic
es
] 
[P
ri
o
r 
ev
id
en
ce
] 
N
o
n
e 
D
is
cl
o
se
d
 
U
n
fa
v
o
u
ra
b
le
 o
r 
fa
v
o
u
ra
b
le
 s
h
if
ts
 
o
v
er
 t
im
e 
Changes in 
updated 
meta-
analyses 
according to 
whether 
results 
become less 
or more 
favorable for 
the 
experimental 
intervention 
Overall 
efficacy 
(death + 
relapse + 
failure) 157 
unfavourable 
shifts vs 125 
favourable 
[56 (50–
62)% 
unfavourable
] 
The 
generalizability 
of our findings 
should be 
explored also in 
other medical 
fields where the 
majority of the 
randomized 
evidence is 
derived from 
relatively small 
trials. 
P
ra
sa
d
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an
n
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E
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u
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v
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h
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N
o
n
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D
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D
e-
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p
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m
en
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ti
o
n
  
Abandonme
nt 
of medical 
interventions
, de-
implementati
on broadly 
as “stopping 
practices 
that are not 
evidence-
based” 
[4 selected 
contradicted 
medical 
practice 
examples, 3 
selected 
examples of 
unproven 
medical 
practices] 
Strategies to 
eliminate 
ineffective and 
harmful 
practices may 
help contain 
healthcare 
spending and 
optimize 
outcomes. 
Ideally, the 
majority of 
medical 
decisions should 
be supported by 
robust data, with 
ambiguous 
decisions made 
only 
within the 
confines of 
ongoing studies. 
The lesson of 
PTAS is that 
higher upfront 
standards 
have potential to 
protect patients 
C
o
n
tr
ad
ic
te
d
 m
ed
ic
al
 p
ra
ct
ic
es
 
Contradicted 
established 
medical 
practices 
When large, 
well-done 
randomized 
trials have 
contradicted 
current 
medical 
practices 
 
U
n
p
r
o
v
en
 
m
ed
i
ca
l 
p
ra
ct
ic
es
 Many 
medical 
practices are 
A-XIV 
 
A-XIV 
largely 
untested or 
have 
insufficient 
evidence 
unable to 
support or 
refute 
interventions 
from ultimately 
flawed care.  
M
ak
ic
 M
B
 
V
o
n
R
u
ed
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R
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 C
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C
h
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w
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E
v
id
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u
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g
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o
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o
w
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o
u
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T
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p
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N
o
n
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D
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o
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S
ac
re
d
 C
o
w
s 
Practices are 
considered 
routine and 
beyond 
dispute 
A clinical 
practice 
despite 
research that 
shows that 
the practice 
is not helpful 
and may 
even be 
harmful to 
the patients 
we serve.  
[7 updated 
guidelines 
with 
removal of 
sacred cows 
and supplies 
evidence-
based 
alternatives] 
Science is 
dynamic and 
ever changing. 
Clinical 
practices should 
be based on 
evidence 
whenever 
possible. The 
challenge is in 
getting 
the evidence in 
the right hands 
and encouraging 
and empowering 
the 
clinicians at the 
bedside to make 
clinical changes, 
moving nursing 
practice away 
from habits of 
tradition. 
A-XV 
 
A-XV 
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ti
v
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In some 
fields of 
research, we 
may 
observe 
diminishing 
effects for 
the strength 
of 
research 
findings and 
rapid 
alternations 
of 
exaggerated 
claims and 
extreme 
contradiction
s 
‘‘Proteus 
phenomenon
,’’ the first 
published 
study on a 
scientific 
question 
may find a 
most 
extravagant 
effect size; 
this is 
followed by 
the 
publication 
of 
another 
study that 
shows a 
large 
contradicting 
effect. 
Subsequent 
studies 
report 
effect sizes 
between 
these 
extremes + 
Replication 
of research 
findings in 
different 
studies 
3 spuriously 
effective 
treatments, 2 
Discrepancie
s and 
diminishing 
effects 
over time, 2 
Diminishing 
and refuted 
effects, 1 
refuted 
Given that we 
currently have 
too many 
research 
findings, often 
with low 
credibility, 
replication and 
rigorous 
evaluation 
become as 
important as 
or even more 
important than 
discovery.  
1. Promote 
multidisciplinary 
communication. 
2. Foster 
systematic, 
evidence-based 
approaches to 
research. 
3. Acknowledge 
in earnest the 
difficulty and 
even the failures 
of the scientific 
enterprise. 
4. Examine 
which pathways 
have led to 
specific 
successes and 
failures in 
translation. 
5. Focus on 
credibility rather 
than simply the 
statistical 
significance of 
research 
findings. 
6. Synthesize 
evidence 
systematically 
from many 
studies and 
teams of 
investigators and 
anticipate this 
integration from 
the design phase 
A-XVI 
 
A-XVI 
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How much 
the treatment 
effect has 
changed 
over time  
How much 
the pooled 
treatment 
effect will 
change in 
the future. 
Extreme 
early 
fluctuations 
in the 
treatment 
effect 
were 
observed in 
three 
interventions 
(magnesium 
in 
myocardial 
infarction, 
calcium and 
antiplatelet 
agents for 
prevention 
of 
preeclampsia
), 
where recent 
mega-trials 
have 
contradicted 
prior meta-
analyses, 
as well as in 
four other 
examples 
where early 
large 
treatment 
effects were 
dissipated 
when more 
data 
appeared 
When 
cumulative 
treatment effect 
estimates change 
widely over 
time, results 
should be 
interpreted with 
caution because 
large changes, in 
either direction, 
may 
sometimes be 
observed again 
in the future. + 
In the presence 
of wide early 
oscillations, 
clinicians should 
also wait for a 
more complete 
picture to evolve  
Full registration 
and 
publication of all 
trials is an 
ethical 
imperative 
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Practices 
[that] are 
considered 
routine and 
beyond 
dispute  
A clinical 
practice 
despite 
research that 
shows that 
the practice 
is not helpful 
and may 
even be 
harmful to 
the patients 
we serve. 
[4 updated 
guidelines 
supplies 
evidence-
based 
alternatives] 
None 
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Interventions 
that robust 
evidence 
reveals are 
of no 
benefit, or 
even 
harmful 
Widespread 
use of 
ineffective 
interventions
, which may 
consume up 
to 30% of 
healthcare 
budgets  
2 reversals  
More than 
150 high-
volume 
clinical 
services on 
the Medicare 
Benefits 
Schedule 
that are 
potentially 
of low-
value, with 
almost half 
being 
ineffective 
or harmful 
on the basis 
of multiple 
trials and 
systematic 
reviews 
If as clinicians, 
we wish to avoid 
being 
marginalised in 
debates around 
minimising use 
of ineffective or 
harmful 
interventions 
and reduce the 
risk of being 
governed by 
policy decree 
with its inherent 
clumsiness and 
potential for 
unintended 
consequences, 
we 
will have no 
choice but to 
define low-value 
care and answer 
the question 
‘how much 
evidence is 
enough to 
change beliefs?’ 
A-XIX 
 
A-XIX 
Io
an
n
id
is
 J
P
 
T
ri
k
al
in
o
s 
T
A
 
N
tz
an
i 
E
E
 
C
o
n
to
p
o
u
lo
s-
Io
an
n
id
is
 D
G
 
G
en
et
ic
 a
ss
o
ci
at
io
n
s 
in
 l
ar
g
e 
v
er
su
s 
sm
al
l 
st
u
d
ie
s:
 a
n
 e
m
p
ir
ic
al
 a
ss
es
sm
en
t.
4
5
 
S
y
st
em
at
ic
 R
ev
ie
w
 
W
e 
u
p
d
at
ed
 a
 d
at
ab
as
e 
o
f 
3
6
 m
et
a-
an
al
y
se
s,
 b
y
 i
n
cl
u
d
in
g
 
1
9
 n
ew
 q
u
al
if
y
in
g
 m
et
a-
an
al
y
se
s 
an
d
 r
ep
la
ci
n
g
 f
o
u
r 
w
it
h
 
m
o
re
 r
ec
en
t 
o
n
es
. 
 
[F
ir
st
/S
m
al
le
r 
S
tu
d
ie
s]
 
[L
ar
g
e/
su
b
se
q
u
en
t 
st
u
d
ie
s]
 
N
o
n
e 
D
is
cl
o
se
d
 
D
is
cr
ep
an
ci
es
 o
f 
ef
fe
ct
 o
v
er
 t
im
e 
Discrepancie
s of effect 
over time 
The 
magnitude 
of the 
genetic 
effect 
differed 
significantly 
in large 
versus 
smaller 
studies in ten 
(18%), 20 
(36%), and 
21 (38%) 
meta-
analyses 
with tests of 
rank 
correlation, 
regression 
on SE, and 
regression 
on inverse of 
variance, 
respectively 
The results 
of the first 
studies 
differed 
significantly 
from 
the results of 
subsequent 
research in 
14 (26%) 
metaanalyse
s, 
on the basis 
of both fixed 
and random 
effects 
Information with 
respect to 
genetic 
associations 
should be 
thoroughly 
examined and 
cautiously 
scrutinised 
before its 
integration into 
clinical practice. 
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Quantitative 
signals for 
updating 
were 
changes in 
statistical 
significance 
or relative 
changes in 
effect 
magnitude 
of at 
least 50% 
involving 1 
of the 
primary 
outcomes of 
the original 
systematic 
review or 
any 
mortality 
outcome. 
Qualitative 
signals 
included 
substantial 
differences 
in 
characterizat
ions of 
effectiveness
, 
new 
information 
about harm, 
and caveats 
about the 
previously 
reported 
findings that 
would affect 
clinical 
decision 
making. 
A qualitative 
or 
quantitative 
signal for 
updating 
occurred for 
57% of 
reviews 
(95% 
CI, 47% to 
67%). 
Median 
duration of 
survival free 
of a signal 
for 
updating 
was 5.5 
years (CI, 
4.6 to 7.6 
years). 
However, a 
signal 
occurred 
within 2 
years for 
23% of 
reviews and 
within 1 year 
for 
15%. In 7%, 
a signal had 
already 
occurred at 
the time of 
publication.  
When the 
process of 
submission and 
rejection 
from other 
journals has 
resulted in the 
passage of more 
than 1 year from 
the date of the 
previous search, 
authors 
should update 
the search before 
resubmission + 
users of 
systematic 
reviews need to 
recognize that 
changes 
in evidence 
relevant to 
clinical decision 
making can 
occur 
within relatively 
short time 
frames. Once the 
search date is 
older than even 
1 year, users 
should check for 
more recent 
trials on the 
same topic to see 
whether new 
evidence has 
altered the 
findings of a 
given systematic 
review 
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Ineffective 
or harmful 
interventions
, ineffective 
or non-cost-
effective + 
Legacy 
items: Long-
established 
technologies 
that have 
never had 
their 
costeffective
ness 
assessed — 
look for 
coupling 
with other 
identificatio
n items. + 
Technology 
development
: When an 
intervention 
has evolved 
to the 
point that it 
differs 
markedly 
from the 
initial or 
prototype 
intervention 
that was 
originally 
assessed or 
funded, then 
the initial 
intervention 
should be 
reviewed 
(eg, 256-
slice 
compared 
with four-
slice 
computed 
tomography)
. + Assess 
new 
intervention 
— displace 
23 
ineffective 
or harmful 
interventions
, 6 
ineffective 
or non-cost-
effective 
Criteria based on 
those developed 
for health 
technology 
assessment 
(HTA) might 
facilitate the 
systematic and 
transparent 
identification of 
existing, 
potentially 
ineffective 
practices on 
which to 
prioritise 
candidates for 
assessment as 
to their cost-
effectiveness. 
• The process 
could be jointly 
funded by all 
relevant 
stakeholders but 
centrally 
administered, 
with HTA 
groups 
resourced to 
undertake 
identification 
and assessment 
and to 
liaise with 
clinicians, 
consumers and 
funding 
stakeholders. 
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Medical 
reversal 
refers to the 
phenomenon 
of a new 
superior trial 
that 
contradicts 
current 
clinical 
practice 
flawed 
theory and 
small studies 
x3 + positive 
results from 
trials based 
on 
surrogate 
measures 
that 
are 
subsequently 
overturned 
by trials 
based on 
clinically 
meaningful 
outcomes x6 
+ 2x 
introductory 
medical 
reversal  
However, we 
should not fear 
the 
disequilibrium 
that comes from 
truth, but 
embrace it as the 
path to better 
patient care. 
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“the 
phenomenon 
of a new 
trial — 
superior to 
predecessors 
because of 
better 
design, 
increased 
power, or 
more 
appropriate 
controls 
— 
contradicting 
current 
clinical 
practice” + 
reversal: A 
medical 
practice falls 
out of favor 
not by 
being 
surpassed, 
but when we 
discover that 
it did not 
work all 
along, either 
failing to 
achieve its 
intended 
goal or 
carrying 
harms 
that 
outweighed 
the benefits 
13 medical 
reversals 
The solution to 
reversal is 
upfront, 
randomized 
clinical trials for 
new clinical 
practices and a 
systematic 
method to 
evaluate 
practices 
already in 
existence. 
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In molecular 
epidemiolog
y, it is very 
common to 
see an early 
succession 
of the most 
extreme 
opposing 
estimates of 
effect 
followed by 
studies that 
show inter 
mediate 
results. 
Typically, 
the study 
with the 
most 
prominent 
effect size is 
published 
first. This is 
immediately 
followed by 
the study 
that shows 
the 
most 
opposite 
effect ever 
observed. 
This creates 
extreme 
between-
study 
heterogeneit
y in the 
results of 
these early 
studies. 
Many 
studies then 
follow that 
report results 
that are 
intermediate 
between 
these two 
extremes. 
The 
between-
Among 
highly-cited 
articles 
published in 
1990-2003 
and 
receiving 
over 1000 
citations by 
2004, 5 of 6 
efficacy 
findings 
based on 
non-
randomized 
trials were 
already 
contradicted 
or 
found to be 
exaggerated 
by 2004. 
Moreover, 
efficacy 
findings 
were already 
contradicted 
or found to 
be 
exaggerated 
in 9 of 39 
interventions 
[13]. Many 
of 
these 
contradiction
s such as the 
impact of 
various 
vitamins on 
cardiovascul
ar or cancer 
mortality 
[14], 
or the effect 
of hormone 
replacement 
therapy on 
coronary 
artery 
disease in 
postmenopa
usal women 
Therefore, 
getting rid of 
tentative-but-
wrong research 
findings should 
become at least 
as important as 
finding new 
ones.  
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Do not do 
recommenda
tions: The do 
not do 
recommenda
tions 
database 
contains 
clinical 
practices, 
identified 
during the 
development 
of guidance 
that should 
be 
discontinued 
or not used 
routinely. 
Each 
recommenda
tion contains 
information 
on the 
healthcare 
setting and 
links to the 
relevant 
NICE 
guidance or  
987 Do-Not-
Do 
Recommend
ations/1793 
NICE 
Savings and 
Productivity 
Collection 
Do not do items 
should be 
discontinued or 
not used 
routinely 
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Nonreplicati
on 
occurs when 
the GWA 
study 
proposes 
that 
there is a 
gene-disease 
association, 
but the 
accumulatio
n 
of data from 
subsequent 
studies find 
no genetic 
effect. 
Inconsistenc
y occurs 
when there 
is large 
between-
study 
heterogeneit
y (diversity) 
in the 
magnitude 
of the 
genetic 
effects. 
The seven 
studies 
fulfilling 
these ad hoc 
eligibility 
criteria 
are shown in 
table 1 . As 
of 1/2007, 
for 3 studies 
[19– 
21] the 
replication 
effort was 
confined to 
investigation
s 
published in 
the same 
issue as the 
GWA or 
even in the 
same paper. 
Two of these 
three 
‘internally’ 
replicated 
articles 
found some 
hints of 
inconsistenc
y across 
different 
study 
populations: 
the 
protective 
effect of an 
IL23R 
variant 
for 
inflammator
y disease 
was not seen 
for 
ulcerative 
colitis in 
Jewish 
people [21] 
and the 
association 
of the QT 
interval with 
Public 
registration of 
protocols and 
databases, as in 
the Wellcome 
Trust and 
NCBI’s database 
of Genotype 
AND Phenotype 
(dbGAP) 
initiatives, may 
also help 
obviating these 
biases. Efforts 
should converge 
towards 
allowing 
transparent 
and systematic 
integration of 
both GWA data 
[87] 
and subsequent 
evidence. 
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 ineffective 
and/or 
unsafe 
services, 
treatments 
not proven 
to be clinical 
effective 
A total of 
5209 articles 
were 
screened for 
eligibility, 
resulting in 
156 
potentially 
ineffective 
and/or 
unsafe 
services 
being 
identified for 
consideratio
n. 
The list 
includes 
examples 
where 
practice 
optimisation 
(ie, assessing 
relative 
value of a 
service 
against 
comparators) 
might be 
required. 
The list of health 
care services 
produced 
provides a 
launchpad for 
expert clinical 
detailing. 
Exploring the 
dimensions of 
how, and under 
what 
circumstances, 
the 
appropriateness 
of certain 
services has 
fallen into 
question, 
will allow 
prioritisation 
within health 
technology 
reassessment 
initiatives. 
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practices are 
considered 
routine and 
beyond 
dispute + a 
clinical 
practice 
despite 
research that 
shows that 
the practice 
is not helpful 
and may 
even be 
harmful to 
the patients 
we serve. + 
“The 
integration 
of best 
research, 
clinical 
expertise, 
and patient 
values in 
making 
decisions 
about the 
care 
of 
individualize
d patients.” 
4 updated 
guidelines 
supplies 
evidence-
based 
alternatives 
None 
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established 
standards 
must be 
abandoned 
not because 
a better 
replacement 
has been 
identified 
but simply 
because 
what was 
thought 
to be 
beneficial 
was not. 
For example, 
percutaneous 
coronary 
intervention 
performed 
for stable 
coronary 
artery 
disease 
and hormone 
therapy 
prescribed 
for 
postmenopa
usal 
women cost 
billions of 
dollars and 
supported 
the existence 
of entire 
specialties 
for many 
years + In an 
evaluation of 
35 trials 
that were 
published in 
a major 
clinical 
journal in 
2009 and 
that tested an 
established 
clinical 
practice, 16 
(46%) 
reported 
results 
consistent 
with current 
beneficial 
practice, 
16 (46%) 
reported 
evidence 
that 
contradicted 
current 
practice 
and 
constituted a 
reversal, and 
Given the slow 
rate of 
abandonment of 
ineffective 
medical 
practices, the 
standards 
governing drug 
and device 
approval 
must be 
strengthened. 
This means that 
newly proposed 
innovations 
should be 
evaluated in 
sufficiently large 
randomized 
trials that 
demonstrate 
improvement in 
important 
clinical end 
points before 
being widely 
disseminated. 
+ Large trials of 
new innovations 
should be 
designed and 
conducted by 
investigators 
without 
conflicts of 
interest, under 
the auspices of 
nonconflicted 
scientific bodies. 
Instead of 
designing, 
controlling, 
and conducting 
the trials, 
manufacturers 
may offer the 
respective 
budget to a 
centralized 
public pool of 
funding, keeping 
the trial design 
and conduct 
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The level of 
evidence 
classification 
combines an 
objective 
description 
of the 
existence 
and the types 
of studies 
supporting 
the 
recommenda
tion and 
expert 
consensus, 
according to 
1 of the 
following 3 
categories: 
•Level of 
evidence A: 
recommenda
tion based 
on evidence 
from 
multiple 
randomized 
trials or 
meta-
analyses 
•Level of 
evidence B: 
recommenda
tion based 
on evidence 
from a single 
randomized 
trial or 
nonrandomiz
ed studies 
•Level of 
evidence C: 
recommenda
tion based 
on expert 
opinion, case 
studies, or 
standards of 
care. 
 
The class of 
recommenda
Among 
guidelines 
with at least 
1 revision or 
update by 
September 
2008, the 
number of 
recommenda
tions 
increased 
from 1330 to 
1973 
(+48%) from 
the first to 
the current 
version, with 
the largest 
increase 
observed in 
use of class 
II 
recommenda
tions. 
Considering 
the 16 
current 
guidelines 
reporting 
levels of 
evidence, 
only 314 
recommenda
tions of 2711 
total are 
classified as 
level of 
evidence A 
(median, 
11%), 
whereas 
1246 
(median, 
48%) are 
level of 
evidence C. 
Level of 
evidence 
significantly 
varies across 
categories of 
guidelines 
(disease, 
Our finding that 
a large 
proportion of 
recommendation
s in ACC/AHA 
guidelines are 
based on lower 
levels of 
evidence or 
expert opinion 
highlights 
deficiencies in 
the sources of 
definitive data 
available for the 
generation of 
cardiovascular 
guidelines. To 
remedy this 
problem, the 
medical research 
community 
needs to 
streamline 
clinical trials, 
focus on areas of 
deficient 
evidence, and 
expand funding 
for clinical 
research. In 
addition, the 
process of 
developing 
guidelines needs 
to be improved 
with information 
about the impact 
that 
recommendation
s based on lower 
levels of 
evidence has on 
clinical practice. 
Finally, 
clinicians need 
to exercise 
caution when 
considering 
recommendation
s not supported 
by solid 
evidence. 
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practices are 
considered 
routine and 
beyond 
dispute + a 
clinical 
practice 
despite 
research that 
shows that 
the practice 
is not helpful 
and may 
even be 
harmful to 
the patients 
we serve. + 
“The 
integration 
of best 
research, 
clinical 
expertise, 
and patient 
values in 
making 
decisions 
about the 
care 
of 
individualize
d patients.” 
7 updated 
guidelines 
with 
removal of 
sacred cows 
and supplies 
evidence-
based 
alternatives 
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0 = no 
evidence, 1-
2 = slight, 3 
= 
conflicting, 
4 = 
promising, 5 
= good, 6 = 
strong 
64 no 
evidence, 77 
slight, 26 
conflicting, 
21 
promising, 3 
good, 6 
strong out of 
192 
None 
A-XXXII 
 
A-XXXII 
M
cC
an
d
le
ss
, 
D
. 
S
n
ak
e 
O
il
 
S
u
p
p
le
m
e
n
ts
?5
8
 C
o
ll
e
ct
io
n
 
o
f 
S
tu
d
i
es
 
S
el
ec
te
d
 
ex
am
p
le
s 
 
N
ew
 
o
r 
ex
is
ti
n
g
 
p
ra
ct
ic
e 
P
ri
o
r 
ev
id
e
n
ce
 
N
o
n
e 
D
is
cl
o
se
d
 
w
o
rt
h
 
it
/n
o
t worth it/not 124 not 
worth it, 45 
worth it 
None 
M
cC
an
d
le
ss
, 
D
. 
S
n
ak
e 
O
il
 V
er
si
o
n
 2
.5
9
 
C
o
ll
ec
ti
o
n
 o
f 
S
tu
d
ie
s 
S
el
ec
te
d
 e
x
am
p
le
s 
 
N
ew
 o
r 
ex
is
ti
n
g
 
p
ra
ct
ic
e 
P
ri
o
r 
ev
id
en
ce
 
N
o
n
e 
D
is
cl
o
se
d
 
0
 =
 n
o
 e
v
id
en
ce
, 
1
-2
 =
 
sl
ig
h
t,
 3
 =
 c
o
n
fl
ic
ti
n
g
, 
4
 =
 p
ro
m
is
in
g
, 
5
 =
 
g
o
o
d
, 
6
 =
 s
tr
o
n
g
 
0 = no 
evidence, 1-
2 = slight, 3 
= 
conflicting, 
4 = 
promising, 5 
= good, 6 = 
strong 
25 no 
evidence, 47 
slight, 12 
conflicting, 
8 promising, 
5 good, 1 
strong out of 
98 
None 
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 wasteful or 
unnecessary 
medical 
tests, 
treatments 
and 
procedures 
73 percent of 
physicians 
say the 
frequency of 
unnecessary 
tests and 
procedures 
is a very or 
somewhat 
serious 
problem. 
66 percent of 
physicians 
feel they 
have a great 
deal of 
responsibilit
y to make 
sure their 
patients 
avoid 
unnecessary 
tests and 
procedures. 
53 percent of 
physicians 
say that even 
if they know 
a medical 
test is 
unnecessary, 
they order it 
if a patient 
insists. 
58 percent of 
physicians 
say they are 
in the best 
position to 
address the 
problem, 
with the 
government 
as a distant 
second 
(15%). 
72 percent of 
physicians 
say the 
average 
medical 
doctor 
prescribes an 
national medical 
organizations 
continue to 
release lists of 
tests, treatments 
and procedures 
that patients do 
not need in all 
circumstances  
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the threat to 
human 
health posed 
by 
overdiagnosi
s and the 
waste of 
resources on 
unnecessary 
care. 
awareness of 
the benefits 
and harms of 
treatments 
and 
technologies 
and develop 
ways to 
wind back 
medical 
excess, 
safely and 
fairly.  
“Red flags” 
for possible 
overdiagnosi
s 
- The 
incidence is 
increasing 
while 
mortality 
stays the 
same 
  
- Labelling 
of a risk 
factor or 
biomarker to 
sound like a 
disease 
  
- Shift in 
diagnostic 
definitions 
or thresholds 
with no clear 
evidence 
that benefits 
are greater 
than harms 
  
 
60 
diagnostic 
tests or 
screening 
tests that 
cause 
overdiagnosi
s/all 
screening 
and 
diagnostic 
tests 
 escalating 
healthcare 
spending and the 
threats to health 
from climate 
change. Winding 
back 
unnecessary 
tests and 
treatments, 
unhelpful labels 
and diagnoses 
won’t only 
benefit those 
who directly 
avoid harm, it 
can also help us 
create a more 
sustainable 
future 
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Unnecessary 
tests, 
treatments 
and 
procedures 
do not add 
value to 
care. In fact, 
they take 
away from 
care by 
potentially 
exposing 
patients to 
harm, 
leading to 
more testing 
to 
investigate 
false 
positives and 
contributing 
to stress for 
patients. 
And of 
course 
unnecessary 
tests, 
treatments 
and 
procedures 
put 
increased 
strain on the 
resources of 
our health 
care system. 
The lists are 
based on 
definitive 
evidence 
that these 
specific 
interventions 
provide no 
benefit to 
patients. 
151 
Physician 
Recommend
ations and 
27 Patients 
Recommend
ations/All 
tests, 
treatments 
and 
procedures 
national medical 
organizations 
continue to 
release lists of 
tests, treatments 
and procedures 
that patients do 
not need in all 
circumstances  
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the 
phenomenon 
of a new 
trial—
superior to 
predecessors 
because of 
better 
design, 
increased 
power, 
or more 
appropriate 
controls—
contradicting 
current 
clinical 
practice 
Of the 124 
studies, 61 
(49%) 
reported a 
new practice 
surpassing 
current care; 
12 (10%) 
reported a 
new practice 
failing 
to improve 
on current 
practice; 16 
(13%) 
reported 
an existing 
practice that 
was upheld 
as beneficial 
and 16 
(13%) 
constituted 
reversal; and 
19 (15%) 
were 
classified 
as 
inconclusive
. 
The implications 
of reversal are 
notable. 
Reversal implies 
error or harm to 
patients who 
underwent the 
practice 
in question, 
during the years 
it was 
considered 
effective. 
Reversal also 
undermines trust 
in the medical 
system. 
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Medical 
reversal 
happens 
when new 
trials—better 
powered, 
designed or 
controlled 
than 
predecessors
--contradict 
current 
standard of 
care 
Selected 
examples 
These reversals 
are instructive in 
that many of the 
therapies 
overturned were 
widely adopted 
and based on 
either sound 
physiologic 
reasoning or 
observational 
trials. 
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Health care 
services that 
provide little 
or no 
benefit— 
whether 
through 
overuse or 
misuse 
1 low value 
in specified 
population, 
22.5% of 
procedures 
for patients 
who 
receive a 
non–
evidence-
based 
automatic 
implantable 
cardiac 
defibrillator 
was waste 
There are 
strong 
imperatives for 
identifying such 
waste: (1) an 
ethical 
imperative to 
ensure patient 
safety and thus 
avoid tests 
and treatments 
that cause harm 
directly or 
indirectly 
without 
providing 
commensurate 
benefit; (2) a 
quality 
imperative 
to measure and 
reward best 
practices; and 
(3) an economic 
imperative to 
reduce spending 
and enhance the W
as
te
 
  
Inappropriat
e overuse of 
an 
otherwise 
effective 
intervention. 
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diffusion of cost-
effective 
innovations. 
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D: The 
USPSTF 
recommends 
against the 
service. 
There is 
moderate or 
high 
certainty that 
the service 
has no net 
benefit or 
that the 
harms 
outweigh the 
benefits. 
Discourage 
the use of 
this service.  
I: The 
USPSTF 
concludes 
that the 
current 
evidence is 
insufficient 
to assess the 
balance of 
benefits and 
harms of the 
service. 
Evidence is 
lacking, of 
poor quality, 
or 
conflicting, 
and the 
balance of 
benefits and 
harms 
cannot be 
determined. 
Read the 
clinical 
consideratio
ns section of 
USPSTF 
Recommend
ation 
Statement. If 
the service is 
offered, 
patients 
21 Grade A, 
33 Grade B, 
7 Grade C, 
30 Grade D, 
49 Grade I, 
out of 140 
recommenda
tions 
None 
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Uncertaintie
s about the 
effects of 
treatments. 
To help 
ensure that 
treatments 
are likely to 
do more 
good than 
harm, these 
gaps in 
knowledge 
must be 
identified 
and those 
deemed 
sufficiently 
important 
must be 
addressed in 
research 
10479/All 
Treatments 
Sometimes 
unanswered 
questions about 
the effects of 
treatment can be 
addressed by 
preparing or 
updating 
systematic 
reviews of 
existing research 
evidence.  
Sometimes, up-
to-date 
systematic 
reviews make 
clear that 
additional 
research is 
needed, often 
controlled trials. 
Information 
about specific 
controlled trials 
can be found 
through the 
gateway 
established by 
the World 
Health 
Organization. 
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No proven 
value by 
current 
Grading of 
Recommend
ations 
Assessment, 
Developmen
t and 
Evaluation 
(GRADE) 
guidelines, 
US 
Preventive 
Task Force 
Services 
criteria, or 
other similar 
criteria 
2 selected 
examples 
Long-standing 
regulatory 
requirements 
and IRB policies 
have 
inadvertently 
discouraged 
rigorous 
evaluation and 
encouraged 
routine clinical 
use of unproven 
therapies.  
The double 
standard for 
obtaining 
informed 
consent for 
unproven 
therapies in 
clinical research 
but 
not in clinical 
practice is 
illogical. 
The risk of 
administering an 
unproven 
therapy is not 
greater in 
clinical research 
than clinical 
practice. 
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Modification
s or even 
retractions, 
of important 
medical 
practice 
recommenda
tion 
Challenge 
traditional 
medical 
opinion 
6 selected 
examples 
1 Poor 
design and 
small size  
1 Focus on 
disease-
oriented 
evidence  
2 
Application 
of findings 
to non-study 
populations  
3 
Unidentified 
harms  
2 Economic 
factors 
To minimize the 
dizzying impact 
of changing 
recommendation
s, physicians 
should focus on 
patient-oriented 
evidence, and 
not be distracted 
by disease-
oriented 
evidence. 
Physicians 
should become 
familiar 
with the basic 
principles of 
good research, 
and avoid 
drawing 
premature 
conclusions 
from 
observational 
studies or studies 
with design 
flaws. 
Physicians 
should 
also recognize 
the 
pharmaceutical 
industry’s 
influence 
on research 
studies and 
practice 
recommendation
s. 
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Treatments 
once 
common 
practice but 
now known 
not to work - 
or worse, 
cause harm 
17 selected 
examples 
None 
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Table 13: Evidence Reversal in Systematic Reviews 
Systematic 
Review 
Reversal 
Prasad et al, 
2013 1 
“40.2% reversals/existing practices publishing as original articles in NEJM” 1  
[146 reversals/363 existing practices] [363 existing practices, 1344 medical practices, 2044 original articles, Reversals are 10.9% of established practices and 7.1% 
of all original articles in NEJM]. 1 
Thorlund et 
al, 2009 40 
[3 false positive/12 included meta-analyses] 40 
Ioannidis, 
2011 41 
“For 30 of the 35 (86%), the highly cited studies had a stronger effect estimate than the largest study; for 3 the largest study was also the highly cited study; and 
only twice was the effect size estimate stronger in the largest than in the highly cited study. For 29 of the 35 (83%) highly cited studies, the corresponding meta-
analysis found a smaller effect estimate.” 41 
Ioannidis, 
2005 39 
"Of 49 highly cited original clinical research studies, 45 claimed that the intervention was effective. Of these, 7 (16%) were contradicted by subsequent studies, 7 
others (16%) had found effects that were stronger than those of subsequent studies, 20 (44%) were replicated, and 11 (24%) remained largely unchallenged." 39 
Ioannidis 
and 
Trikalinos, 
2005 42 
"The maximal between-study variance was more likely to be recorded early in the 44 eligible meta-analyses of genetic associations than in the 37 meta-analyses of 
health care interventions (P=0.013). At the time of the first heterogeneity assessment, the most favorable-ever result in support of a specific association was more 
likely to appear than the least favorable-ever result (22 vs. 10, P=0.017); the opposite was seen at the second heterogeneity assessment (15 vs. 5, P=0.031). Such a 
sequence of extreme opposite results was not seen in the clinical trials meta-analyses. The estimated between-study variance decreased over time in genetic 
association studies (P=0.010), but not in clinical trials (P=0.30)." 42 
Trikalinos, 
2004 43 
"The three efficacy outcomes (death, relapse, and failure) showed overall a larger number of unfavorable than favorable changes over time for the experimental 
intervention.” 43 
“The efficacy of a pharmacotherapy versus placebo was significantly more likely to decrease than increase over time for the failure outcome alone and for all 
efficacy outcomes pooled together (P=0.009).” 43  
[Overall efficacy (death + relapse + failure) 157 unfavourable shifts vs 125 favourable, 56 (50–62)% of shifts were unfavourable.] 43 
Ioannidis 
and Lau, 
2001 44 
"Extreme early fluctuations in the treatment effect were observed in three interventions (magnesium in myocardial infarction, calcium and antiplatelet agents for 
prevention of preeclampsia), where recent mega-trials have contradicted prior meta-analyses, as well as in four other examples where early large treatment effects 
were dissipated when more data appeared" 44 
Ioannidis et 
al, 2003 45 
"The magnitude of the genetic effect differed significantly in large versus smaller studies in ten (18%), 20 (36%), and 21 (38%) meta-analyses with tests of rank 
correlation, regression on SE, and regression on inverse of variance, respectively.” 45 
“The results of the first studies differed significantly from the results of subsequent research in 14 (26%) meta-analyses, on the basis of both fixed and random 
effects." 45 
Shojania, 
2007 46 
"A qualitative or quantitative signal for updating occurred for 57% of reviews (95% CI, 47% to 67%). Median duration of survival free of a signal for updating was 
5.5 years (CI, 4.6 to 7.6 years). However, a signal occurred within 2 years for 23% of reviews and within 1 year for 15%. In 7%, a signal had already occurred at the 
time of publication." 46 
NICE4 [987 Do-not-do Recommendations/1793 NICE Savings and Productivity Collection] 4 
Ioannidis, 
2007 47 
"As of 1/2007, for 3 studies the replication effort was confined to investigations published in the same issue as the GWA or even in the same paper. Two of these 
three ‘internally’ replicated articles found some hints of inconsistency across different study populations: the protective effect of an IL23R variant for inflammatory 
disease was not seen for ulcerative colitis in Jewish people and the association of the QT interval with an NOS1AR variant [20] had inconsistent magnitude in 
males. While these soft signals may simply reflect spurious subgroup differences, these associations require further ‘external’ replication by other independent 
teams not participating in the original publications.”47 
“Of the 4 GWA studies that were followed by extensive external replication efforts, one was replicated repeatedly with large-scale evidence on over 15,000 cases 
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and controls, the association of a CFH variant with age-related macular degeneration. Nevertheless, even for this association, dissenting papers have claimed that 
the effect does not exist in Asian descent populations where the frequency of the variant is much lower than in European populations.”47 
“The findings of 3 GWA studies have not been replicated. Large-scale studies and meta-analyses thereof comprising anywhere between 13,000 and 21,000 
genotyped subjects have consistently found effects indistinguishable from the null for the INSIG2 –neighboring variant that was claimed to be associated with body 
mass index and obesity risk, the 13 polymorphisms implicated in Parkinson disease, and the LTA variant implicated in myocardial infarction.”47 
“These studies used mostly early platforms with relatively limited number of SNPs compared with what can be achieved currently. Failures may be more common 
with early trial-and-errors and novel designs. Nevertheless, the presence of non-replication and between- study inconsistency cannot be ignored."47 
Elshaug et 
al, 201348 
156 potentially ineffective and/or unsafe services being identified for consideration as low value practices/5209 articles.48 
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Table 14: Terms and Definitions for Evidence Reversal 
Terms Used Definitions Used Number of Reviews 
Using the Term 
Medical Reversal 1. “Reversal was designated when a current medical practice was found to be inferior to a lesser or prior standard.” 1  
2. “The phenomenon of a new trial—superior to predecessors because of better design, increased power, or more appropriate 
controls—contradicting current clinical practice” 2 
3. “Established standards must be abandoned not because a better replacement has been identified but simply because what 
was thought to be beneficial was not.” 49 
4. “Oftentimes, years after a practice was introduced, the medical community puts it to the test in large, well done 
randomized trials. Empirical evidence suggests that when this happens, nearly half of those practices are contradicted. We 
call this phenomenon ‘medical reversal’.” 12 
5. “A phenomenon in which ‘a medical practice is found to be inferior to some lesser or prior standard of care’.” 23 
6. “The phenomenon of a new superior trial that contradicts current clinical practice.” 35 
7. “The phenomenon of a new trial — superior to predecessors because of better design, increased power, or more 
appropriate controls – contradicting current clinical practice.” 36 
“A medical practice falls out of favor not by being surpassed, but when we discover that it did not work all along, either failing to 
achieve its intended goal or carrying harms that outweighed the benefits.” 36 
8. “Medical reversal happens when new trials—better powered, designed or controlled than predecessors--contradict current 
standard of care.” 51 
9. “Modifications or even retractions, of important medical practice recommendation… [which] Challenge traditional 
medical opinion” 52 
9 
Research updates 
most likely to 
change clinical 
practice 
“Research updates most likely to change clinical practice.” 14,15,16,17,18,19,20,21 8 
Low Value Practice 1. “Clinical decisions that are of little value to patients, amenable to improvement through standardization, and actionable by 
front-line providers.” 11 
2. “Ineffective or lack evidence on their effectiveness, negative risk-benefit balance, more cost-effective alternatives exists, 
obsolete due to the introduction of new technologies.” 13 
3. “Interventions that robust evidence reveals are of no benefit, or even harmful.” 33 
4. “Ineffective and/or unsafe services, treatments not proven to be clinical effective.” 48 
5. “Health care services that provide little or no benefit – whether through overuse or misuse.” 53 
5 
Sacred Cows 
(Practices Not 
Supported by the 
Evidence) 
“Practices are considered routine and beyond dispute” 30, 32,38,56 
“A clinical practice despite research that shows that the practice is not helpful and may even be harmful to the patients we serve.” 30, 
32,38,56 
*32 used this definition for “Practices not supported by evidence” and authors were the same as 30&38 
4 
Contradicted 
established medical 
practices  
“Contradicted established medical practices.” 29  
“Subsequent studies that reach opposite conclusions.” 39,31 
3 
Disinvestment 1. “The process of withdrawing health resources from any existing healthcare practices, procedures, technologies and 3 
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pharmaceuticals that are deemed to deliver no or low health gain for their cost and thus [do] not [represent] efficient health 
resource allocation.” 25 
“The cessation or restriction of potentially harmful, clinically ineffective or cost inefficient practices.” 25 
“The process of taking resources from one service in order to use them for other purposes (i.e. reallocation of resources).” 25 
2. “The processes of withdrawing (partially or completely) resources from any existing healthcare practices, procedures, 
technologies or pharmaceuticals that are deemed to deliver little or no health gain relative to their cost, and thus are not 
efficient health resource allocations.” 26 
3. “Removing currently used ineffective, or inappropriately applied, health care practices.” 27 
Snake Oil Nutritional supplements that are not worth it (inconclusive, slight or no evidence of efficacy). 57,58,59 3 
Proteus 
phenomenon 
1. “Rapid, early succession of extreme findings.” 42 
“Studies reporting very contradictory conclusions in short sequence.” 42 
2. “In some fields of research, we may observe diminishing effects for the strength of research findings and rapid alternations 
of exaggerated claims and extreme contradictions.” 31 
“The first published study on a scientific question may find a most extravagant effect size; this is followed by the publication of 
another study that shows a large contradicting effect. Subsequent studies report effect sizes between these extremes.” 31 
3. “In molecular epidemiology, it is very common to see an early succession of the most extreme opposing estimates of effect 
followed by studies that show intermediate results. Typically, the study with the most prominent effect size is published 
first. This is immediately followed by the study that shows the most opposite effect ever observed. This creates extreme 
between-study heterogeneity in the results of these early studies. Many studies then follow that report results that are 
intermediate between these two extremes. The between-study variance diminishes and the summary data across all studies 
seem to gravitate towards some consensus.” 37 
3 
Uncertainty 1. “Uncertainties about the effects of treatments. To help ensure that treatments are likely to do more good than harm, these 
gaps in knowledge must be identified and those deemed sufficiently important must be addressed in research.” 3 
2. “How much the treatment effect has changed over time.” 44 
“How much the pooled treatment effect will change in the future.” 44 
2 
Waste 1. “Avoidable waste or inefficiency in biomedical research.” 24 
“Research decisions not based on questions relevant to users of research.” 24  
“Inappropriate research designs, methods, or analysis.” 24  
“Inefficient research regulation or management.” 24 
“Inaccessible research information.” 24 
“Biased or unusable research reports.” 24 
2. “Inappropriate overuse of an otherwise effective intervention.” 53 
2 
Unproven Practices 1. “Many medical practices are largely untested or have insufficient evidence unable to support or refute interventions.” 43 
2. “No proven value by current Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
guidelines, US Preventive Task Force Services criteria, or other similar criteria.” 55 
2 
False positive “Report a treatment effect when in reality there is no effect.” 40,41 2 
Legacy items 1. “Long-established technologies that have never had their cost-effectiveness assessed — look for coupling with other 
identification items. Automatically considered and assessed for disinvestment.” 34 
1 
Technology 
development  
1. “When an intervention has evolved to the point that it differs markedly from the initial or prototype intervention that was 
originally assessed or funded, then the initial intervention should be reviewed (eg, 256-slice compared with four-slice 
computed tomography).” 34 
1 
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De-implementation  1. “Abandonment of medical interventions.” 29 
“Stopping practices that are not evidence-based.” 29 
1 
Negative Evidence 1. “When they claimed the tested experimental intervention was ineffective, harmful, or no better from the control 
intervention.” 39 
1 
Obsolete/ 
outmoded/ 
abandoned 
technologies 
1. “Those that have been superseded or demonstrated to be ineffective or harmful.” 25 1 
Overused or 
Misused Tests and 
Treatments 
1. “Unnecessary tests and procedures that don’t benefit the patient and can even cause harm.” 28 1 
Ineffective, non-
cost-effective or 
harmful 
interventions  
1. “Ineffective, non-cost-effective or harmful interventions.” 34 1 
Unnecessary tests, 
treatments and 
procedures 
1. “Unnecessary tests, treatments and procedures do not add value to care. In fact, they take away from care by potentially 
exposing patients to harm, leading to more testing to investigate false positives and contributing to stress for patients. And 
of course unnecessary tests, treatments and procedures put increased strain on the resources of our health care system. The 
lists are based on definitive evidence that these specific interventions provide no benefit to patients.” 6 
1 
Ineffective or 
harmful 
interventions 
1. “Treatments once common practice but now known not to work - or worse, cause harm.” 54 1 
Inappropriate use of 
testing/ procedures 
1. “To determine whether testing/ procedures are appropriate for MBS reimbursement, considering the safety, efficacy, 
effectiveness of the tests and the effect that the results of the test have on treatment.” 22 
1 
“Things Providers 
and Patients Should 
Question” 
1. “Wasteful or unnecessary medical tests, treatments and procedures.” 5 1 
Too Much 
Medicine 
1. “The threat to human health posed by overdiagnosis and the waste of resources on unnecessary care. Awareness of the 
benefits and harms of treatments and technologies and develop ways to wind back medical excess, safely and fairly.” 7 
1 
Overdiagnosis 1. “The incidence is increasing while mortality stays the same.” 7 
“Labelling of a risk factor or biomarker to sound like a disease.” 7 
“Shift in diagnostic definitions or thresholds with no clear evidence that benefits are greater than harms.” 7 
1 
Inflated results 1. “RRs were in opposite direction, larger, more than twice as large, or more than 4 times as large in the highly cited vs the 
largest study and in the highly cited study vs the meta-analysis.” 41 
1 
Unfavourable or 
favourable shifts 
over time 
1. “Changes in updated meta-analyses according to whether results become less or more favorable for the experimental 
intervention.” 43 
1 
Discrepancies of 
effect over time 
1. “Discrepancies of effect over time.” 45 1 
Spuriously 1. “Spuriously effective treatments.” 31 1 
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effective treatments 
Non-replication  1. “Occurs when the GWA study proposes that there is a gene-disease association, but the accumulation of data from 
subsequent studies find no genetic effect.” 47 
1 
Between-study 
inconsistent results 
1. “Inconsistency occurs when there is large between-study heterogeneity (diversity) in the magnitude of the genetic effects.” 
47 
1 
The average time to 
changes in evidence 
that are sufficiently 
important to 
warrant updating 
systematic reviews. 
1. “Quantitative signals for updating were changes in statistical significance or relative changes in effect magnitude of at least 
50% involving 1 of the primary outcomes of the original systematic review or any mortality outcome. Qualitative signals 
included substantial differences in characterizations of effectiveness, new information about harm, and caveats about the 
previously reported findings that would affect clinical decision making.” 46 
1 
Classes of 
recommendation 
1. “Class II: conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of 
a procedure or treatment.” 60 
“Class IIa: weight of evidence/opinion is in favor of usefulness/efficacy.” 60 
“Class IIb: usefulness/efficacy is less well established by evidence/opinion.” 60 
“Class III: conditions for which there is evidence and/or general agreement that the procedure/treatment is not 
useful/effective and in some cases may be harmful.” 60 
1 
Do not do 
recommendations 
1. “The do not do recommendations database contains clinical practices, identified during the development of guidance that 
should be discontinued or not used routinely. Each recommendation contains information on the healthcare setting and 
links to the relevant NICE guidance or Quality Standard.” 4 
1 
Grade D 
Recommendations 
1. “D: The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or 
that the harms outweigh the benefits. Discourage the use of this service.” 61 
1 
Grade I 
Recommendations 
1. “I: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the 
service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined. 
Read the clinical considerations section of USPSTF Recommendation Statement. If the service is offered, patients should 
understand the uncertainty about the balance of benefits and harms.” 61  
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A "Top Five" list for 
emergency medicine: a 
policy and research agenda 
for stewardship to improve 
the value of emergency care. 
11 
Unclear Unclear Unclear No No Yes No No N/A N/A No 1 
A Decade of Reversal: An 
Analysis of 146 Contradicted 
Medical Practices. 1 
Yes Yes No No No Yes No No N/A N/A No 3 
A medical burden of proof: 
Towards a new ethic. 12 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Adding value to health care 
through discontinuation of 
low-value practices: 
ESSENCIAL Project in 
Catalonia. 13 
Yes Unclear Unclear No No No No No N/A N/A No 1 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Fall 2012. 14 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Fall 2013. 15 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
A-LI 
 
A-LI 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Spring 
2013. 16 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Spring 
2014. 17 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Summer 
2013. 18 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Summer 
2014. 19 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Winter 
2012. 20 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Advancing evidence-based 
practice - a quarterly 
compilation of research 
updates most likely to change 
clinical practice. Winter 
2013. 21 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
A-LII 
 
A-LII 
Australian Government 
Department of Health and 
Ageing, Medicare 
‘Comprehensive 
Management Framework’ 
environmental scan 
(Australia). 22 
Yes Unclear Unclear No No Yes Yes Yes N/A N/A No 4 
Back to the future: Medical 
reversals and perioperative 
medicine. 23 
No No Unclear No No Yes No No N/A N/A No 1 
Biomedical research: 
increasing value, reducing 
waste. 24 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Breaking up is hard to do: 
why disinvestment in medical 
technology is harder than 
investment. 25 
No Unclear Unclear No No Yes No No N/A N/A No 1 
Building the Evidence Base 
for Disinvestment from 
Ineffective Health Care 
Practices: A Case Study in 
Obstructive Sleep Apnoea 
Syndrome. 26 
Yes Unclear Unclear Unclear No Yes No No N/A N/A No 2 
Can trial sequential 
monitoring boundaries 
reduce spurious inferences 
from meta-analyses? 40 
Yes Unclear Yes No No Yes Yes Yes N/A N/A No 5 
Challenges in Australian 
policy processes for 
disinvestment from existing, 
ineffective health care 
practices. 27 
Unclear Unclear Unclear No No Yes No No N/A N/A No 1 
Choosing wisely in headache 
medicine: the American 
Headache Society's list of 
five things physicians and 
patients should question. 28 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
A-LIII 
 
A-LIII 
Comparison of effect sizes 
associated with biomarkers 
reported in highly cited 
individual articles and in 
subsequent meta-analyses. 41 
Yes Yes Yes No No Yes No No N/A N/A No 4 
Contradicted and initially 
stronger effects in highly 
cited clinical research. 39 
No Yes Yes No No Yes No No N/A N/A No 3 
Early extreme contradictory 
estimates may appear in 
published research: the 
Proteus phenomenon in 
molecular genetics research 
and randomized trials. 42 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
Effect sizes in cumulative 
meta-analyses of mental 
health randomized trials 
evolved over time. 43 
Unclear Unclear No No No Yes No No N/A N/A No 1 
Evidence-based de-
implementation for 
contradicted, unproven, and 
aspiring healthcare practices. 
29 
No Unclear Unclear No No Yes No No N/A N/A No 1 
Evidence-based practice 
habits: putting more sacred 
cows out to pasture. 30 
Yes Unclear Unclear Unclear No No No No N/A N/A No 1 
Evolution and translation of 
research findings: from bench 
to where? 31 
Yes No Unclear No No No No No N/A N/A No 1 
Evolution of treatment effects 
over time: empirical insight 
from recursive cumulative 
metaanalyses. 44 
Yes Unclear Yes No No Yes No No N/A N/A No 3 
Examining the Evidence to 
Guide Practice: Challenging 
Practice Habits. 32 
Yes Unclear Unclear No No No No No N/A N/A No 1 
Foregoing low-value care: 
how much evidence is 
needed to change beliefs? 33 
Unclear Unclear Unclear No No Yes No No N/A N/A No 1 
A-LIV 
 
A-LIV 
Genetic associations in large 
versus small studies: an 
empirical assessment. 45 
Unclear Unclear No No No Yes No No N/A N/A No 1 
How Quickly Do Systematic 
Reviews Go out of Date? A 
Survival Analysis. 46 
Yes Yes No No No Yes No No N/A N/A No 3 
Identifying existing health 
care services that do not 
provide value for money. 34 
No Unclear Unclear Unclear No Yes No No N/A N/A No 1 
Medical reversal: What are 
you doing wrong for your 
patient today? 35 
Unclear Unclear Unclear No No Yes No No N/A N/A No 1 
Medical reversal: why we 
must raise the bar before 
adopting new technologies. 36 
Yes Unclear Unclear No No No No No N/A N/A No 1 
Molecular bias. 37 Unclear No Unclear Unclear No Yes No No N/A N/A No 1 
National Institute for Health 
and Care Excellence (NICE) 
“Do not do” List. 4 
Yes Yes Yes Yes Yes Yes Yes Yes N/A N/A No 8 
Non-replication and 
inconsistency in the genome-
wide association setting. 47 
No No No No No Yes No No N/A N/A No 1 
Over 150 potentially low-
value health care practices: 
an Australian study. 48 
Yes Yes Yes Yes No Yes No No N/A N/A No 5 
Putting Evidence Into 
Nursing Practice: Four 
Traditional Practices Not 
Supported by the Evidence. 38 
Yes Unclear Unclear No No No No No N/A N/A No 1 
Reversals of established 
medical practices: evidence 
to abandon ship. 49 
No Unclear Unclear Unclear No Yes No No N/A N/A No 1 
Scientific evidence 
underlying the ACC/AHA 
clinical practice guidelines. 60 
Yes Unclear Unclear No No Yes Yes Yes N/A N/A No 4 
Seven evidence-based 
practice habits: putting some 
sacred cows out to pasture. 56 
Yes Unclear Unclear No No No No No N/A N/A No 1 
Snake Oil Superfoods? 57 
 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
A-LV 
 
A-LV 
Snake Oil Supplements? 58 
 
No Unclear Unclear No No Yes No No N/A N/A No 1 
Snake Oil Version 2. 59 
 
Yes Unclear Unclear No No Yes No No N/A N/A No 2 
The American Board of 
Internal Medicine (ABIM) 
Foundation Initiative 
Choosing Wisely. 5 
Unclear Unclear Yes Unclear No No No No N/A N/A No 1 
The BMJ's Too Much 
Medicine. 7 
Unclear Unclear Unclear Unclear No Yes No No N/A N/A No 1 
The Canadian Medical 
Association (CMA) 
Campaign Choosing Wisely. 
6 
Unclear Unclear Yes Unclear No No No No N/A N/A No 1 
The frequency of medical 
reversal. 2 
Unclear Yes No No No Yes No No N/A N/A No 2 
The reversal of cardiology 
practices: interventions that 
were tried in vain. 51 
Unclear Yes No No No Yes No No N/A N/A No 2 
The Value of Low-Value 
Lists. 53 
Unclear Unclear Unclear Unclear No Yes No No N/A N/A No 1 
U.S. Preventive Services 
Task Force (USPSTF) 
“Grade ‘D’ 
recommendations” for 
preventive health services. 61 
Yes Unclear Unclear No No Yes Yes Yes N/A N/A No 4 
UK Database of 
Uncertainties about the 
Effects of Treatments (UK 
DUETs). 3 
Yes Unclear Unclear Unclear No Yes No No N/A N/A No 2 
Unproven Therapies in 
Clinical Research and 
Practice: The Necessity to 
Change the Regulatory 
Paradigm. 55 
Unclear Unclear Unclear No No Yes No No N/A N/A No 1 
When medicine reverses 
itself: avoiding practice 
pitfalls. 52 
Unclear Unclear Unclear No No Yes No No N/A N/A No 1 
Why do doctors use 
treatments that do not work? 
54 
Unclear Unclear Unclear Unclear No Yes No No N/A N/A No 1 
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Appendix B: Evidence Reversal: A Formal Examination of 
Contradicted Medical Practices – Protocol 
1. TOPIC PREPARATION 
1.1. BACKGROUND AND RATIONALE 
Recently a number of tools to support Evidence-Based Medicine (EBM) were introduced to 
the field focusing on risk of bias in clinical trials, including a suggested hierarchy of evidence to 
guide clinical decision-making by identifying the best quality of evidence: a guideline for rating 
the quality and confidence in evidence was proposed by the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE). 
1-3
 
Newly adopted medical practices should, in theory, replace established practices when high 
quality evidence emerges if the evidence demonstrates adequate proof of superiority or non-
inferiority. 
4
 However, many established practices are untested or have insufficient evidence 
supporting their implementation. 
5
 Of 1016 completed systematic reviews published in the 
Cochrane Library, 49% were not able to support or refute their analyzed interventions. 
5
 
Evidence maturity, sufficiency, stability, confirmation, and reversal are key components of 
evidence-based medicine and all are indicators of the robustness of evidence supporting or 
refuting an established practice or theory. Evidence maturity is indicated through sufficiency and 
stability. 
6,7
 Evidence maturity occurs when enough information has accumulated to imply any 
further research is unnecessary and can be estimated through cumulative meta-analysis. 
Cumulative meta-analysis is a meta-analysis which is updated with each trial reported to 
demonstrate evolution of evidence over time. 
6
 While in an ideal world evidence maturity would 
be calculated using a balance of all known risks and all known benefits, we will first apply this 
concept to the primary outcome – which we will also assume is clinically important. 
Evidence sufficiency occurs when a cumulative meta-analysis adequately demonstrates that a 
clinical practice is statistically superior to another practice or placebo and is not limited to 
situations of statistical significance, but rather is also related to enough evidence to infer that the 
95% confidence intervals are narrow enough to rule out any clinical important differences worth 
further investigation. 
6,7 
Evidence stability occurs when the direction and magnitude of the 
measured effect is consistent over time as new studies are added to the meta-analysis. 
6,7
 
An established practice, when compared to a prior or lesser practice will demonstrate either 
evidence confirmation or reversal, through verification or contradiction of the claims supporting 
its implementation and can also demonstrate evidence maturity. 
4,8
 Evidence confirmation occurs 
when new evidence – better designed, executed or analyzed than its predecessors – verifies 
previous claims, confirming superiority of established practices and theories over lesser or prior 
standards. 
4,8 
Evidence Reversal occurs when new evidence – better designed, executed or 
analyzed than its predecessors – contradicts previous claims, upsetting established practices and 
theories based on presumably “definitive” evidence from original studies. 4,8-11  
To develop further understanding of Evidence Reversal, we will update, replicate, and 
expand A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices by Prasad et 
al to the most recent complete year of publication. 
4
 We will describe the characteristics of 
Reversals, and develop a framework of Reasons for Evidence Reversal. 
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1.2. OBJECTIVES 
1.2.1. OVERALL 
To describe the frequency and characteristics of Evidence Reversals in the 
medical literature 
 
1.2.2. SPECIFIC 
1. Expand and update A Decade of Reversal: An Analysis of 146 Contradicted 
Medical Practices by Prasad et al (2013) to include the most recent complete 
year of publication, and to incorporate additional variables. 
4
 
2. Describe characteristics of Evidence Reversals (‘Epidemiology of Reversals’) 
based on the above cohort of evidence, and develop a framework of reasons for 
Evidence Reversal. 
 
 
 
1.3. ELIGIBILITY CRITERIA FOR THIS REVIEW 
1.3.1. TYPES OF STUDIES 
Only studies indicating a clinical practice will be included.  
 
Studies indicating a clinical practice include: a screening, stratifying, or diagnostic test; a 
medication; a procedure or surgery; or any kind of change in health care provision systems. 
4
 
Both randomized trials and observational studies will be included. 
 
Articles not indicating a clinical practice – such as studies investigating pathophysiology, 
animals and molecular basis of disease – will be excluded. 4 
 
1.3.2. TYPES OF PUBLICATIONS 
Publications must be under the heading of “Original Articles” published in the New England 
Journal of Medicine from 2000 to 2014. These years cover the 2000 to 2010 years originally 
reviewed by A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices by 
Prasad et al to the most complete year of publication at the time of investigation. 
4
  
 
The New England Journal of Medicine was chosen as the highest impact journal by the 
authors of A Decade of Reversal 
4
 based on the 5-year Hirsch index for Top Publications in 
Health and Medical Sciences, and represents the ‘highest’ threshold for new clinical trials to 
reach publication. 
12
 Presumably, this may represent the least-likely cohort of studies to be 
reversed, if ‘rigor’ of acceptance for publication and journal impact are assumed to serve as 
initial indicators of trial quality and relevance.  
B-III 
 
B-III 
2. SEARCH STRATEGY AND SELECTION OF REVIEWS FOR INCLUSION 
2.1. ELECTRONIC SEARCHES 
2.1.1. DATABASES TO BE SEARCHED 
The New England Journal of Medicine Journal online database will be the sole source.  
 
 
 
2.2. SEARCHING OTHER RESOURCES: 
2.2.1. HAND-SEARCHES 
Hand searches will be conducted for the following journal for all “Original Articles”:  
– New England Journal of Medicine (NEJM) 
 
Appendix 1 (20.1) shows all inclusion/exclusion criteria for this journal. 
 
 
2.2.2. GREY LITERATURE AND PUBLIC REQUEST FOR INFORMATION 
No grey literature will be searched for this review.  
 
 
 
2.3. DUPLICATE CITATIONS 
The results pertaining to a literature search will be downloaded into Microsoft Excel® 
software. Exact article duplicates will be removed from the main project with an annotated 
reason, but retained in “quarantine” for later retrieval if necessary.  
 
Multiple publications from the same study population identified during full-text review will 
be evaluated for duplicate data. These multiple publications will be retained as a series, because 
longer follow up may lead to maturation of evidence. Lack of follow up may be a reason for 
Reversal. 
 
 
 
2.4. WITHDRAWN ARTICLES/ERRATA 
Publications with errata or which have been withdrawn will also be obtained and examined 
for potential reasons for Reversal. 
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2.5. SCREENING STUDIES FOR ELIGIBILITY 
The review team (DS) will be trained using written documentation on review eligibility with 
an initial pilot phase to improve clarity of inclusion and exclusion language as well as improve 
accuracy and consistency of inclusion. Appendix 1 (20.1) shows inclusion/exclusion criteria for 
each screening stage.  
 
The primary reason for excluding studies shall be when an article does not meet the 
definition of “Original Article” according to our eligibility criteria. A secondary reason for 
exclusion will be if a study does not meet the definition of “Clinical Practice” as per our 
eligibility criteria. Since NEJM is published in English, there will be no concern with non-
English articles requiring translation.  
 
The initial team members’ (DS) screening will be reviewed by another team member (JM) to 
authenticate selection. Initially, articles will be reviewed at the title level from New England 
Journal of Medicine (DS). Articles that are under the heading “Original Articles” will be 
included. All others will be excluded. 
 
Any abstracts meeting inclusion criteria at the title level will be obtained for review (DS). 
Articles that clearly address a clinical practice will be included, while articles not indicating a 
clinical practice – such as studies investigating pathophysiology and molecular mechanism of 
disease – will be excluded. 4  
 
Articles indicating clinical practice include studies on screening, stratifying, or diagnostic 
test; a medication; a procedure or surgery; or any change in health care provision systems. 
4
 If 
the practice is unclear from the abstract, it will be included for full text review. 
 
Articles meeting inclusion criteria at both title and abstract level will be obtained for full-text 
review. Publications that cannot be assessed for relevance at the abstract level will also be 
obtained to determine eligibility based on full-text review instead. Studies will not be considered 
when both title and abstract clearly indicate that the study does not meet inclusion criteria. 
 
Full-text eligibility will be conducted with reasons for exclusion annotated and tracked 
according to PRISMA guidelines (DS). 
13
 Articles that clearly address a clinical practice will be 
included, while articles not indicating a clinical practice will be excluded. 
4 
 
 
Flow of articles through screening thresholds will be documented as recommended in the 
PRISMA statement on preferred reporting items for systematic reviews and meta-analyses. 
13
 
PRISMA Flow Diagram Generator supplied by the THETA Collaborative will be used to create 
the study flow schematics. 
14 
A hypothetical flow diagram is shown in Appendix 2 (20.2).  
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3. DATA EXTRACTION FROM STUDIES 
3.1. DATA EXTRACTION AND MANAGEMENT 
We will use customized data extraction forms in Microsoft Excel® to collect the following 
information for each study: General information; Methodology; Results; Conclusions; Additional 
items for potential reasons for reversal; and Conflicts of interest (20.3 for specific items). Data 
extraction will first endeavour to find all relevant information from the abstract. If relevant 
information is not readily available in the abstract, then it will be sought from full-text. If 
relevant information is not available in the abstract or full-text, then it will be denoted 
“Unknown” in the data extraction file. 
 
The initial team members’ (DS, AP, AZ, JT) data extraction will be reviewed by another 
team member (JM, DS) to assure accuracy. All extraction data will be made available publicly in 
a Microsoft Excel
®
 format upon completion through the original publication and on 
ResearchGate.  
 
Risk of Bias will be evaluated (DS) using The Cochrane Collaboration’s Tool for Assessing 
Risk of Bias for randomized studies and A Cochrane Risk Of Bias Assessment Tool: for Non-
Randomized Studies of Interventions (ACROBAT-NRSI) for non-randomized studies. 
15,16
 
Another team member (JM) will review Risk of Bias judgements of initial team member (DS) 
for correctness.  
 
Multiple publications of the same study will be identified by examining author affiliations, 
and study designs. If necessary, study authors will be contacted to clarify their independence. All 
reports will be included as a series to generate potential reasons for Reversal.  
 
Publications with errata or which have been withdrawn will also be obtained and examined 
for potential reasons for Reversal. 
 
When necessary, the review protocol registration or the authors of included studies will be 
contacted to ascertain crucial missing data considered important to summarize study findings or 
to evaluate risk of bias. Attempts to contact authors will be made once, if unsuccessful no further 
attempts will be made. 
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3.2. SUMMARY OF STUDY DESIGN, METHODOLOGY, AND RESULTS 
3.2.1. Objective 1 
To expand and update A Decade of Reversal: An Analysis of 146 Contradicted Medical 
Practices 
4
 by Prasad et al in 2013, the elements in Appendix 3 –20.3 will be summarized for 
each study that meets inclusion criteria and any information that is inferred, converted or 
estimated will be displayed in brackets.  
 
 Included articles will be systematically reviewed to assess the nature and quality of 
Reversals by describing characteristics and methodologies of these articles. 
 
3.2.2. Objective 2 
To generate a framework of Evidence Reversals (‘Epidemiology of Reversals’), we will 
synthesize data extracted from the above cohort of evidence on: type and prevalence of issues 
underlying evidence reversal and to propose a framework for guiding future research and 
practice. Across all original articles, the issues underlying Evidence Reversal will be identified 
and consolidated to develop a data-driven framework of Reasons for Evidence Reversal.  
 
In this paper, we will classify terms for proof of concept underlying Evidence Reversal. 
Previous studies have recognized the presence of Evidence Reversal, but have not thoroughly 
investigated potential reasons. We propose anything which increases or decreases Risk of Bias 
will be directly relevant to this framework. 
 
Development of this framework will promote consistent use of terms and concepts for 
Reversal and may encourage informed choices about study design. This framework will be used 
primarily as guidance for researchers to initiate robust trials and studies, potentially decreasing 
the risk of Reversal. The utility of this framework indicates the inherent risk of bias within each 
classification. 
  
4. DATA DISPLAY 
Individual review findings and risk of bias ratings will be summarized in tabular format and 
will be available in the complete data extraction files (APPENDIX 4 – Study Findings, Risk of 
Bias Ratings, PICOTS Assessment, GRADE Assessment). Data will be presented graphically 
across collections of studies. The information summarized in tables and graphs represents basic 
information for summarizing study findings in literature-based evaluations.  
 
4.1. SOFTWARE USED FOR DATA MANAGEMENT, ANALYSIS, AND DISPLAY 
– Zotero (https://www.zotero.org): Free software used to collect, organize, and cite 
research sources. 
– Microsoft Excel® (http://office.microsoft.com/en-us/excel/): Used to collect and 
organize data extraction. Used for screening organization and analyses.   
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5. ASSESSMENT OF RISK OF BIAS 
Study quality will be evaluated by examining Risk of Bias and adequacy of study design. 
These assessments are indicators of whether study design and/or implementation of a study have 
met or compromised its credibility. 
15
 Adequacy of Study Design will be assessed using items 
presented in APPENDIX 5 – PICOTS Assessment.  
 
Adequacy of Populations, Interventions, Comparators, Outcomes, Timing and Study Designs 
(PICOTS) for individual studies will be assessed by one member (DS) of the review team for 
each study, and will be reviewed by another team member (JM) for accuracy. A pilot phase on a 
subset of relevant studies will be conducted to improve clarity of PICOTS assessment tool and to 
identify issues for revision of training as needed. 
 
Every PICOTS item is answered on a 2 point scale: sufficient, or insufficient. In general, if 
information is itemized in the article or through its respective protocol registration, this is direct 
evidence and “sufficient” is an appropriate response. If information is not itemized or is 
unsuitably changed from the protocol registration, then “insufficient” is an appropriate response. 
 
Risk of Bias for any given individual studies will be assessed using items presented in 
APPENDIX 6 – Risk of Bias Assessment. This tool was developed from the Cochrane 
Handbook Chapter 8.5 and modified to allow consideration of Risk of Bias across a range of 
study designs. 
15
 Not every item is applicable to every article type, therefore a tool developed 
from A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions 
(ACROBAT-NRSI) will be used for observational studies (cohort and case-control). 
16
 These 
tools can be found in Appendix 4 in Sections 20.6.5, 20.6.3, and 20.6.4. 
 
Risk of Bias will be assessed by one member (DS) of the review team for each study, and 
will be reviewed by another team member (JM). A pilot phase on a subset of relevant studies will 
be conducted to improve clarity of Risk of Bias rating tool and to identify issues for revision of 
training as needed (DS). 
 
Every risk of bias item is answered on a 4 point scale: definitely low risk of bias; probably 
low risk of bias; probably high risk of bias; or definitely high risk of bias. 
15 
In general, if 
information is explicitly stated in the article or through contact with the author(s) this is direct 
evidence and “definitely low risk of bias” or “definitely high risk of bias” are appropriate 
responses. If information for the item is not explicitly reported but can be inferred, this is indirect 
evidence and “probably low risk of bias” or “probably high risk of bias” are appropriate 
responses. Separate instructions for rating of each item are provided in Appendix 3 (20.6.3). An 
item can be appropriately be deemed as “probably low risk of bias” if deviations from low-risk-
of-bias practices during the study would not appreciably bias results. 
 
If additional information is required to address an item, author(s) of the original report will 
be contacted to provide further details. Attempts to contact authors will be made once, if 
unsuccessful, no further attempts will be made. If we are unable to obtain sufficient information 
to evaluate a Risk of Bias item then “probably high risk of bias” is an appropriate response. 
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6. CONFIDENCE RATING OF QUALITY OF EVIDENCE 
A confidence rating is developed by considering strengths and weaknesses of a collection of 
articles. Rating reflects confidence in studies’ findings. The confidence rating method described 
below is developed from the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group. 
3
 Our use of GRADE is divergent from its original 
purpose: it was developed for meta-analysis and systematic reviews; for our purposes we will use 
it for individual studies. 
 
There are four confidence levels for the quality of evidence: High Confidence; Moderate 
Confidence; Low Confidence; and Very Low Confidence. High Confidence in literature 
indicates that further research is very unlikely to change this review’s findings and that the true 
effect lies close to the estimate of effect. Very Low Confidence indicates that further research is 
very likely to change findings and the true effect is substantially different than the estimate of 
effect. 
3
  
 
Studies are given initial confidence ratings by key study design features: which are 
downgraded by factors that decrease confidence; and upgraded by factors that increase 
confidence in the findings. Due to the nature of this review, comparisons across studies are not 
possible; as such, items specific to meta-analysis in the GRADE Tool will be disregarded (ie, 
heterogeneity across studies). 
 
 
6.1. INITIAL CONFIDENCE BASED ON STUDY DESIGN 
Initial confidence ratings are based on presence or absence of four key study design features: 
adequately controlled (defined as the exposure to the intervention, is experimentally controlled, 
and eliminates confounding through randomized allocation); temporality (defined as exposure to 
the intervention precedes development of the outcome); individual-level data (defined as using 
individually collected data, not population aggregate data); and use of a comparison group 
(defined as the presence of another intervention for comparison to the intervention of interest).  
 
These design features address whether an intervention preceded and was associated with an 
outcome; and is distinct from the Risk of Bias assessment because they reflect the amount of 
confounding inherent in certain study designs.  
 
Initial ratings are starting points that generally reflect strengths of certain study designs, 
which are then evaluated for factors that downgrade or upgrade confidence in the body of 
evidence for that finding. Randomized controlled trials usually have all four features and 
generally start at a very high level confidence rating and are downgraded by properties that 
increase bias. Observational studies lack adequate control of intervention and are differentiated 
by presence or absence of the other three features; generally they start at a low level confidence 
rating and can be downgraded by properties that increase bias or upgraded by properties that 
decrease bias. 
3
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6.2. DOMAINS THAT CAN REDUCE CONFIDENCE 
There are five properties in a body of evidence that determine if an initial confidence rating 
should be downgraded: risk of bias; unexplained inconsistency; indirectness; imprecision; and 
publication bias. 
6.2.1. RISK OF BIAS  
Risk of Bias for individual studies was described earlier in Section 5.  
 SUMMARY OF RISK OF BIAS RATINGS 
A visual aggregate summary of the Risk of Bias for each Risk of Bias item will be prepared 
to show general strengths and weaknesses of included studies for this topic (20.7).  
 CONSIDERATION OF WHETHER TO DOWNGRADE CONFIDENCE 
BASED ON RISK OF BIAS 
No downgrading will occur if the included study has “probably low risk of bias” or 
“definitely low risk of bias”. A serious downgrade (-1) will occur for a “probably high risk of 
bias” rating. A very serious downgrade (-2) will occur for a “definitely high risk of bias” rating. 
6.2.2. UNEXPLAINED INCONSISTENCY 
Inconsistency occurs when widely differing estimates of treatment effect (i.e. heterogeneity 
or variability in results) across studies suggest true differences in underlying treatment effect. 
When heterogeneity exists, but investigators fail to identify a plausible explanation, quality of 
evidence shall be downgraded, depending on the magnitude of inconsistency. 
3
 
 CONSIDERATION OF WHETHER TO DOWNGRADE CONFIDENCE 
BASED ON INCONSISTENCY 
As pooling of results into a forest plot is illogical – nearly every article will be measuring 
different Populations, Interventions, Comparators, Outcomes, Timing and Study Designs 
(PICOTS) – this item will be disregarded. 
6.2.3. DIRECTNESS AND APPLICABILITY 
Directness refers to whether the body of evidence available actually supplies relevant 
information to address the objectives of a literature review. 
3
   
 CONSIDERATION OF WHETHER TO DOWNGRADE CONFIDENCE 
BASED ON DIRECTNESS AND APPLICABILITY 
Adequacy of Populations, Interventions, Comparators, Outcomes, Timing and Study 
Designs (PICOTS) will be evaluated (20.5). No downgrading will occur if the PICOTS of an 
included study are sufficient and appropriate to answer the question asked. A serious downgrade 
(-1) will occur if the PICOTS are not sufficiently described. A very serious downgrade (-2) will 
occur if the PICOTS is not appropriate. 
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6.2.4. IMPRECISION - MODIFIED 
Results are imprecise when studies include relatively few patients and few events, thus 
having wide confidence intervals around the estimate of effect, or when they are underpowered. 
3
 
 CONSIDERATION OF WHETHER TO DOWNGRADE CONFIDENCE 
BASED ON IMPRECISION 
No downgrading will occur if an included study is adequately powered – meeting modified 
Optimal Information Size (mOIS). A serious downgrade (-1) will occur if the included study is 
inadequately powered – fails to meet the mOIS.  
6.2.5. PUBLICATION BIAS – Modified  
Publication bias is a systematic underestimate or overestimate of beneficial or harmful 
effects due to selective publication of studies. Publication bias arises when investigators delay 
publication or fail to report studies they have undertaken – typically those that show no or 
negative effect. 
3
 
 
Selective Outcome Reporting is another version of publication bias where a systematic 
underestimate or overestimate of the beneficial or harmful effect occurs due to selective 
publication of outcomes. 
3
 
 CONSIDERATION OF WHETHER TO DOWNGRADE CONFIDENCE 
BASED ON PUBLICATION BIAS 
No downgrading will occur if no publication bias is detected. A serious downgrade (-1) will 
occur if publication bias is suspected. A very serious downgrade (-2) will occur if publication 
bias is clearly detected. 
 
Publication bias can be suspected with: early, small, positive studies or early reviews; small, 
positive studies sponsored by industries; or declared conflicts of interest. 
3 
 
Selective outcome bias can be detected when: not all of a study’s pre-specified primary 
outcomes have been reported; one or more primary outcomes is reported using measurements, 
analysis methods, or subsets of data that were not pre-specified; one or more reported primary 
outcomes are incompletely such that they cannot be entered in a meta-analysis; a study fails to 
include results for key outcomes, on which, it is expected to report; or reporting of some 
outcomes and excluding others on the basis of results. 
3
 
 
This section will be evaluated by a comparison between trial protocol registration – with 
specific attention on modifications to the original protocol – and subsequent publication. 
 
No funnel plot for visualization of publication bias will be constructed, as pooling of results 
into a forest plot is illogical since different Populations, Interventions, Comparators, Outcomes, 
Timing and Study Designs (PICOTS) are measured.  
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6.3. DOMAINS THAT CAN INCREASE CONFIDENCE 
There are three properties of a body of evidence that determine when initial confidence 
rating could be upgraded: large magnitude of association of effect; dose-response; and plausible 
confounding would change the effect. Only studies with no threats to validity – not downgraded 
for any reason – can be upgraded. As Evidence Reversal is an emerging field, and this is an early 
review, some downgrading is expected. 
6.3.1. LARGE MAGNITUDE OF ASSOCIATION OF EFFECT 
Confounding is unlikely to explain a relative risk greater than 2 or less than 0.5 and even 
less likely if relative risk is greater than 5 or less than 0.2.3 If baseline risk is <20% and relative 
risk and odds ratio are similar, these guidelines can be applied, but if baseline risk is >40%, then 
a higher threshold for odds ratios is appropriate. 
17
 Additionally, for continuous data: a 
standardized mean difference of 0.8 is considered large. 
17
  
 CONSIDERATION OF WHETHER TO UPGRADE CONFIDENCE 
BASED ON MAGNITUDE OF ASSOCIATION OF EFFECT 
No upgrade will occur if any previous downgrades have occurred.  
 
A level 1 upgrade (+1) will occur if a large magnitude of effect is discovered in the included 
study. For categorical data: a relative risk of >2 or <0.5 with no plausible confounders is 
considered a large magnitude of effect. For continuous data: a standardized mean difference with 
a lower 95% confidence limit of 0.8 to 1.5 or a upper 95% confidence limit of -0.8 to -1.5 is 
considered a large standardized mean difference. 
17
 
 
A level 2 upgrade (+2) will occur if a very large magnitude of effect is discovered. For 
categorical data: a relative risk of >5 or <0.2 based on direct evidence with no major threats to 
validity is considered a very large magnitude of effect. For continuous data: a standardized mean 
difference with a lower 95% confidence limit of >1.5 or an upper 95% confidence limit of >-1.5 
is considered a very large standardized mean difference. 
17 
6.3.2. DOSE-RESPONSE 
Presence of a dose-response gradient may increase our confidence in observational studies 
and thereby increase quality of evidence. Only studies with no threats to validity – not 
downgraded for any reason – can be upgraded. 3 
 CONSIDERATION OF WHETHER TO UPGRADE CONFIDENCE 
BASED ON DOSE-RESPONSE 
No upgrade will occur if no dose-response is observed.  
 
No upgrade will occur if any previous downgrades have occurred.  
 
An upgrade (+1) will occur if a dose-response is observed (differing levels of dose or 
exposure level with differing levels of outcome).  
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6.3.3. PLAUSIBLE CONFOUNDING OR OTHER RESIDUAL BIASES THAT 
WOULD INCREASE OUR CONFIDENCE IN ESTIMATED EFFECT 
All plausible confounders from observational studies or randomized trials may be working 
to reduce the demonstrated effect or increase effect if no effect was observed. Only studies with 
no threats to validity – not downgraded for any reason – can be upgraded. 3 
 CONSIDERATION TO UPGRADE CONFIDENCE BASED ON 
PLAUSIBLE CONFOUNDERS: 
No upgrade will occur if any previous downgrades have occurred.  
 
An upgrade (+1) will occur if there are indications that either residual bias would 
underestimate an apparent association (reduced for RR >>1 or RR <<1) or would suggest a 
spurious effect when results suggest no effect (increased for RR ~1). 
6.3.4. COMBINED CONFIDENCE CONCLUSIONS FOR ALL STUDY TYPES 
Conclusions are based on evidence with highest confidence when considering evidence 
across study types and study type with the highest confidence rating forms the basis for 
confidence conclusion. Consistency across study designs increases confidence in the combined 
body of evidence.  
 CONSIDERATION TO UPGRADE CONFIDENCE BASED ON 
COMBINED CONFIDENCE CONCLUSIONS FOR STUDY TYPES 
As pooling of results into a forest plot is illogical – nearly every article will be measuring 
different Populations, Interventions, Comparators, Outcomes, Timing and Study Designs 
(PICOTS) – this item will be disregarded. 
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7. TRANSLATION OF CONFIDENCE RATINGS INTO RECOMMENDATIONS 
Quality of evidence is represented as: High ++++; Moderate +++O; Low ++OO; or Very 
Low +OOO. 
3
 
 
High quality of evidence (++++) means we are very confident that the true effects lie close 
to that of the effect estimates; further research is unlikely to change findings. 
3
  
 
Moderate quality of evidence (+++O) represents moderate confidence in the effect 
estimates: true effects are likely to be close to the effect estimates, but there is a possibility that 
they are substantially different; further research is somewhat likely to change findings. 
3
  
 
Low quality evidence (++OO) shows that our confidence in the effect estimates is limited: 
true effects may be substantially different from the effect estimates; further research is likely to 
change findings. 
3
  
 
Very low quality (+OOO) suggests very little confidence in the effect estimates: True effects 
are likely to be substantially different from the effect estimates; further research is very likely to 
change findings. 
3
 
 
GRADE recommendations are categorized as: strong or weak; and for or against 
intervention. 
3
 A summation results determines the direction (for or against) and strength (strong 
or weak) of the recommendation. 
3 
As pooling of results into a forest plot is illogical – nearly 
every article will be measuring different Populations, Interventions, Comparators, Outcomes, 
Timing and Study Designs (PICOTS) – this item will be disregarded for the body of evidence. 
Each included study and series will have its own version of a GRADE recommendation. 
 
A visual aggregate summary of Risk of Bias for each Risk of Bias item will be prepared to 
show general strengths and weaknesses of included studies for this topic (20.7). This graph will 
also be constructed for each of the Risk of Reversal Conclusion Items (Replacement, Equivalent 
or Less, Reversal, and Reaffirmation) to highlight any risk of bias items that could be explored 
when evaluating reasons for Reversal. A similar graph will also be created for observation 
studies. 
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8. ANALYSIS PLAN AND OUTPUTS 
8.1. Objective 1 
A table (Appendix 3 – 20.3) detailing the characteristics and main findings of included 
studies will be provided as well as bar graphs (Appendix 7 – 20.7) for Risk of Bias.  
 
Excel sheets allocating inclusion and exclusion for each screening threshold as well as data 
extraction and Risk of Bias ratings for each included study (Appendix 4 – 20.4) will be available 
as separate appendices. 
 
Descriptive statistics from Appendix 4 (20.4) will be used to identify frequency of Reversal 
in this dataset as well as characteristics of Reversed Evidence. 
 
Descriptive statistics from Appendix 4 (20.4) will be summarized using counts and 
percentages to examine the percentage of Reversals caused by each reason for Reversal. 
 
8.2. Objective 2 
Forest plots will be constructed for each Risk of Reversal Conclusion Items (Replacement, 
Equivalent or Less, Reversal, Reaffirmation and Inconclusive) to explore potential patterns, such 
as large effect estimates or wide confidence intervals. Each conclusion item could be further 
described when evaluating reasons for Reversal – since studies will address different 
Populations, Interventions, Comparators, Outcomes, Timing and Study Designs (PICOTS), we 
will attempt to standardize effect sizes through standardized effect size calculations (Cohen’s d) 
whenever the data allows, to allow for synthesis across studies. 
18
 Continuous data will be 
summarized separately from discrete data.  
 
Aggregation of all data types, outcomes and reasons for our criteria defining Evidence 
Reversal will be collected across included articles using data extracted for Objective 1 (8.1). For 
analysis and aggregation, semantically and conceptually similar ideas will be arranged. These 
collected ideas will be grouped together conceptually to form subgroups and marked with the 
total number of reasons associated with each original reason item, and also each subcategory. 
These subcategories will be defined to reflect the reasons within each subcategory, and then 
categorized into conceptually similar categories. These categories will be defined to capture the 
subcategories within each category, and then grouped together to form domains of reasons for 
Reversal. These domains will also be defined to indicate the categories within each domain, with 
the intent of suggesting theories for future research into Evidence Reversal. The entirety of this 
endeavour represents the framework for reasons for Evidence Reversal.  
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9. PEER-REVIEW 
Upon completion, this review will be submitted to a peer-reviewed journal for publication.  
10. REVIEW TEAM 
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 Desirée Sutton (DS) 
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18. PROTOCOL HISTORY AND REVISIONS 
 TBD: Protocol Publically Registered 
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20. APPENDICES 
20.1. APPENDIX 1 – Inclusion/Exclusion Criteria 
 
Stage Inclusion Exclusion 
Title Heading of “Original Article” 
 Including Indications of Erratum 
 Including Withdrawn Articles  
Does not meet criteria for an “Original 
Article” 
Abstract Indicate a clinical practice: 
- Screening, stratifying, or 
diagnostic test 
- A medication 
- A procedure or surgery 
- Any change in health care 
provision systems 
Indications of Erratum 
Indications Article Withdrawn 
Does not meet criteria for a clinical 
practice: 
- Investigating pathophysiology  
- Molecular basis of disease 
Full-Text Indicate a clinical practice: 
- Screening, stratifying, or 
diagnostic test 
- A medication 
- A procedure or surgery 
- Any change in health care 
provision systems 
Indications of Erratum 
Indications Article Withdrawn 
Multiple Publications from same study 
population (Included as a series) 
Does not meet criteria for a clinical 
practice: 
- Investigating pathophysiology  
- Molecular basis of disease 
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20.2. APPENDIX 2 – Hypothetical Flowchart 
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20.3. APPENDIX 3 – Data Extraction and Analysis Elements 
General 
Study 
Information 
Author(s) Authors of the study or trial. 
Title Title of the study or trial. 
DOI Digital Object Identifier for trial. 
Date of Publication Date the trial was published. 
Year of Publication Year the trial was published. 
Registration Number The number or location of pre-specified trial 
protocol.  
Year of Registration Year the trial was registered. 
Year Started Year the trial was reported as starting. 
Year of Completion Year the trial was reported as completed.  
Duration between Trial 
Start and Trial Registration 
Calculated difference in years between the year the 
trial started and when it was registered. 
Duration between trial 
registration and publication 
Calculated difference in years between the year the 
trial was registered and when it was published. 
Duration between trial 
completion and publication 
Calculated difference in years between the year the 
trial was reported as completed and when it was 
published. 
Duration since publication Calculated difference in years between the year the 
trial was published and the year of this review. 
Methodology Population Population in which trial or study is conducted. 
If two trials are reported on in the article, then use 
the first reported trial. 
If two populations are reported on in the article, 
then use the first reported population. 
Intervention Group If two groups are reported, intervention and 
control/ placebo/ comparison/ currently used 
practice, then use groups as reported. 
If two groups are reported, but none are labelled as 
control/ placebo/ comparison/ currently used 
practice: 
- If the two reported groups are one low dose/ risk 
and one high dose/ risk, then use the low dose as 
the comparison group. 
- If the two reported groups are two interventions 
and neither is the control/ placebo/ comparison/ 
currently used practice, then use the first 
reported as the intervention group and the 
second reported as the comparison group. 
If >2 groups are reported, and one is control/ 
placebo/ comparison/ currently used practice, 
then use this as the control, for the intervention 
group: 
- If the other reported groups are low dose/ risk 
and high dose/ risk, then use the low dose as the 
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intervention group. 
- If the two reported groups are two interventions 
and neither is the control/ placebo/ comparison/ 
currently used practice, then use the first 
reported as the intervention group and the 
second reported as the intervention group. 
If >2 groups are reported and none are control/ 
placebo/ comparison/ currently used practice, 
then use the first mentioned group as the 
intervention and the second mentioned group as 
the comparison group. 
If factorial designs, then use the double placebo as 
the control group and the first-mentioned 
intervention-placebo as the intervention group. 
If factorial designs and neither intervention is a 
control/ placebo/ comparison/ currently used 
practice, then the first mentioned group is the 
intervention group and the second mentioned 
group is the comparison group. 
Comparison Group See group selection for intervention group. 
1
o
 Outcome If only one primary outcome is reported, then use 
the sole reported primary outcome. 
If more than one primary outcome is reported, then 
use the first primary outcome reported.  
If no outcomes are reported as the primary 
outcome, then use the first reported outcome as 
the primary outcome. 
If primary outcomes are reported for both safety 
and efficacy, then use the efficacy primary 
outcome. 
2
o
 Outcome (Major) If only one secondary outcome is reported, then 
use the sole reported secondary outcome. 
If more than one secondary outcome is reported, 
then use the most patient-important outcome. 
i.e. mortality 
Study Design - Randomized controlled trial 
- Prospective controlled (but nonrandomized) 
intervention study 
- Observational study (prospective or 
retrospective) 
- Case-control study 
- Other 
Study Type - Diagnosis 
- Prognosis 
- Therapy 
Clinical Practice Type - Screening, stratifying, or diagnostic test 
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- Medication, Procedure or a surgery 
- Any change in health care provision systems 
Randomization - Yes 
- No 
Duration of Follow-Up If the duration of follow-up for the selected 
primary outcome is reported, then use this 
reported duration.  
If the duration of follow-up for the selected 
primary outcome is not reported, then use the 
duration of follow-up for the entire trial or 
study. 
Sample Size Total number randomized. 
Study 
Results 
Loss to Follow-Up Total Total loss to follow-up in entire trial or study. Also 
reported as withdrawn, lack of outcome 
information or protocol violations. 
Loss to Follow-Up in 
Intervention Group 
Loss to follow-up in the selected intervention 
group for the primary outcome. Also reported as 
withdrawn, lack of outcome information or 
protocol violations. 
If only the total loss to follow-up is reported, then 
it is assumed loss to follow-up is equal in all 
groups this is calculated by dividing the total 
loss to follow-up by the number of groups. 
Loss to Follow-Up in 
Comparison Group 
Loss to follow-up in the selected comparison 
group for the primary outcome. Also reported as 
withdrawn, lack of outcome information or 
protocol violations. 
If only the total loss to follow-up is reported, then 
it is assumed loss to follow-up is equal in all 
groups this is calculated by dividing the total 
loss to follow-up by the number of groups. 
p-Value (1
o
 Outcome) Reported p-value for selected primary outcome. 
Significant or Not - SS (p-value is significant) 
- NS (p-value is not significant) 
Point Estimate  Reported point estimate of effect of selected 
primary outcome. 
If both relative and absolute estimates are 
available, then use absolute values. 
If both crude/unadjusted estimates are available, 
then use the crude/unadjusted values. 
If no point estimate is found (common with 
continuous outcomes), then report as 
“Unknown.” 
Intent-to-treat analysis point estimates are used 
over modified-intent-to-treat analysis point 
estimates which are used over per protocol 
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analysis point estimates 
Confidence Interval (1
o
 
Outcome) 
Reported confidence interval or standard deviation 
of selected point estimate of effect of selected 
primary outcome. 
Type of Outcome If both continuous and dichotomous outcomes are 
reported for the selected primary outcome, then 
the dichotomous outcome is preferred. 
- Continuous 
- Dichotomous 
Number of Events in 
Intervention Group 
For dichotomous outcomes, number of events of 
selected primary outcome in the selected 
intervention group. 
Number in Intervention 
Group 
Number of population randomized to selected 
intervention group. 
Intervention Group Rate Calculated by the number of events in intervention 
group divided by the number of population in 
intervention group. 
Number of Events in 
Comparison Group 
For dichotomous outcomes, number of events of 
selected primary outcome in the selected 
comparison group. 
Number in Comparison 
Group 
Number of population randomized to selected 
comparison group. 
Control Group Rate If dichotomous outcome, calculated by the number 
of events in comparison group divided by the 
number of population in intervention group. 
Absolute Risk Reduction If dichotomous outcome, calculated by the 
intervention group rate divided by the 
comparison group rate. 
- Absolute Risk Increase if Negative 
Number Needed to Treat If dichotomous outcome, calculated by the inverse 
of absolute risk reduction.  
- Number Needed to Harm if Negative 
Total Number of Events If dichotomous outcome, calculated by the 
summation of events in the selected intervention 
group and the comparison group. 
Relative Risk Reduction If dichotomous outcome, calculated by the 
absolute risk reduction divided by the 
comparison group rate. 
- Relative Risk Increase if Negative 
Fragility Index If dichotomous outcome with a significant p-value, 
calculated by recalculating the two-sided p-
value for Fischer’s exact test after adding an 
event from the group with the fewer reported 
events while subtracting a non-event from that 
group. This process continues iteratively until 
the calculated p-value becomes greater or equal 
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to 0.05. The number reported in this review is 
the number of added events required to change 
the p-value from significant to non-significant.
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Intervention Group Mean 
or Median 
If continuous outcome, the reported mean or 
median for the selected primary outcome in the 
selected intervention group. 
Intervention Group 
Standard Deviation or 
Interquartile Range 
If continuous outcome, the reported standard 
deviation or interquartile range for the selected 
primary outcome in the selected intervention 
group. 
Control Group Mean or 
Median 
If continuous outcome, the reported mean or 
median for the selected primary outcome in the 
selected comparison group. 
Control Group Standard 
Deviation or Interquartile 
Range 
If continuous outcome, the reported standard 
deviation or interquartile range for the selected 
primary outcome in the selected comparison 
group. 
Pooled Standard Deviation If continuous outcome, calculated by: (one less 
than the intervention group number) times 
intervention standard deviation squared plus 
(one less than the comparison group number) 
times comparison group standard deviation 
squared all over two less than the total number 
in the two groups. 
Standard Effect Size If continuous outcome, calculated by the 
summation of means divided by the pooled 
standard deviation. 
Authors' 
Conclusion 
End Point Conclusions - Positive conclusions  
o If selected intervention group is reported as 
beneficial/ better than the selected 
comparison group, then use positive. 
- Negative conclusions or No difference 
o If selected intervention group is reported as 
not beneficial/ harmful/ no different than 
the selected comparison group, then use 
negative or no difference. 
Conclusion Abstract conclusion. 
Does the article contradict 
current medical practice? 
Based on abstract conclusion. 
If new practice versus current practice/placebo 
beneficial, then yes. 
If new practice versus current practice/placebo not 
beneficial/harmful/no different, then no. 
If current practice versus prior/inferior practice not 
beneficial/harmful/no different, then yes. 
If current practice versus prior/inferior practice 
beneficial, then no. 
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- Yes 
- No 
How does the article 
contradict current medical 
practice? 
Abstract introduction. 
Was the conclusion based 
on subgroup analysis? 
Based on abstract conclusion. 
- Yes 
- No 
Was the conclusion based 
on a secondary outcome? 
Based on abstract conclusion. 
- Yes 
- No 
Risk of 
Reversal 
Items  
Withdrawn Presence - Yes 
- No 
Reason Reason article was withdrawn. 
Erratum Presence - Yes 
- No 
Reason Reason article was corrected. 
Clinical Practice  If the intervention is based on a new practice then 
use new. 
If the intervention is based on an existing practice 
then use existing. 
- New 
- Existing 
Conclusion 
*based on trial or study 
authors’ conclusion not 
systematic review. 
- Replacement: current research shows superiority 
of new practice over current practice. 
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- Equivalent or Less: current research shows new 
practice is equivalent or less than current 
practice. 
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- Reversal: current research shows current 
practice is ineffective or harmful. 
9
 
- Confirmation: current research shows current 
practice is superior to previous standard of 
practice/ is effective/ is beneficial. 
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Conflict(s) of 
Interest 
Conflicts of Interest If both industry and non-industry reported, then 
use industry. 
- Industry 
- Non-Industry 
- None disclosed. 
Other Conflicts of Interest Reason for conflict. 
Documentation of Author Contact for 
Further Information  
 
Modified Optimal Information Size If dichotomous, fails to meet mOIS if (in 
decreasing order of importance): 
- Doesn’t meet sample size calculation provided 
in article. 
- 95% CI includes both no effect and either harm 
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or benefit. 
- Total number of events <300. 
If continuous, fails to meet mOIS if (in decreasing 
order of importance): 
- Doesn’t meet sample size calculation provided 
in article. 
- 95% CI includes 0.5 effect size in either 
direction. 
- Total sample size <400. 
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20.4. APPENDIX 4 – Study Findings, Risk of Bias Ratings, PICOTS Assessment, 
GRADE Assessment 
General 
Study 
Information 
Author(s)  
Title  
DOI  
Date of Publication  
Year of Publication  
Registration Number  
Year of Registration  
Year Started  
Year of Completion  
Duration between Trial 
Start and Trial Registration 
 
Duration between trial 
registration and publication 
 
Duration between trial 
completion and publication 
 
Duration since publication  
Methodology Population  
Intervention  
Comparison  
1
o
 Outcome  
2
o
 Outcome (Major)  
Study Design - Randomized controlled trial 
- Prospective controlled (but nonrandomized) 
intervention study 
- Observational study (prospective or 
retrospective) 
- Case-control study 
- Other 
Study Type - Diagnosis 
- Prognosis 
- Therapy 
Clinical Practice Type - Screening, stratifying, or diagnostic test 
- Medication, Procedure or a surgery 
- Any change in health care provision systems 
Randomization - Yes 
- No 
Duration of Follow-Up  
Sample Size  
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Study 
Results 
Loss to Follow-Up Total  
Loss to Follow-Up in 
Intervention Group 
 
Loss to Follow-Up in 
Control Group 
 
p-Value (1
o
 Outcome)  
Significant or Not - SS 
- NS 
Point Estimate   
Confidence Interval (1
o
 
Outcome) 
 
Type of Outcome - Continuous 
- Dichotomous 
Number of Events in 
Intervention Group 
 
Number in Intervention 
Group 
 
Intervention Group Rate  
Number of Events in 
Control Group 
 
Number in Control Group  
Control Group Rate  
Absolute Risk Reduction - Absolute Risk Increase if Negative 
Number Needed to Treat - Number Needed to Harm if Negative 
Total Number of Events  
Relative Risk Reduction - Relative Risk Increase if Negative 
Fragility Index  
Intervention Group Mean 
or Median 
 
Intervention Group 
Standard Deviation or 
Interquartile Range 
 
Control Group Mean or 
Median 
 
Control Group Standard 
Deviation or Interquartile 
Range 
 
Pooled Standard Deviation  
Standard Effect Size  
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Authors' 
Conclusion 
End Point Conclusions - Positive conclusions  
- Negative conclusions or No difference 
Conclusion  
Does the article contradict 
current medical practice? 
- Yes 
- No 
How does the article 
contradict current medical 
practice? 
 
Was the conclusion based 
on subgroup analysis? 
- Yes 
- No 
Was the conclusion based 
on a secondary outcome? 
- Yes 
- No 
Risk of 
Reversal 
Items  
Withdrawn Presence - Yes 
- No 
Reason  
Erratum Presence - Yes 
- No 
Reason  
Clinical Practice  - New 
- Existing 
Conclusion - Replacement: current research shows 
superiority of new practice over current 
practice9 
- Equivalent or Less: current research shows 
new practice is equivalent or less than current 
practice9 
- Reversal: current research shows current 
practice is ineffective or harmful9 
- Confirmation: current research shows current 
practice is superior to previous standard of 
practice/ is effective/ is beneficial9 
- Inconclusive: current research did not show 
any of the above indications9 
Conflict(s) of 
Interest 
Funding - Industry 
- Non-Industry 
Other Conflicts of Interest - Industry 
- Non-Industry 
Documentation of Author Contact for 
Further Information  
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Risk of Bias 
Assessment 
(Trials) 
Sequence 
Generation 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Allocation 
Concealment  
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Blinding Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Incomplete 
Outcome 
Data 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Selective 
Outcome 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Other 
Sources of 
Bias 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Overall - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
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Risk of Bias 
Assessment 
(Studies) 
Bias due to 
confounding 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Bias in 
selection of 
participants 
into the study 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Bias in 
measurement 
of 
interventions 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Bias due to 
departures 
from 
intended 
interventions 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Bias due to 
missing data 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Bias in 
measurement 
of outcomes 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Bias in 
selection of 
the reported 
result 
Description - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
Reason  
Overall - Definitely Low Risk of Bias 
- Probably Low Risk of Bias 
- Probably High Risk of Bias 
- Definitely High Risk of Bias 
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GRADE 
Assessment 
Study Design Type - Trial 
- Study 
Initial Level 
of 
Confidence 
- Very High 
- Low 
Risk of Bias Description - Overall Risk of Bias Assessment 
Downgrade - 0 
- -1 
- -2 
Inconsistency Disregarded 
Directness 
and 
Applicability 
Description - Overall PICOTS Assessment 
Downgrade - 0 
- -1 
- -2 
Imprecision Description - Proper Modified Optimal Information Size 
Downgrade - 0 
- -1 
Publication 
Bias - 
Modified 
Description - Undetected 
- Suspected 
- Detected 
Downgrade - 0 
- -1 
- -2 
Total Downgrades  
Large 
Magnitude of 
Association 
of Effect 
Description - None 
- Large 
- Very Large  
Upgrade - 0 
- 1 
- 2 
Dose-
Response 
Relationship 
Description - None 
- Detected 
Upgrade - 0 
- 1 
Plausible 
Confounding 
Description - None 
- Detected 
Upgrade - 0 
- 1 
Total Upgrades  
Overall Quality of Evidence  
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20.5. APPENDIX 5 – PICOTS Assessment 
PICOTS Sufficient Insufficient 
Patient The ‘right’ patient population is identified 
The patient population is appropriately 
generalizable or restricted, included or 
excluded 
 
The ‘right’ setting is identified. 
The setting is appropriately generalizable or 
restricted (multi-centre or single-centre) 
 
Appropriately similar to protocol registration 
The ‘right’ patient population is not identified 
The patient population is inappropriately 
generalizable or restricted, included or excluded 
 
 
The ‘right’ setting is not identified 
The setting is inappropriately generalizable or 
restricted (multi-centre or single-centre) 
 
Inappropriately different from protocol 
registration 
Intervention An appropriate intervention is identified 
The dosage used is specified and scientifically 
justified 
The frequency of treatment is specified and 
scientifically justified 
 
Appropriately similar to protocol registration 
An appropriate intervention is not identified 
The dosage used is not specified or scientifically 
justified 
The frequency of treatment is not specified or 
scientifically justified 
 
Inappropriately different from protocol 
registration 
Comparator The comparator is appropriate. 
Next best alternative to intervention 
Competing alternative to intervention 
Standard of care 
Gold standard 
The placebo is appropriate 
Appears similar to intervention 
 
The dosage used is specified and scientifically 
justified 
The frequency of treatment is specified and 
justified 
 
Appropriately similar to protocol registration 
The comparator is inappropriate 
Inferior to other alternatives / standards 
of care 
Placebo used instead of an existing 
standard of care 
 
 
 
The dosage used is not specified or 
scientifically justified 
The frequency of treatment is not specified or 
justified 
 
Inappropriately different from protocol 
registration 
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Outcomes The primary outcome is valid. The secondary 
outcome(s) are valid 
Patient-important, clinically relevant, hard 
(affect how a patient functions / feels / 
survives) 
Appropriate surrogate (validated) 
Surrogate is correlated with the hard 
outcome of interest 
Surrogate fully captures the net 
effect of treatment on the hard 
outcome of interest 
Appropriate composite (validated) 
Component endpoints of similar 
importance to patients 
Component endpoints occur with 
similar frequency 
Component endpoints are likely to 
have similar relative risk reductions 
 
 
If mortality is measured, then so is all-cause 
mortality  
 
The timing / duration of outcome measurement 
is appropriate 
 
Appropriately similar to protocol registration 
The primary outcome is invalid. The secondary 
outcome(s) are invalid 
Not patient-important, or a patient 
important outcome is missed 
 
Inappropriate surrogate (validated) 
Surrogate is not correlated with the 
hard outcome of interest 
Surrogate does not fully capture the 
net effect of treatment on the hard 
outcome of interest 
Inappropriate composite (validated) 
Component endpoints are not of 
similar importance to patients 
Component endpoints do not occur 
with similar frequency 
Component endpoints are not likely 
to have similar relative risk 
reductions 
 
If morality is measured, only cause-specific or 
x-year survival are measured 
 
The timing / duration of outcome measurement 
is inappropriate  
 
Inappropriately different from protocol 
registration 
Study 
Design 
The study design is appropriate and the best 
possible scenario to answer the question 
 
Appropriately similar to protocol registration 
The study design is inappropriate or not the best 
possible scenario to answer the question 
 
Inappropriately different from protocol 
registration 
Study 
Purpose 
Purpose / question is easily detectable and 
clearly phrased 
Should [intervention] be used for [health 
problem]? 
Should [intervention] versus [comparison] 
be used for [health problem]? 
Should [intervention] be used in 
[population]? 
Should [intervention] versus [comparison] 
be used in [population]? 
 
Appropriately similar to protocol registration 
Purpose / question is not detectable or clearly 
phrased 
 
 
 
 
 
 
 
 
 
Inappropriately different from protocol 
registration 
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20.6. APPENDIX 6 – Risk of Bias Assessment  
20.6.1. Risk of Bias Ratings and Interpretation 
Risk of Bias Interpretation 
Definitely Low Risk of Bias Plausible bias unlikely to seriously alter the results. 
Probably Low Risk of Bias Plausible bias that raises some doubt about the results but 
unlikely to seriously alter the results 
Not Applicable Not Applicable 
Probably High Risk of Bias Plausible bias that raises some doubt about the results and likely 
to weaken confidence in results. 
Definitely High Risk of Bias Plausible bias that seriously weakens confidence in results. 
20.6.2. Risk of Bias Items, Judgement and Support 
 Trial 
Trial Judgement Support 
Quote Comment 
Sequence Generation    
Allocation Concealment    
Blinding    
Incomplete Outcome Data    
Selective Outcome Reporting     
Other Sources of Bias    
 
 Study 
Study (Cohort or Case-Control) Judgement Support 
Quote Comment 
Bias due to confounding    
Bias in selection of participants 
into the study  
   
Bias in measurement of 
interventions  
   
Bias due to departures from 
intended interventions 
   
Bias due to missing data    
Bias in measurement of outcomes     
Bias in selection of the reported 
result 
   
Overall bias    
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20.6.3. Definitions and Criteria for Judgement – Trial  
Risk of 
Bias 
Sequence 
Generation 
Allocation 
Concealment 
Blinding Incomplete Outcome 
Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Definition Method used to 
generate the 
allocation sequence is 
described sufficient 
detail to allow an 
assessment of 
whether it should 
produce comparable 
groups. 
Method used to 
conceal the allocation 
sequence is described 
in sufficient detail to 
determine whether 
intervention 
allocations could 
have been foreseen in 
advance or, or during, 
enrolment. 
Described all 
measures used, if any, 
to blind study 
participants, 
personnel, and 
outcome assessors 
from knowledge of 
which intervention a 
participant received. 
 
Provided any 
information relating 
to whether the 
intended blinding was 
effective. 
Described the 
completeness of 
outcome data for each 
main outcome, 
including attrition and 
exclusions from the 
analysis.  
 
Stated whether 
attrition and 
exclusions were 
reported, the numbers 
in each intervention 
group (compared with 
total randomized 
participants), reasons 
for attrition/ 
exclusions were 
reported, and any re-
inclusions in analyses 
performed by authors. 
Stated how the 
possibility of 
selective outcome 
reporting was 
examined by the 
authors, and what was 
found. 
Stated any important 
concerns about bias 
not addressed in other 
domains in the tool.  
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Risk of 
Bias 
Sequence 
Generation 
Allocation 
Concealment 
Blinding Incomplete Outcome 
Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Criteria 
for a 
Judgement 
of 
Definitely 
Low Risk 
of Bias 
The investigators 
describe a random 
component in the 
sequence generation 
process: random 
number table, 
computer random 
number generator, 
coin tossing, shuffling 
cards/envelopes, 
throwing dice, 
drawing lots. 
Participants and 
investigators 
enrolling participants 
could not foresee 
assignments because 
one of the following, 
or an equivalent 
method, was used to 
conceal allocation: 
central allocation 
(telephone/ web-
based/ pharmacy-
controlled 
randomization); 
sequentially 
numbered drug 
containers of identical 
appearance; 
sequentially numbers, 
opaque, sealed 
envelopes. 
No blinding, but 
authors judge the 
outcome and the 
outcome 
measurement are not 
likely to be 
influenced by lack of 
blinding. 
 
Blinding of 
participants and key 
study personnel; and 
unlikely that blinding 
could have been 
broken. 
 
Either participants or 
some key study 
personnel were not 
blinded, but outcome 
assessment was 
blinded and the non-
blinding of others is 
unlikely to introduce 
bias. 
No missing outcome 
data. 
 
Reasons for missing 
outcome data unlikely 
to be related to true 
outcome. 
 
Missing outcome data 
balanced in numbers 
across intervention 
groups, with similar 
reasons for missing 
data across groups. 
 
Missing data have 
been imputed using 
appropriate methods. 
The study protocol is 
available and all of 
the study’s pre-
specified (1
o
 and 2
o
) 
outcomes that are of 
interest in the review 
have been reported in 
the pre-specified way. 
 
 
The study appears to 
be free of other 
sources of bias. 
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Risk of 
Bias 
Sequence 
Generation 
Allocation 
Concealment 
Blinding Incomplete Outcome 
Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Criteria 
for a 
Judgement 
of 
Probably 
Low Risk 
of Bias 
Sequence generation 
process is not 
described but it is 
clear that the 
investigators used a 
random component in 
their process. 
 
Allocation 
Concealment is not 
described in complete 
detail but it is clear 
that the investigators 
used a method of 
concealment. 
Blinding is not 
described in detail but 
it is clear that 
appropriate blinding 
has been used.  
For dichotomous 
outcome data, the 
proportion of missing 
outcomes compared 
with observed event 
rate not enough to 
have a clinically 
relevant impact on the 
intervention effect 
estimate. 
 
For continuous 
outcome data, 
plausible effect size 
(difference in means 
or standardized 
difference in means) 
among missing 
outcomes not enough 
to have a clinically 
relevant impact on 
observed effect size. 
The study protocol is 
not available, but it is 
clear the published 
reports include all 
expected outcomes, 
including those that 
were pre-specified. 
It is unclear if the 
study is completely 
free of other sources 
of bias but any 
potential bias is not 
enough to have a 
clinically relevant 
impact. 
Criteria 
for a 
Judgement 
of 
Probably 
High Risk 
of Bias 
Insufficient 
information about 
sequence generation 
process to permit 
judgement. 
 
Sequence generation 
process is not 
described and it is 
unclear whether the 
investigators used a 
random component in 
their process. 
Insufficient 
information to permit 
judgement.  
 
This is usually the 
case if method of 
concealment is not 
described or not 
described in sufficient 
detail to allow a 
definite judgement. 
Insufficient 
information to permit 
judgement.  
 
The study did not 
address this outcome. 
Insufficient reporting 
of attrition/exclusions 
to permit judgement. 
 
The study did not 
address this outcome. 
The study protocol is 
not available, and it is 
unclear if the 
published reports 
include all expected 
outcomes, including 
those that were pre-
specified. 
 
Insufficient 
information to permit 
judgement.  
Insufficient 
information to assess 
whether an important 
risk of bias exists. 
 
Insufficient rationale 
or evidence that an 
identified problem 
will induce bias. 
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Risk of 
Bias 
Sequence 
Generation 
Allocation 
Concealment 
Blinding Incomplete Outcome 
Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Criteria 
for a 
Judgement 
of 
Definitely 
High Risk 
of Bias 
The investigators 
describe a non-
random component in 
the sequence 
generation process.  
 
Usually, the 
description involves 
some systematic, non-
random approach: 
odd/even date of 
birth, day/date of 
admission, 
hospital/clinic record 
number. 
 
Other: judgement of 
clinician, preference 
of participant, results 
of laboratory 
test/series of tests, 
availability of 
intervention. 
Participants or 
investigators 
enrolling participants 
could possibly 
foresee assignments 
and thus introduce 
selection bias: open 
random allocation 
schedule, assignment 
envelopes (missing 
sequential numbers, 
opaque or sealed), 
alternation/rotation, 
date of birth, case 
record number, any 
other explicitly 
unconcealed 
procedure. 
No blinding or 
incomplete blinding, 
and outcome or 
outcome measure is 
likely to be 
influenced by lack of 
blinding. 
 
Blinding of key study 
and personnel 
attempted, but likely 
that blinding could 
have been broken. 
 
Either participants or 
key study personnel 
were not blinded, and 
the non-blinding of 
others is likely to 
introduce bias. 
Reason for missing 
outcome data likely to be 
related to the true 
outcome, with either 
imbalance in numbers or 
reasons for missing data 
across intervention 
groups. 
 
For dichotomous outcome 
data, the proportion of 
missing outcomes 
compared with observed 
event risk enough to 
induce clinically relevant 
bias in intervention effect 
estimate. 
For continuous outcome 
data, plausible effect side 
among missing outcomes 
enough to induce 
clinically relevant bias in 
observed effect size. 
 
‘As-treated” analysis 
done with substantial 
departure of the 
intervention received 
from that assigned at 
randomization. 
 
Potentially inappropriate 
application of simple 
imputation. 
 
Loss to follow-up and 
failure to adhere to the 
intention to treat principle 
when indicated. 
Not all of the study’s 
pre-specified primary 
outcomes have been 
reported. 
 
One or more primary 
outcomes are reported 
using measurements, 
analysis methods, or 
subsets of the data 
that were not pre-
specified. 
 
One or more reported 
primary outcomes of 
interest in the review 
are reported 
incompletely such 
that they cannot be 
entered in a meta-
analysis. 
 
The study fails to 
include results for a 
key outcome that 
would be expected to 
have been reported in 
such a study. 
 
Reporting some 
outcomes and not 
others on the basis of 
the results. 
Potential source of 
bias related to the 
specific study design 
used. 
 
Stopped early due to 
some data-dependent 
process (including 
formal-stopping rule). 
 
Extreme baseline 
imbalance. 
 
Claimed to have been 
fraudulent. 
 
Carry-over effects in 
cross-over trials. 
 
Use of un-validated 
patient-reported 
outcomes. 
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20.6.4. Definitions and Criteria for Judgement – Cohort-Type Study 
Source of Bias Assessment Questions, Risk of Bias Judgement Not Applicable (NA) / Yes (Y) /  
Probably Yes (PY) / Probably No (PN) /  
No (N) / No Information (NI) 
Description / 
Support / 
Rationale 
Bias due to 
confounding 
1.1 Is confounding of the effect of intervention unlikely in this study? 
If Y or PY to 1.1: the study can be considered to be at low risk of bias due to 
confounding and no further signalling questions need be considered 
  
If N or PN to 1.1:   
1.2. Were participants analysed according to their initial intervention 
group throughout follow up? 
If Y or PY to 1.2, answer questions 1.4 to 1.6, which relate to baseline 
confounding 
  
1.3. If N or PN to 1.2: Were intervention discontinuations or switches 
unlikely to be related to factors that are prognostic for the outcome? 
If Y or PY to 1.3, answer questions 1.4 to 1.6, which relate to baseline 
confounding 
If N or PN to 1.1 and 1.2 and 1.3, answer questions 1.7 and 1.8, which 
relate to time-varying confounding 
  
If Y or PY to 1.2, or Y or PY to 1.3   
1.4. Did the authors use an appropriate analysis method that 
adjusted for all the critically important confounding domains? 
  
1.5. If Y or PY to 1.4: Were confounding domains that were adjusted 
for measured validly and reliably by the variables available in this 
study? 
  
1.6. Did the authors avoid adjusting for post-intervention variables?   
If N or PN to 1.2 and 1.3    
1.7. Did the authors use an appropriate analysis method that 
adjusted for all the critically important confounding domains and 
for time-varying confounding? 
  
1.8. If Y or PY to 1.7: Were confounding domains that were adjusted 
for measured validly and reliably by the variables available in this 
study? 
  
RISK OF BIAS JUDGEMENT    
Optional: What is the predicted direction of bias due to confounding? 
Favours experimental / Favours comparator / Unpredictable 
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Source of Bias Assessment Questions, Risk of Bias Judgement  (NA) / (Y) / (PY) / (PN) / (N) / (NI) Support  
Bias in 
selection of 
participants 
into the study 
2.1. Was selection into the study unrelated to intervention or unrelated to 
outcome? 
  
2.2. Do start of follow-up and start of intervention coincide for most 
subjects? 
  
2.3. If N or PN to 2.1 or 2.2: Were adjustment techniques used that are 
likely to correct for the presence of selection biases? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to selection of 
participants into the study? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias in 
measurement 
of 
interventions  
3.1 Is intervention status well defined?    
3.2 Was information on intervention status recorded at the time of 
intervention? 
  
3.3 Was information on intervention status unaffected by knowledge of the 
outcome or risk of the outcome? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to measurement of 
outcomes or interventions? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias due to 
departures 
from intended 
interventions 
4.1. Were the critical co-interventions balanced across intervention groups?   
4.2. Were numbers of switches to other interventions low?    
4.3. Was implementation failure minor?   
4.4. If N or PN to 4,1, 4.2 or 4.3: Were adjustment techniques used that 
are likely to correct for these issues? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to departures from the 
intended interventions? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
 
 
 
B-XXV 
 
B-XXV 
Source of Bias Assessment Questions, Risk of Bias Judgement  (NA) / (Y) / (PY) / (PN) / (N) / (NI) Support  
Bias due to 
missing data 
5.1 Are outcome data reasonably complete?   
5.2 Was intervention status reasonably complete for those in whom it was 
sought? 
  
5.3 Are data reasonably complete for other variables in the analysis?   
5.4 If N or PN to 5.1, 5.2 or 5.3: Are the proportion of participants and 
reasons for missing data similar across interventions? 
  
5.5 If N or PN to 5.1, 5.2 or 5.3: Were appropriate statistical methods used 
to account for missing data? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to missing data? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias in 
measurement 
of outcomes  
6.1 Was the outcome measure objective?   
6.2 Were outcome assessors unaware of the intervention received by study 
participants? 
  
6.3 Were the methods of outcome assessment comparable across intervention 
groups? 
  
6.4 Were any systematic errors in measurement of the outcome unrelated to 
intervention received?   
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to measurement of 
outcomes? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias in selection 
of the reported 
result 
Is the reported effect estimate unlikely to be selected, on the basis of the 
results, from... 
  
7.1. ... multiple outcome measurements within the outcome domain?    
7.2 ... multiple analyses of the intervention-outcome relationship?   
7.3 ... different subgroups?   
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to selection of the reported 
result? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Overall bias RISK OF BIAS JUDGEMENT   
Optional:  
What is the overall predicted direction of bias for this outcome? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
 
B-XXVI 
 
B-XXVI 
20.6.5. Definitions and Criteria for Judgement – Case-Control-Type Study 
Source of Bias Assessment Questions, Risk of Bias Judgement Not Applicable (NA)/Yes (Y)/ 
Probably Yes (PY)/Probably No 
(PN)/No (N)/No Information (NI) 
Description / 
Support / 
Rationale 
Bias due to 
confounding 
1.1 Is confounding of the effect of intervention unlikely in this study? 
If Y or PY to 1.1: the study can be considered to be at low risk of bias due to confounding 
and no further signalling questions need be considered 
  
If N or PN to 1.1:   
1.4. Did the authors use an appropriate analysis method that adjusted for all the critically 
important confounding domains? 
  
1.5. If Y or PY to 1.4: Were confounding domains that were adjusted for measured 
validly and reliably by the variables available in this study? 
  
1.6. Did the authors avoid adjusting for post-intervention variables?   
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to confounding? 
Favours experimental / Favours comparator / Unpredictable 
  
Bias in selection 
of participants 
into the study 
2.4 Were the controls sampled from the population that gave rise to the cases, or using 
another method that avoids selection bias? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to selection of participants into the 
study? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias in 
measurement 
of interventions 
3.1 Is intervention status well defined?    
3.2 Was information on intervention status recorded at the time of intervention?   
3.3 Was information on intervention status unaffected by knowledge of the outcome or risk 
of the outcome? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to measurement of outcomes or 
interventions? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias due to 
departures 
from intended 
interventions 
4.1. Were the critical co-interventions balanced across intervention groups?   
4.2. Were numbers of switches to other interventions low?    
4.3. Was implementation failure minor?   
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to departures from the intended 
interventions? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
 
B-XXVII 
 
B-XXVII 
Source of Bias Assessment Questions, Risk of Bias Judgement  (NA) / (Y) / (PY) / (PN) / (N) / (NI) Support  
Bias due to 
missing data 
5.1 Was outcome status reasonably complete for those in whom it was sought?   
5.2 Were data on intervention status reasonably complete?   
5.3 Are data reasonably complete for other variables in the analysis?   
5.4 If N or PN to 5.1, 5.2 or 5.3: Are the proportion of participants and 
reasons for missing data similar across cases and controls? 
  
5.5 If N or PN to 5.1, 5.2 or 5.3: Were appropriate statistical methods used 
to account for missing data? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to missing data? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias in 
measurement 
of outcomes 
6.1 Was the definition of case status (and control status, if applicable) based on 
objective criteria? 
  
6.2 Was the definition of case status (and control status, if applicable) applied 
without knowledge of the intervention received? 
  
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to definitions of case and 
control status? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Bias in 
selection of 
the reported 
result 
Is the reported effect estimate unlikely to be selected, on the basis of the 
results, from... 
  
7.1. ... multiple definitions of the intervention?    
7.2 ... multiple analyses of the intervention-outcome relationship?   
7.3 ... different subgroups?   
RISK OF BIAS JUDGEMENT   
Optional: What is the predicted direction of bias due to selection of the reported 
result? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
Overall bias RISK OF BIAS JUDGEMENT   
Optional:  What is the overall predicted direction of bias? 
Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable 
  
 
  
B-XXVIII 
 
B-XXVIII 
20.6.6. Preliminary Consideration of Confounders 
 Within each confounding domain listed in the review protocol, list the relevant variables, if any, measured in this study.  
 List additional confounding domains, if any, specific to the setting of this particular study. Within each domain, list the relevant variables, if any, 
measured in this study. 
 List additional domains and corresponding measured variables, if any, that the study authors identified as potential confounders that are not included in 
the above domains. 
In the table below, “critically important” confounding domains are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of 
the intervention. “Validity” refers to whether the confounding variable or variables fully measure the domain, while “reliability” refers to the precision of the measurement (more measurement error 
means less reliability). 
Confounding 
domain 
Is the domain 
critically 
important?* 
Measured 
Variable  
Did the authors demonstrate that 
controlling for this variable was 
unnecessary?* 
Is the domain measured validly 
and reliably by this variable (or 
these variables)? 
OPTIONAL: Is adjusting for 
this variable (alone) expected 
to move the effect estimate up 
or down? ** 
 Yes / No 
  
Yes / No / No information 
Up / Down / No information 
   
  
  
 
 
   
* In the context of a particular study, variables can be demonstrated not to be confounders and so not included in the analysis: (a) if they are not predictive of the outcome; (b) if they are not predictive of 
intervention; or (c) because adjustment makes no or minimal difference to the estimated effect of the primary parameter. Note that “no statistically significant association” is not the same as “not 
predictive”. 
** i.e., if the crude effect estimate is 1.3, adjustment to 1.6 is up, while adjustment to 0.7 is down. If the effect estimate is 0.7, adjustment to 1.1 is up while adjustment to 0.4 is down. 
20.6.7. Preliminary Consideration of Co-Interventions 
 Are the (pre-specified) co-interventions likely to be administered in the context of this study? 
 List additional co-interventions, if any, specific to the setting of this particular study.  
 
In the table below, “critically important” co-interventions are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the 
intervention. “Validity” refers to whether the variables fully measure the co-intervention, while “reliability” refers to the precision of the measurement (more measurement error means less reliability). 
Co-
intervention 
Is the co-
intervention 
critically 
important?* 
Did the authors 
demonstrate that 
controlling for this co-
intervention was 
unnecessary? 
Is the co-intervention 
measured validly and 
reliably? 
Is presence of this co-intervention likely to favour outcomes in the 
experimental or the control group 
 Yes / No  Yes / No / No information Favour experimental / Favour comparator / No information 
 Yes / No  Yes / No / No information Favour experimental / Favour comparator / No information 
 Yes / No  Yes / No / No information Favour experimental / Favour comparator / No information 
  
B-XXIX 
 
B-XXIX 
20.7. APPENDIX 7 – Hypothetical Visual Aggregate Rating of Risk of Bias 
Items 
 
 
Figure 30: Hypothetical Visual Aggregate Rating of Risk of Bias Items 
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Appendix C: A Systematic Examination of Contradicted Practices – Initial Pilot Phase 
Table 16: Inclusion/Exclusion, General Study Information, and Registration Data Extraction 
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Peginterferon Alfa-2a in Patients 
with Chronic Hepatitis C 
10.1056/
NEJM20
0012073
432301 
07-Dec-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
N
o
n
-R
C
T
 Brief Report: Treatment of 
Ménétrier's Disease with a 
Monoclonal Antibody against the 
Epidermal Growth Factor 
Receptor 
10.1056/
NEJM20
0012073
432305 
07-Dec-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
N
o
n
-R
C
T
 Regression of Metastatic Renal-
Cell Carcinoma after 
Nonmyeloablative Allogeneic 
Peripheral-Blood Stem-Cell 
Transplantation 
10.1056/
NEJM20
0009143
431101 
14-Sep-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
R
C
T
 
Amiodarone to Prevent 
Recurrence of Atrial Fibrillation 
10.1056/
NEJM20
0003303
421302 
30-Mar-
00 
2000 doi:10.10
16/S0002
-
9149(97)
00396-2 
1995 N/A N/A 5 N/A N/A 15 
N
o
n
-
R
C
T
 
Early Expression of Angiogenesis 
Factors in Acute Myocardial 
Ischemia and Infarction 
10.1056/
NEJM20
0003023
420904 
02-Mar-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
C-II 
 
C-II 
N
o
n
-
R
C
T
 
Cost Effectiveness of Early 
Discharge after Uncomplicated 
Acute Myocardial Infarction 
10.1056/
NEJM20
0003163
421101 
16-Mar-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
R
C
T
 
Daily Interruption of Sedative 
Infusions in Critically Ill Patients 
Undergoing Mechanical 
Ventilation 
10.1056/
NEJM20
0005183
422002 
18-May-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
N
o
n
-
R
C
T
 
Brief Report: Protection against 
Pemphigus Foliaceus by 
Desmoglein 3 in Neonates 
10.1056/
NEJM20
0007063
430105 
06-Jul-00 2000 N/A N/A N/A N/A N/A N/A N/A 15 
R
C
T
 
Low-Dose Nitric Oxide Therapy 
for Persistent Pulmonary 
Hypertension of the Newborn 
10.1056/
NEJM20
0002173
420704 
17-Feb-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
R
C
T
 
A Comparison of Methotrexate 
with Placebo for the Maintenance 
of Remission in Crohn's Disease 
10.1056/
NEJM20
0006013
422202 
01-Jun-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
N
o
n
-
R
C
T
 
Brief Report: HTLV-II–
Associated Cutaneous T-Cell 
Lymphoma in a Patient with HIV-
1 Infection 
10.1056/
NEJM20
0003303
421304 
30-Mar-
00 
2000 N/A N/A N/A N/A N/A N/A N/A 15 
N
o
n
-R
C
T
 
Brief Report: Treatment of the 
Immune Dysregulation, 
Polyendocrinopathy, Enteropathy, 
X-Linked Syndrome (IPEX) by 
Allogeneic Bone Marrow 
Transplantation 
10.1056/
NEJM20
0106073
442304 
07-Jun-
01 
2001  N/A N/A N/A N/A N/A N/A N/A 14 
R
C
T
 
Race and the Response to 
Adrenergic Blockade with 
Carvedilol in Patients with 
Chronic Heart Failure 
10.1056/
NEJM20
0105033
441803 
03-May-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
R
C
T
 
The Effect of Irbesartan on the 
Development of Diabetic 
Nephropathy in Patients with 
Type 2 Diabetes 
10.1056/
NEJMoa
011489 
20-Sep-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
C-III 
 
C-III 
N
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n
-
R
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Serratia liquefaciens Bloodstream 
Infections from Contamination of 
Epoetin Alfa at a Hemodialysis 
Center 
10.1056/
NEJM20
0105173
442001 
17-May-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
R
C
T
 
Comparison of Coronary-Artery 
Bypass Surgery and Stenting for 
the Treatment of Multivessel 
Disease 
10.1056/
NEJM20
0104123
441502 
12-Apr-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
N
o
n
-
R
C
T
 
Keratin 8 Mutations in Patients 
with Cryptogenic Liver Disease 
10.1056/
NEJM20
0105243
442103 
24-May-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
N
o
n
-R
C
T
 Noninvasive Diagnosis of Renal-
Allograft Rejection by 
Measurement of Messenger RNA 
for Perforin and Granzyme B in 
Urine 
10.1056/
NEJM20
0103293
441301 
29-Mar-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
N
o
n
-
R
C
T
 
Rickettsia africae, a Tick-Borne 
Pathogen in Travelers to Sub-
Saharan Africa 
10.1056/
NEJM20
0105173
442003 
17-May-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
N
o
n
-
R
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T
 
High Serum IgG4 Concentrations 
in Patients with Sclerosing 
Pancreatitis 
10.1056/
NEJM20
0103083
441005 
08-Mar-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
N
o
n
-
R
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T
 
Fomepizole for the Treatment of 
Methanol Poisoning 
10.1056/
NEJM20
0102083
440605 
08-Feb-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
N
o
n
-
R
C
T
 
Control of Vancomycin-Resistant 
Enterococcus in Health Care 
Facilities in a Region 
10.1056/
NEJM20
0105103
441903 
10-May-
01 
2001 N/A N/A N/A N/A N/A N/A N/A 14 
R
C
T
 
Prophylactic Implantation of a 
Defibrillator in Patients with 
Myocardial Infarction and 
Reduced Ejection Fraction 
10.1056/
NEJMoa
013474 
21-Mar-
02 
2002 doi: 
10.1111/j
.1542-
474X.19
99.tb003
69.x 
N/A N/A N/A N/A N/A N/A 13 
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 Kidney Transplantation from 
Donors without a Heartbeat 
10.1056/
NEJMoa
020274 
25-Jul-02 2002 N/A N/A N/A N/A N/A N/A N/A 13 
N
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T
 
Response to Imatinib Mesylate in 
Patients with Chronic 
Myeloproliferative Diseases with 
Rearrangements of the Platelet-
Derived Growth Factor Receptor 
Beta 
10.1056/
NEJMoa
020150 
15-Aug-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
N
o
n
-
R
C
T
 Brief Report: Two Patients with 
Unusual Forms of Varicella–
Zoster Virus Vasculopathy 
10.1056/
NEJMoa
020841 
07-Nov-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
N
o
n
-
R
C
T
 
A Long-Term Study of Prognosis 
in Monoclonal Gammopathy of 
Undetermined Significance 
10.1056/
NEJMoa
0113320
2 
21-Feb-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
R
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T
 Primary Chemoprevention of 
Familial Adenomatous Polyposis 
with Sulindac 
10.1056/
NEJMoa
012015 
04-Apr-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
R
C
T
 Tissue Plasminogen Activator in 
Cardiac Arrest with Pulseless 
Electrical Activity 
10.1056/
NEJMoa
012885 
16-May-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
N
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Pulmonary Dead-Space Fraction 
as a Risk Factor for Death in the 
Acute Respiratory Distress 
Syndrome 
10.1056/
NEJMoa
012835 
25-Apr-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
R
C
T
 Fumagillin Treatment of 
Intestinal Microsporidiosis 
10.1056/
NEJMoa
012924 
20-Jun-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
N
o
n
-
R
C
T
 Prevalence of Impaired Glucose 
Tolerance among Children and 
Adolescents with Marked Obesity 
10.1056/
NEJMoa
012578 
14-Mar-
02 
2002 N/A N/A N/A N/A N/A N/A N/A 13 
R
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T
 
Treatment of Rheumatoid 
Arthritis by Selective Inhibition 
of T-Cell Activation with Fusion 
Protein CTLA4Ig 
10.1056/
NEJMoa
035075 
13-Nov-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
N
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n
-
R
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 A Cluster of Cases of Severe 
Acute Respiratory Syndrome in 
Hong Kong 
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030666 
15-May-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
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N
o
n
-
R
C
T
 Genetic, Clinical, and 
Radiographic Delineation of 
Hallervorden–Spatz Syndrome 
10.1056/
NEJMoa
020817 
02-Jan-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
N
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Brief Report: Preimplantation 
Diagnosis for Sonic Hedgehog 
Mutation Causing Familial 
Holoprosencephaly 
10.1056/
NEJMoa
022652 
10-Apr-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
N
o
n
-
R
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T
 The Renal Arterial Resistance 
Index and Renal Allograft 
Survival 
10.1056/
NEJMoa
022602 
10-Jul-03 2003 N/A N/A N/A N/A N/A N/A N/A 12 
N
o
n
-
R
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T
 Puberty and Genetic 
Susceptibility to Breast Cancer in 
a Case–Control Study in Twins 
10.1056/
NEJMoa
021293 
05-Jun-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
N
o
n
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R
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T
 Coronary Microvascular 
Dysfunction and Prognosis in 
Hypertrophic Cardiomyopathy 
10.1056/
NEJMoa
025050 
11-Sep-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
R
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T
 Comparison of Sequential Three-
Drug Regimens as Initial Therapy 
for HIV-1 Infection 
10.1056/
NEJMoa
030264 
11-Dec-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
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Computed Tomographic Virtual 
Colonoscopy to Screen for 
Colorectal Neoplasia in 
Asymptomatic Adults 
10.1056/
NEJMoa
031618 
04-Dec-
03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
R
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 A Controlled Trial of 
Natalizumab for Relapsing 
Multiple Sclerosis 
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020696 
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03 
2003 N/A N/A N/A N/A N/A N/A N/A 12 
N
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 Prediction of Survival in Diffuse 
Large-B-Cell Lymphoma Based 
on the Expression of Six Genes 
10.1056/
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032520 
29-Apr-
04 
2004 N/A N/A N/A N/A N/A N/A N/A 11 
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 Methylprednisolone, 
Valacyclovir, or the Combination 
for Vestibular Neuritis 
10.1056/
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22-Jul-04 2004 N/A N/A N/A N/A N/A N/A N/A 11 
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 Clinical Features and Prognostic 
Factors in Adults with Bacterial 
Meningitis 
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A Multigene Assay to Predict 
Recurrence of Tamoxifen-
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2004 N/A N/A N/A N/A N/A N/A N/A 11 
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Probability of Viremia with HBV, 
HCV, HIV, and HTLV among 
Tissue Donors in the United 
States 
10.1056/
NEJMoa
032510 
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04 
2004 N/A N/A N/A N/A N/A N/A N/A 11 
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Mannose-Binding Lectin Variant 
Alleles and the Risk of Arterial 
Thrombosis in Systemic Lupus 
Erythematosus 
10.1056/
NEJMoa
033122 
15-Jul-04 2004 N/A N/A N/A N/A N/A N/A N/A 11 
R
C
T
 A Comparison of High-Dose and 
Standard-Dose Epinephrine in 
Children with Cardiac Arrest 
10.1056/
NEJMoa
032440 
22-Apr-
04 
2004 N/A N/A N/A N/A N/A N/A N/A 11 
R
C
T
 Intensive versus Moderate Lipid 
Lowering with Statins after Acute 
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Table 19: Sample Size, Conclusion, and Conflict of Interest Data Extraction 
    Imprecision Author's 
Conclusion 
      Reversal 
Items 
  Conflicts of 
Interest 
Title Sample 
Size 
Sample Size 
(OIS) 
End Point 
Conclusions 
Contradict 
current 
medical 
practice? 
Based on 
subgroup 
analysis? 
Based on 
secondary 
outcome? 
Clinical 
Practice 
Reversal 
Conclusion 
Funding 
Peginterferon Alfa-2a in 
Patients with Chronic 
Hepatitis C 
531 Insufficient Positive Yes No No New Replacement Industry 
Amiodarone to Prevent 
Recurrence of Atrial 
Fibrillation 
403 Insufficient Positive Yes No No New Replacement Non-
Industry 
Daily Interruption of 
Sedative Infusions in 
Critically Ill Patients 
Undergoing Mechanical 
Ventilation 
150 Insufficient Positive Yes No No New Replacement None 
Disclosed 
Low-Dose Nitric Oxide 
Therapy for Persistent 
Pulmonary Hypertension 
of the Newborn 
248 Sufficient Positive Yes No No New Replacement Industry 
A Comparison of 
Methotrexate with Placebo 
for the Maintenance of 
Remission in Crohn's 
Disease 
76 Insufficient Positive Yes No No New Replacement Non-
Industry 
Race and the Response to 
Adrenergic Blockade with 
Carvedilol in Patients with 
Chronic Heart Failure 
217 Insufficient Negative or No 
Difference 
No No No New Equivalent or 
Less 
Industry 
The Effect of Irbesartan on 
the Development of 
Diabetic Nephropathy in 
Patients with Type 2 
Diabetes 
590 Sufficient Positive Yes No Yes New Replacement Industry 
Comparison of Coronary-
Artery Bypass Surgery and 
Stenting for the Treatment 
of Multivessel Disease 
1205 Sufficient Positive Yes No Yes Existing Reversal Industry 
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Prophylactic Implantation 
of a Defibrillator in 
Patients with Myocardial 
Infarction and Reduced 
Ejection Fraction 
1232 Sufficient Positive Yes No No Existing Reversal Industry 
Primary Chemoprevention 
of Familial Adenomatous 
Polyposis with Sulindac 
41 Insufficient Negative or No 
Difference 
No No No New Equivalent or 
Less 
Industry 
Tissue Plasminogen 
Activator in Cardiac Arrest 
with Pulseless Electrical 
Activity 
289 Sufficient Negative or No 
Difference 
No No No New Equivalent or 
Less 
Industry 
Fumagillin Treatment of 
Intestinal Microsporidiosis 
12 Insufficient Positive Yes No No New Replacement Non-
Industry 
Treatment of Rheumatoid 
Arthritis by Selective 
Inhibition of T-Cell 
Activation with Fusion 
Protein CTLA4Ig 
339 Sufficient Positive Yes No Yes New Replacement Industry 
Comparison of Sequential 
Three-Drug Regimens as 
Initial Therapy for HIV-1 
Infection 
620 Sufficient Positive No No No Existing Confirmation Industry 
A Controlled Trial of 
Natalizumab for Relapsing 
Multiple Sclerosis 
213 Sufficient Positive Yes No No New Replacement Industry 
Methylprednisolone, 
Valacyclovir, or the 
Combination for 
Vestibular Neuritis 
141 Sufficient Positive Yes No No New Replacement None 
Disclosed 
A Comparison of High-
Dose and Standard-Dose 
Epinephrine in Children 
with Cardiac Arrest 
68 Sufficient Positive Yes No No New Replacement None 
Disclosed 
Intensive versus Moderate 
Lipid Lowering with 
Statins after Acute 
Coronary Syndromes 
4162 Sufficient Positive Yes No No New Replacement Industry 
Coronary-Artery 
Revascularization before 
Elective Major Vascular 
510 Insufficient Negative or No 
Difference 
Yes No No Existing Reversal Non-
Industry 
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Surgery 
Natalizumab Induction and 
Maintenance Therapy for 
Crohn's Disease 
905 Sufficient Positive Yes No No New Replacement Industry 
Peginterferon Alfa-2a, 
Lamivudine, and the 
Combination for HBeAg-
Positive Chronic Hepatitis 
B 
814 Sufficient Positive Yes No No New Replacement Industry 
Single-Dose Azithromycin 
versus Penicillin G 
Benzathine for the 
Treatment of Early 
Syphilis 
628 Sufficient Positive Yes No No New Replacement Non-
Industry 
Sirolimus-Eluting versus 
Uncoated Stents in Acute 
Myocardial Infarction 
718 Sufficient Positive Yes No No New Replacement Industry 
N-Acetylcysteine and 
Contrast-Induced 
Nephropathy in Primary 
Angioplasty 
354 Sufficient Positive Yes No No New Replacement Non-
Industry 
A Randomized, Placebo-
Controlled Trial of 
Natalizumab for Relapsing 
Multiple Sclerosis 
942 Sufficient Positive Yes No No New Replacement Industry 
Fetal Pulse Oximetry and 
Cesarean Delivery 
5341 Insufficient Negative or No 
Difference 
Yes No No Existing Reversal Non-
Industry 
Chemotherapy with 
Preoperative Radiotherapy 
in Rectal Cancer 
1011 Sufficient Negative or No 
Difference 
Yes No No New Replacement Non-
Industry 
Treatment of Periodontal 
Disease and the Risk of 
Preterm Birth 
823 Sufficient Negative or No 
Difference 
No No Yes Existing Confirmation Non-
Industry 
Immunotherapy with a 
Ragweed–Toll-Like 
Receptor 9 Agonist 
Vaccine for Allergic 
Rhinitis 
25 Insufficient Positive Yes No No New Replacement Industry 
HER2 and Response to 
Paclitaxel in Node-Positive 
1500 Sufficient Positive Yes Yes No New Replacement Industry 
C-XXXIX 
 
C-XXXIX 
Breast Cancer 
Asthma Control during the 
Year after Bronchial 
Thermoplasty 
112 Insufficient Positive Yes No No New Replacement Industry 
Omeprazole before 
Endoscopy in Patients with 
Gastrointestinal Bleeding 
638 Sufficient Positive Yes No No New Replacement Industry 
A Communication 
Strategy and Brochure for 
Relatives of Patients Dying 
in the ICU 
126 Sufficient Positive Yes No No New Replacement Industry 
Randomized Trial of 
Pulsed Corticosteroid 
Therapy for Primary 
Treatment of Kawasaki 
Disease 
199 Sufficient Negative or No 
Difference 
No No No New Equivalent or 
Less 
Non-
Industry 
Treatment of Periodontitis 
and Endothelial Function 
120 Sufficient Negative or No 
Difference 
No No No New Equivalent or 
Less 
Industry 
Weight Loss with a Low-
Carbohydrate, 
Mediterranean, or Low-Fat 
Diet 
322 Sufficient Negative or No 
Difference 
No No No Existing Confirmation Non-
Industry 
A Clinical Trial of a 
Whole-Virus H5N1 
Vaccine Derived from Cell 
Culture 
275 Sufficient Positive Yes No No New Replacement Industry 
A Randomized Trial of 
Arthroscopic Surgery for 
Osteoarthritis of the Knee 
188 Sufficient Positive No No No New Equivalent or 
Less 
Non-
Industry 
Rivaroxaban versus 
Enoxaparin for 
Thromboprophylaxis after 
Hip Arthroplasty 
4541 Sufficient Positive Yes No No New Replacement Industry 
Platinum-Based 
Chemotherapy plus 
Cetuximab in Head and 
Neck Cancer 
442 Sufficient Positive Yes No No New Replacement Industry 
Testosterone for Low 
Libido in Postmenopausal 
Women Not Taking 
814 Sufficient Positive Yes No No New Replacement Industry 
C-XL 
 
C-XL 
Estrogen 
Diacetylmorphine versus 
Methadone for the 
Treatment of Opioid 
Addiction 
251 Sufficient Positive Yes No No New Replacement Industry 
A Novel Influenza A 
(H1N1) Vaccine in 
Various Age Groups 
2200 Sufficient Positive Yes Yes No New Replacement Industry 
Early Use of TIPS in 
Patients with Cirrhosis and 
Variceal Bleeding 
63 Sufficient Positive Yes No No New Replacement Industry 
Oral Rivaroxaban for 
Symptomatic Venous 
Thromboembolism 
3449 Sufficient Positive Yes No No New Replacement Industry 
An Oral Spleen Tyrosine 
Kinase (Syk) Inhibitor for 
Rheumatoid Arthritis 
457 Sufficient Positive Yes No Yes New Replacement Industry 
Effect of Nateglinide on 
the Incidence of Diabetes 
and Cardiovascular Events 
9518 Sufficient Negative or No 
Difference 
No No No New Equivalent or 
Less 
Industry 
Immunogenicity and 
Safety of a Meningococcal 
A Conjugate Vaccine in 
Africans 
601 Insufficient Positive Yes Yes Yes New Replacement Non-
Industry 
Fidaxomicin versus 
Vancomycin for 
Clostridium difficile 
Infection 
629 Sufficient Negative or No 
Difference 
Yes Yes Yes New Replacement Industry 
Sunitinib Malate for the 
Treatment of Pancreatic 
Neuroendocrine Tumors 
171 Insufficient Positive Yes No Yes New Replacement Industry 
Coronary-Artery Bypass 
Surgery in Patients with 
Left Ventricular 
Dysfunction 
1212 Insufficient Positive Yes No Yes New Replacement Industry 
Ulipristal Acetate versus 
Placebo for Fibroid 
Treatment before Surgery 
242 Sufficient Positive Yes No Yes New Replacement Industry 
Effect of a Monoclonal 
Antibody to PCSK9 on 
134 Sufficient Positive Yes No No New Replacement Industry 
C-XLI 
 
C-XLI 
LDL Cholesterol 
Efficacy Results of a Trial 
of a Herpes Simplex 
Vaccine 
8323 Insufficient Positive Yes No No New Replacement Industry 
Pyronaridine–Artesunate 
versus Mefloquine plus 
Artesunate for Malaria 
1271 Sufficient Positive Yes No No New Replacement Industry 
Placebo-Controlled Phase 
3 Study of Oral BG-12 or 
Glatiramer in Multiple 
Sclerosis 
1430 Sufficient Positive Yes No No New Replacement Industry 
Oral Immunotherapy for 
Treatment of Egg Allergy 
in Children 
55 Sufficient Positive Yes No No New Replacement Non-
Industry 
Controlled Trial of 
Psychotherapy for 
Congolese Survivors of 
Sexual Violence 
494 Sufficient Positive Yes No No New Replacement Non-
Industry 
Endovascular Therapy 
after Intravenous t-PA 
versus t-PA Alone for 
Stroke 
656 Insufficient Negative or No 
Difference 
Yes No No Existing Reversal Industry 
Oral Apixaban for the 
Treatment of Acute 
Venous Thromboembolism 
5400 Sufficient Positive Yes No No New Replacement Industry 
Results of the Two 
Incidence Screenings in 
the National Lung 
Screening Trial 
53,454 Sufficient Positive Yes No No New Replacement Non-
Industry 
A Phase 3 Trial of 
Semagacestat for 
Treatment of Alzheimer's 
Disease 
1537 Insufficient Negative or No 
Difference 
No No Yes New Equivalent or 
Less 
Industry 
Vedolizumab as Induction 
and Maintenance Therapy 
for Ulcerative Colitis 
895 Insufficient Positive Yes No No New Replacement Industry 
Single-Dose Oritavancin in 
the Treatment of Acute 
Bacterial Skin Infections 
968 Sufficient Positive Yes No No New Replacement Industry 
Bevacizumab plus 921 Sufficient Positive Yes No Yes New Replacement Industry 
C-XLII 
 
C-XLII 
Radiotherapy–
Temozolomide for Newly 
Diagnosed Glioblastoma 
A Randomized Trial of 
Prolonged Co-trimoxazole 
in HIV-Infected Children 
in Africa 
760 Insufficient Positive No No Yes New Equivalent or 
Less 
Industry 
A Randomized Trial of 
Protocol-Based Care for 
Early Septic Shock 
1341 Sufficient Negative or No 
Difference 
No Yes No New Equivalent or 
Less 
Industry 
Oral Glucocorticoid-
Sparing Effect of 
Mepolizumab in 
Eosinophilic Asthma 
135 Sufficient Positive Yes No Yes New Replacement Industry 
Treatment of HCV with 
ABT-450/r–Ombitasvir 
and Dasabuvir with 
Ribavirin 
631 Sufficient Positive No No No Existing Confirmation Industry 
ABT-450/r–Ombitasvir 
and Dasabuvir with 
Ribavirin for Hepatitis C 
with Cirrhosis 
380 Sufficient Positive No No No Existing Confirmation Industry 
Table 20: Risk of Bias Assessment 
  Risk of Bias Assessment - Trial  
Title Sequence 
Generation 
Allocation 
Concealment 
Blinding Incomplete 
Outcome Data 
Selective 
Outcome 
Other Overall Bias 
Peginterferon Alfa-2a in 
Patients with Chronic 
Hepatitis C 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Amiodarone to Prevent 
Recurrence of Atrial 
Fibrillation 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Daily Interruption of Sedative 
Infusions in Critically Ill 
Patients Undergoing 
Mechanical Ventilation 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Low-Dose Nitric Oxide Definitely Low Definitely Low Definitely Low Definitely Low Probably Low Probably High Probably Low 
C-XLIII 
 
C-XLIII 
Therapy for Persistent 
Pulmonary Hypertension of 
the Newborn 
Risk of Bias Risk of Bias Risk of Bias Risk of Bias Risk of Bias Risk of Bias Risk of Bias 
A Comparison of 
Methotrexate with Placebo 
for the Maintenance of 
Remission in Crohn's Disease 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Race and the Response to 
Adrenergic Blockade with 
Carvedilol in Patients with 
Chronic Heart Failure 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
The Effect of Irbesartan on 
the Development of Diabetic 
Nephropathy in Patients with 
Type 2 Diabetes 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Comparison of Coronary-
Artery Bypass Surgery and 
Stenting for the Treatment of 
Multivessel Disease 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Prophylactic Implantation of 
a Defibrillator in Patients 
with Myocardial Infarction 
and Reduced Ejection 
Fraction 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Primary Chemoprevention of 
Familial Adenomatous 
Polyposis with Sulindac 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Tissue Plasminogen Activator 
in Cardiac Arrest with 
Pulseless Electrical Activity 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Fumagillin Treatment of 
Intestinal Microsporidiosis 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Treatment of Rheumatoid 
Arthritis by Selective 
Inhibition of T-Cell 
Activation with Fusion 
Protein CTLA4Ig 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
C-XLIV 
 
C-XLIV 
Comparison of Sequential 
Three-Drug Regimens as 
Initial Therapy for HIV-1 
Infection 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
A Controlled Trial of 
Natalizumab for Relapsing 
Multiple Sclerosis 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Methylprednisolone, 
Valacyclovir, or the 
Combination for Vestibular 
Neuritis 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
A Comparison of High-Dose 
and Standard-Dose 
Epinephrine in Children with 
Cardiac Arrest 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Intensive versus Moderate 
Lipid Lowering with Statins 
after Acute Coronary 
Syndromes 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Coronary-Artery 
Revascularization before 
Elective Major Vascular 
Surgery 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Natalizumab Induction and 
Maintenance Therapy for 
Crohn's Disease 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Peginterferon Alfa-2a, 
Lamivudine, and the 
Combination for HBeAg-
Positive Chronic Hepatitis B 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Single-Dose Azithromycin 
versus Penicillin G 
Benzathine for the Treatment 
of Early Syphilis 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Sirolimus-Eluting versus 
Uncoated Stents in Acute 
Myocardial Infarction 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
C-XLV 
 
C-XLV 
N-Acetylcysteine and 
Contrast-Induced 
Nephropathy in Primary 
Angioplasty 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
A Randomized, Placebo-
Controlled Trial of 
Natalizumab for Relapsing 
Multiple Sclerosis 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Fetal Pulse Oximetry and 
Cesarean Delivery 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Chemotherapy with 
Preoperative Radiotherapy in 
Rectal Cancer 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Treatment of Periodontal 
Disease and the Risk of 
Preterm Birth 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Immunotherapy with a 
Ragweed–Toll-Like Receptor 
9 Agonist Vaccine for 
Allergic Rhinitis 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
HER2 and Response to 
Paclitaxel in Node-Positive 
Breast Cancer 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Asthma Control during the 
Year after Bronchial 
Thermoplasty 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Omeprazole before 
Endoscopy in Patients with 
Gastrointestinal Bleeding 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
A Communication Strategy 
and Brochure for Relatives of 
Patients Dying in the ICU 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Randomized Trial of Pulsed 
Corticosteroid Therapy for 
Primary Treatment of 
Kawasaki Disease 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
C-XLVI 
 
C-XLVI 
Treatment of Periodontitis 
and Endothelial Function 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Weight Loss with a Low-
Carbohydrate, Mediterranean, 
or Low-Fat Diet 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
A Clinical Trial of a Whole-
Virus H5N1 Vaccine Derived 
from Cell Culture 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
A Randomized Trial of 
Arthroscopic Surgery for 
Osteoarthritis of the Knee 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Rivaroxaban versus 
Enoxaparin for 
Thromboprophylaxis after 
Hip Arthroplasty 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Platinum-Based 
Chemotherapy plus 
Cetuximab in Head and Neck 
Cancer 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Testosterone for Low Libido 
in Postmenopausal Women 
Not Taking Estrogen 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Diacetylmorphine versus 
Methadone for the Treatment 
of Opioid Addiction 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
A Novel Influenza A (H1N1) 
Vaccine in Various Age 
Groups 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Early Use of TIPS in Patients 
with Cirrhosis and Variceal 
Bleeding 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Oral Rivaroxaban for 
Symptomatic Venous 
Thromboembolism 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
An Oral Spleen Tyrosine 
Kinase (Syk) Inhibitor for 
Rheumatoid Arthritis 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
C-XLVII 
 
C-XLVII 
Effect of Nateglinide on the 
Incidence of Diabetes and 
Cardiovascular Events 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Immunogenicity and Safety 
of a Meningococcal A 
Conjugate Vaccine in 
Africans 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Fidaxomicin versus 
Vancomycin for Clostridium 
difficile Infection 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Sunitinib Malate for the 
Treatment of Pancreatic 
Neuroendocrine Tumors 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Coronary-Artery Bypass 
Surgery in Patients with Left 
Ventricular Dysfunction 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Ulipristal Acetate versus 
Placebo for Fibroid 
Treatment before Surgery 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Effect of a Monoclonal 
Antibody to PCSK9 on LDL 
Cholesterol 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Efficacy Results of a Trial of 
a Herpes Simplex Vaccine 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Pyronaridine–Artesunate 
versus Mefloquine plus 
Artesunate for Malaria 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Placebo-Controlled Phase 3 
Study of Oral BG-12 or 
Glatiramer in Multiple 
Sclerosis 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Oral Immunotherapy for 
Treatment of Egg Allergy in 
Children 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Controlled Trial of 
Psychotherapy for Congolese 
Survivors of Sexual Violence 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
C-XLVIII 
 
C-XLVIII 
Endovascular Therapy after 
Intravenous t-PA versus t-PA 
Alone for Stroke 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Oral Apixaban for the 
Treatment of Acute Venous 
Thromboembolism 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Results of the Two Incidence 
Screenings in the National 
Lung Screening Trial 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
A Phase 3 Trial of 
Semagacestat for Treatment 
of Alzheimer's Disease 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Vedolizumab as Induction 
and Maintenance Therapy for 
Ulcerative Colitis 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
Single-Dose Oritavancin in 
the Treatment of Acute 
Bacterial Skin Infections 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Bevacizumab plus 
Radiotherapy–Temozolomide 
for Newly Diagnosed 
Glioblastoma 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
A Randomized Trial of 
Prolonged Co-trimoxazole in 
HIV-Infected Children in 
Africa 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Probably Low 
Risk of Bias 
A Randomized Trial of 
Protocol-Based Care for 
Early Septic Shock 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably High 
Risk of Bias 
Oral Glucocorticoid-Sparing 
Effect of Mepolizumab in 
Eosinophilic Asthma 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably Low 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Probably Low 
Risk of Bias 
Treatment of HCV with 
ABT-450/r–Ombitasvir and 
Dasabuvir with Ribavirin 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
ABT-450/r–Ombitasvir and 
Dasabuvir with Ribavirin for 
Probably Low 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely High 
Risk of Bias 
Probably High 
Risk of Bias 
Definitely Low 
Risk of Bias 
Definitely High 
Risk of Bias 
Definitely High 
Risk of Bias 
C-XLIX 
 
C-XLIX 
Hepatitis C with Cirrhosis 
Table 21: GRADE Assessment 
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Peginterferon Alfa-2a in 
Patients with Chronic 
Hepatitis C 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Somewhat 
Insufficient 
-1 Insufficient -1 Undetected 0 -4 Very Low 
Quality 
Amiodarone to Prevent 
Recurrence of Atrial 
Fibrillation 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Somewhat 
Insufficient 
-1 Insufficient -1 Undetected 0 -3 Very Low 
Quality 
Daily Interruption of 
Sedative Infusions in 
Critically Ill Patients 
Undergoing Mechanical 
Ventilation 
Very High 
Confidence 
Definitely 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
Low-Dose Nitric Oxide 
Therapy for Persistent 
Pulmonary Hypertension 
of the Newborn 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
A Comparison of 
Methotrexate with 
Placebo for the 
Maintenance of 
Remission in Crohn's 
Disease 
Very High 
Confidence 
Definitely 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
Race and the Response to 
Adrenergic Blockade 
with Carvedilol in 
Patients with Chronic 
Heart Failure 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Clearly 
Insufficient 
-2 Insufficient -1 Undetected 0 -4 Very Low 
Quality 
The Effect of Irbesartan 
on the Development of 
Diabetic Nephropathy in 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Suspected -1 -2 Low 
Quality 
C-L 
 
C-L 
Patients with Type 2 
Diabetes 
Comparison of 
Coronary-Artery Bypass 
Surgery and Stenting for 
the Treatment of 
Multivessel Disease 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -2 Low 
Quality 
Prophylactic 
Implantation of a 
Defibrillator in Patients 
with Myocardial 
Infarction and Reduced 
Ejection Fraction 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -2 Low 
Quality 
Primary 
Chemoprevention of 
Familial Adenomatous 
Polyposis with Sulindac 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
Tissue Plasminogen 
Activator in Cardiac 
Arrest with Pulseless 
Electrical Activity 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Fumagillin Treatment of 
Intestinal 
Microsporidiosis 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
Treatment of 
Rheumatoid Arthritis by 
Selective Inhibition of T-
Cell Activation with 
Fusion Protein CTLA4Ig 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Comparison of 
Sequential Three-Drug 
Regimens as Initial 
Therapy for HIV-1 
Infection 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -2 Low 
Quality 
A Controlled Trial of 
Natalizumab for 
Relapsing Multiple 
Sclerosis 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Suspected -1 -2 Low 
Quality 
Methylprednisolone, 
Valacyclovir, or the 
Combination for 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
C-LI 
 
C-LI 
Vestibular Neuritis 
A Comparison of High-
Dose and Standard-Dose 
Epinephrine in Children 
with Cardiac Arrest 
Very High 
Confidence 
Definitely 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Intensive versus 
Moderate Lipid 
Lowering with Statins 
after Acute Coronary 
Syndromes 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Coronary-Artery 
Revascularization before 
Elective Major Vascular 
Surgery 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Insufficient -1 Undetected 0 -2 Low 
Quality 
Natalizumab Induction 
and Maintenance 
Therapy for Crohn's 
Disease 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Suspected -1 -2 Low 
Quality 
Peginterferon Alfa-2a, 
Lamivudine, and the 
Combination for HBeAg-
Positive Chronic 
Hepatitis B 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Single-Dose 
Azithromycin versus 
Penicillin G Benzathine 
for the Treatment of 
Early Syphilis 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Sirolimus-Eluting versus 
Uncoated Stents in Acute 
Myocardial Infarction 
Very High 
Confidence 
Definitely 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
N-Acetylcysteine and 
Contrast-Induced 
Nephropathy in Primary 
Angioplasty 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
A Randomized, Placebo-
Controlled Trial of 
Natalizumab for 
Relapsing Multiple 
Sclerosis 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
C-LII 
 
C-LII 
Fetal Pulse Oximetry and 
Cesarean Delivery 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
Chemotherapy with 
Preoperative 
Radiotherapy in Rectal 
Cancer 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Treatment of Periodontal 
Disease and the Risk of 
Preterm Birth 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Immunotherapy with a 
Ragweed–Toll-Like 
Receptor 9 Agonist 
Vaccine for Allergic 
Rhinitis 
Very High 
Confidence 
Definitely 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
HER2 and Response to 
Paclitaxel in Node-
Positive Breast Cancer 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Asthma Control during 
the Year after Bronchial 
Thermoplasty 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Insufficient -1 Detected -2 -4 Very Low 
Quality 
Omeprazole before 
Endoscopy in Patients 
with Gastrointestinal 
Bleeding 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Detected -2 -3 Very Low 
Quality 
A Communication 
Strategy and Brochure 
for Relatives of Patients 
Dying in the ICU 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Detected -2 -3 Very Low 
Quality 
Randomized Trial of 
Pulsed Corticosteroid 
Therapy for Primary 
Treatment of Kawasaki 
Disease 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Treatment of 
Periodontitis and 
Endothelial Function 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Suspected -1 -2 Low 
Quality 
Weight Loss with a Low-
Carbohydrate, 
Mediterranean, or Low-
Fat Diet 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Suspected -1 -1 Moderate 
Quality 
C-LIII 
 
C-LIII 
A Clinical Trial of a 
Whole-Virus H5N1 
Vaccine Derived from 
Cell Culture 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -2 Low 
Quality 
A Randomized Trial of 
Arthroscopic Surgery for 
Osteoarthritis of the 
Knee 
Very High 
Confidence 
Definitely 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Rivaroxaban versus 
Enoxaparin for 
Thromboprophylaxis 
after Hip Arthroplasty 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Platinum-Based 
Chemotherapy plus 
Cetuximab in Head and 
Neck Cancer 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -2 Low 
Quality 
Testosterone for Low 
Libido in 
Postmenopausal Women 
Not Taking Estrogen 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Diacetylmorphine versus 
Methadone for the 
Treatment of Opioid 
Addiction 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
A Novel Influenza A 
(H1N1) Vaccine in 
Various Age Groups 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -2 Low 
Quality 
Early Use of TIPS in 
Patients with Cirrhosis 
and Variceal Bleeding 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Oral Rivaroxaban for 
Symptomatic Venous 
Thromboembolism 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
An Oral Spleen Tyrosine 
Kinase (Syk) Inhibitor 
for Rheumatoid Arthritis 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Effect of Nateglinide on 
the Incidence of Diabetes 
and Cardiovascular 
Events 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
C-LIV 
 
C-LIV 
Immunogenicity and 
Safety of a 
Meningococcal A 
Conjugate Vaccine in 
Africans 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
Fidaxomicin versus 
Vancomycin for 
Clostridium difficile 
Infection 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -2 Low 
Quality 
Sunitinib Malate for the 
Treatment of Pancreatic 
Neuroendocrine Tumors 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Somewhat 
Insufficient 
-1 Insufficient -1 Undetected 0 -3 Very Low 
Quality 
Coronary-Artery Bypass 
Surgery in Patients with 
Left Ventricular 
Dysfunction 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -1 Moderate 
Quality 
Ulipristal Acetate versus 
Placebo for Fibroid 
Treatment before 
Surgery 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Effect of a Monoclonal 
Antibody to PCSK9 on 
LDL Cholesterol 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Efficacy Results of a 
Trial of a Herpes 
Simplex Vaccine 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Insufficient -1 Undetected 0 -2 Low 
Quality 
Pyronaridine–Artesunate 
versus Mefloquine plus 
Artesunate for Malaria 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -3 Very Low 
Quality 
Placebo-Controlled 
Phase 3 Study of Oral 
BG-12 or Glatiramer in 
Multiple Sclerosis 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Oral Immunotherapy for 
Treatment of Egg 
Allergy in Children 
Very High 
Confidence 
Definitely 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
Controlled Trial of 
Psychotherapy for 
Congolese Survivors of 
Sexual Violence 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
C-LV 
 
C-LV 
Endovascular Therapy 
after Intravenous t-PA 
versus t-PA Alone for 
Stroke 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Somewhat 
Insufficient 
-1 Insufficient -1 Detected -2 -6 Very Low 
Quality 
Oral Apixaban for the 
Treatment of Acute 
Venous 
Thromboembolism 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Results of the Two 
Incidence Screenings in 
the National Lung 
Screening Trial 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
A Phase 3 Trial of 
Semagacestat for 
Treatment of Alzheimer's 
Disease 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Somewhat 
Insufficient 
-1 Insufficient -1 Detected -2 -6 Very Low 
Quality 
Vedolizumab as 
Induction and 
Maintenance Therapy for 
Ulcerative Colitis 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Sufficient 0 Insufficient -1 Detected -2 -5 Very Low 
Quality 
Single-Dose Oritavancin 
in the Treatment of 
Acute Bacterial Skin 
Infections 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Bevacizumab plus 
Radiotherapy–
Temozolomide for 
Newly Diagnosed 
Glioblastoma 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Sufficient 0 Sufficient 0 Undetected 0 0 High 
Quality 
A Randomized Trial of 
Prolonged Co-
trimoxazole in HIV-
Infected Children in 
Africa 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Insufficient -1 Undetected 0 -2 Low 
Quality 
A Randomized Trial of 
Protocol-Based Care for 
Early Septic Shock 
Very High 
Confidence 
Probably 
High Risk 
of Bias 
-1 Disregarded Sufficient 0 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
Oral Glucocorticoid-
Sparing Effect of 
Mepolizumab in 
Eosinophilic Asthma 
Very High 
Confidence 
Probably 
Low Risk of 
Bias 
0 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -1 Moderate 
Quality 
C-LVI 
 
C-LVI 
Treatment of HCV with 
ABT-450/r–Ombitasvir 
and Dasabuvir with 
Ribavirin 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -3 Very Low 
Quality 
ABT-450/r–Ombitasvir 
and Dasabuvir with 
Ribavirin for Hepatitis C 
with Cirrhosis 
Very High 
Confidence 
Definitely 
High Risk 
of Bias 
-2 Disregarded Somewhat 
Insufficient 
-1 Sufficient 0 Undetected 0 -3 Very Low 
Quality 
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